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Abstract 
Duchenne Muscular Dystrophy (DMD) is a fatal multi-system neuromuscular 
disease caused by loss of dystrophin. The loss of dystrophin from membranes of 
contractile muscle cells and the dysregulation of the DAPC, induces chronic 
inflammation due to tissue necrosis and eventual replacement with collagen which 
weakens muscular force and strength. Patients are wheel chair bound by their teen 
years and premature death is typically due to respiratory failure. 
  
However, different isoforms of dystrophin are present in other tissues, including 
smooth muscle and neurons although the consequences for loss of dystrophin in 
these tissues are poorly understood. Indeed, under-diagnosed features of DMD 
include mood disorders such as depression and anxiety and dysfunction of the 
gastrointestinal tract. 
 
The first study in the thesis examined mood in the dystrophin-deficient mdx 
mouse model of DMD and examined the effects of the tri-cyclic antidepressant, 
amitriptyline on behaviours. Amitriptyline had anti-depressant and anxiolytic effects 
in the mdx mice possibly through effects on stress factors such as corticotrophin-
releasing factor (CRF). This anti-depressant also reduced skeletal muscle 
inflammation and caused a reduction in circulating interleukin (IL)-6 levels.  
 
In the second and third studies, we specifically blocked IL-6 signalling and 
used Urocortin 2, CRFR2 agonist to investigate their potential as therapeutic targets 
in mdx mice pathophysiology. Isometric and isotonic contractile properties of the 
diaphragm, were compared in mdx mice treated with anti IL-6 receptor antibodies 
(anti IL-6R) and/or Urocortin 2. Deficits in force production, work and power 
detected in mdx mice were improved with treatment.  
  
In study three I investigated contractile properties in gastrointestinal smooth muscle. 
As compared to wild type mice, mdx mice had slower faecal transit times, shorter 
colons with thickened muscle layers and increased contractile activity in response to 
recombinant IL-6. Blocking IL-6 signalling resulted in an increase in colon length, 
normalised faecal output times and a reduction in IL-6-evoked contractile activity. 
XVII 
 
Interestingly, mdx mice treated with Urocortin 2 also had beneficial results in 
gastrointestinal function.   
The findings from these studies indicate that for both diaphragm and 
gastrointestinal function in a dystrophin-deficient model, targeting of IL-6 and 
CRFR2 signalling has beneficial therapeutic effects. 
1 
 
Chapter 1: Introduction 
  
2 
 
1.1 Duchenne Muscular Dystrophy 
Duchenne Muscular Dystrophy (DMD) is a fatal X-chromosome linked recessive 
disorder caused by the truncation or deletion of the dystrophin gene (Bulfield 1984). 
It is a multi–system disorder with manifestations in striated and smooth muscle and 
the nervous system (Torelli et al. 1999).  DMD is the most frequently occurring type 
of muscular dystrophy, its incidence worldwide is 1 in every 3,500 live male births 
(Emery & Muntoni 2003) and has the most severe symptoms of the muscular 
dystrophies.  
The most obvious and debilitating characteristic is the progressive weakening 
of skeletal muscles resulting in severe disability and premature death (Yiu & 
Kornberg 2008). This is due to a loss of the functional protein dystrophin, which acts 
to anchor the extracellular matrix to the actin cytoskeleton and is associated with a 
protein complex called the hetero-oligomeric protein complex named the dystrophin 
associated protein complex (DAPC) which spans the sarcolemma. In DMD, 
disruptions in the reading frame result in loss of dystrophin, whereas in Becker’s 
Muscular Dystrophy (BMD) an in-frame deletion results in a truncated protein and a 
milder form of the disease (Koenig et al. 1989).  Myofibres are the contractile cell 
type in muscle responsible for movement (Podhorska-Okolow et al. 1998) and in the 
absence of dystrophin, a  muscle contraction mechanically stresses the plasma 
membrane, inducing damage to the myofibres (Gumerson & Michele 2011).  
Clinical presentation of DMD occurs between 3 and 5 years of age with 
motor delay or abnormal gait as key indicators. Such phenotypical presentation of 
the disease is the first step in diagnosing DMD in young patients who exhibit 
developmental delays (Essex & Roper 2001). Affected boys have difficulty in 
running, they tend to walk on their toes, fall frequently, cannot jump (Manzur et al. 
2007) and exhibit pseudo - hypertrophy of the calf muscles (Cros et al. 1989). In the 
past, the classical diagnostic test for DMD was to test raised serum enzyme levels, 
such as lutamic-oalacetic transaminase, glutamic-pyruvic transmaine, aldolase and 
most known creatine kinase (CK) levels (Dubowitz 1976) and was used as an early 
biomarker of the disease. However, genetic testing (Ashton et al. 2008; den Dunnen 
& Beggs 2006) now complements this assay as a definitive diagnostic test. 
Molecular diagnosis of the disease along with muscle biopsy to test for the presence 
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or absence of dystrophin at a cellular level (Itto et al. 2013; Sang-Jun et al. 2013; 
Essex & Roper 2001) is now commonly used. Patients are usually wheelchair-bound 
by age twelve (Wagner 2008) and have an average life expectancy of just over 
twenty years, with cardiomyopathy later in the disease (Yiu & Kornberg 2008). 
Although, therapeutic strategies such as ventilators are raising life expectancy and 
improving the quality of life for boys affected with the disease (Yiu & Kornberg 
2008) there is currently no effective cure for DMD. 
1.2 Dystrophin  
1.2.1 The Dystrophin Gene 
DMD is an X-chromosome linked recessive disorder caused by mutations in the 
dystrophin gene at Xp21.  The dystrophin gene consists of 2.6 million base pairs and 
contains 79 exons. Introns make up 99.4% of the gene. It is the largest human gene 
corresponding to 0.1% of the entire human genome (Passamano et al. 2012). Its 
relatively large size makes it susceptible to genetic rearrangements and mutations. A 
third of all cases of DMD result from mutations which arise spontaneously (Muntoni 
et al. 2003). Approximately 65% of patients suffering from DMD have intragenic 
out-of-frame deletions, 10% have duplications of one or more exons of the gene and 
the remaining 25% have various point mutations (Aartsma-Rus et al. 2006). Frame-
shift deletion of the dystrophin gene results in DMD, as seen in 90% of cases 
(Koenig et al. 1989). Other mutations of the gene result in BMD, where a truncated 
dystrophin protein is translated. In this case, some function is restored to the DAPC 
(Muntoni et al. 1994; Koenig et al. 1989; Hu et al. 1991; Feng et al. 2013; Wang et 
al. 2013; Lochmüller & Bushby 2013). 
The dystrophin protein has 7 different promoter sites, resulting in different 
isoforms of the protein. The most common isoform is the Dp427 m-isoform, found 
in skeletal muscle (Monaco et al. 1986; Koenig et al. 1987), other variants of 427kD 
length in humans include Dp427-l, -c and –p, expressed in lymphoblastoid cells 
(Nishio et al. 1994), cortical (Nudel et al. 1989) and purkinje cells (Byers et al. 1993) 
respectively. A shorter protein named Dp260 is expressed in the retina (Kameya et 
al. 1997; Ervasti 2007). Dp140 isoform is found in the central nervous system (CNS) 
and kidney (Kameya et al. 1997), Dp116 in Schwann cells (Byers et al. 1993), Dp71 
and Dp40 (Tinsley et al. 1993) expressed  ubiquitously.  
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1.2.2 The Dystrophin Protein 
1.2.2.1 Structure 
Translation of the dystrophin gene results in a rod-shaped cytoskeletal protein (see 
Figure 1.1). Its long m - isoform (which is not present in DMD) is composed of 
3,685 amino acid residues with a molecular weight of 427kD (Hoffman et al. 1987). 
Dystrophin protein is found on the cytoplasmic surface of cell membranes in muscle 
(Ervasti 2004). It comprises of a carboxyl end, which binds to the DAPC of the 
sarcolemma, and an amino end which binds to the cytoskeletal actin (Chamberlain et 
al. 1997). The protein is made up of 4 distinct domains: the N-terminal globular 
domain which consists of 240 amino acids; the second rod-shaped domain consisting 
of 24 homologous spectrin-like repeats with around 109 amino acids, the third, a 
cysteine rich domain with binding sites which have uncertain physiological 
significance, and the fourth, a C-terminus of 420 amino acids, which binds to 
proteins of the DAPC; providing a link between individual fibre contractile 
components and the extracellular matrix (Blake et al. 1996). This structure facilitates 
the function of dystrophin which is described below. 
  
Figure 1.1: Dystrophin Protein Structure 
Comprised of a carboxyl end (C-Terminal Domain which binds to proteins of the DAPC) the 
second rod-shaped domain consisting of 24 homologous spectrin-like repeats with around 109 
amino acids, the third, a cysteine rich domain and an amino end (Actin Binding Domain). 
Adapted from (Hoffman et al. 2003). 
 
                               
Actin Binding Domain and Spectrin Repeat Rod Domain  
Hinge Regions Hinge Regions 
Cysteine-Rich 
Domain 
C-Terminal Domain N-Terminal Domain 
5 
 
1.2.2.2 Function 
In muscle, the structure of the dystrophin protein facilitates the essential protection 
of the sarcolemma against mechanical stress due to repeated contractions, through 
the link between the sub-sarcolemmal cytoskeletal actin and the extra cellular matrix 
(Petrof et al. 1993) through the DAPC in the sarcolemma. Destabilization of this 
hetero-oligomeric protein complex, in the absence of dystrophin leads to progressive 
damage of the muscle fibres and the compromised membrane due to these stretch 
induced tears (Deconinck & Dan 2007). This subsequently results in mechanical 
damage of muscle fibres, loss of cell integrity and eventual necrosis.  
Regeneration of muscle fibres does occur initially but when this regenerative 
capacity is exhausted, fibrosis predominates and fatty tissue infiltrates result in 
muscle weakness and loss of functional contractile myofibres (Cros et al. 1989).   
As dystrophin has significant interactions with the DAPC it is not surprising 
that its absence affects the proteins of the complex. The expression of proteins of the 
DAPC is changed in DMD an example being the de-localization of the syntrophin-
dystrobrevin sub complex (Compton et al. 2005; Matsumura et al. 1992),  the change 
which suggests a role for dystrophin in the organisation of the complex (Ervasti & 
Campbell 1991).  
Phosphorylation of dystrophin affects its affinity to bind actin and syntrophin (a 
protein in the DAPC) which has led to the hypothesis that dystrophin has a part in 
intracellular signalling (Michele & Campbell 2003; Lapidos et al. 2004)  and it has 
been demonstrated that dystrophin has a role in the control of signalling molecules 
such as proteins involved in intra-cytoplasmic calcium homeostasis and nitric oxide 
synthesis (Davies & Nowak 2006). 
Dystrophin Associated Protein Complex (DAPC) 
The DAPC is primarily a mechano-transducer, translating physical signals from 
extra-cellular matrix to changes in gene expression in the nucleus. Moreover, 
contractile force is communicated outward to the interfiber connective space where 
there is evidence that the DAPC is involved in transmembrane signalling (Lapidos et 
al. 2004). Disruption to the complex of proteins disturbs cell signalling pathways, 
and cellular defence mechanisms which are regulated by signalling cascades (Petrof, 
Shrager, et al. 1993; Rando 2001) such as reactive oxygen species (ROS) (Menazza 
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et al. 2010) and Kappa-light-chain-enhancer of activated B cells (NFĸB) activation 
(Evans et al. 2010). The DAPC describes the association of dystrophin with a 
number of other proteins, including dystroglycans, sarcoglycans, dystrobrevins, 
syntrophins and sarcospan (Waite et al. 2009) (see Figure 1.2). Mutations in the 
DAPC can cause other muscular dystrophies, for instance, a mutation in any of the 
sarcospan-SG proteins results in limb-girdle type muscular dystrophies (Duclos et al. 
1998). Abnormal expression of dystroglycan results in Fukuyama congenital 
muscular dystrophy, muscle–eye–brain disease, Walker–Warburg syndrome, 
congenital muscular dystrophies type 1C and 1D, and limb-girdle muscular 
dystrophy 2I (Godfrey et al. 2011). Mutations in components of the extra-cellular 
matrix associated with the DAPC can also cause muscular dystrophies, e.g. 
congenital muscular dystrophy (MDC1A) is caused by mutations in the LAMA2 
gene that encodes the laminin a2-chain. Mutations in collagen VI genes cause 
Ullrich syndrome and Bethlem myopathy (Kanagawa & Toda 2008). 
  
Figure 1.2: Dystrophin Associated Protein Complex (DAPC) 
The DAPC comprises proteins bound to dystrophin on the subsarcolemmel side of 
the membrane including α-dystrobrevin, and membrane bound proteins; sarcospan, 
α-, β-, γ-, δ-sarcoglycan, α-, β-dystroglycans and laminin. Dystrophin anchors the 
extracellular collagen matrix to intra cellular cytoskeletal actin through the 
complex. Adapted from (Ervasti 2004). 
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1.3 The Role of Dystrophin in the Pathogenesis of DMD 
There are three main hypotheses for the role of dystrophin in DMD, the mechanical, 
calcium and inflammatory hypothesis (Summarised in Figure 1.3). 
1.3.1 Mechanical Hypothesis 
As dystrophin functions to protect muscle fibres from the mechanical stress of 
contraction, loss of this protein causes increased sarcolemmal fragility making them 
susceptible to mechanical damage (Moens et al. 1993). Indeed, in the dystrophin-
deficient mdx mouse, its myofibres are more susceptible to contraction- and stretch- 
induced damage manifesting as sarcolemmal tears (Moens et al. 1993). The degree 
of mechanical damage has been correlated to muscle fibre diameter and weight 
bearing capacity of the muscle. Thus, larger weight bearing muscles, such as the 
proximal muscles of the leg are the first to show signs of weakness and fatigue in 
DMD (Petrof et al. 1993). It is noteworthy to note that this models disease profile is 
age dependant. In contrast, muscle fibres of smaller diameter which bear less weight 
such as the distal foot muscles undergo less mechanical damage, and are spared until 
later in the pathogenesis of the disease (Boland et al. 1995). 
1.3.2 Calcium Hypothesis 
The calcium hypothesis explains the destructive effects of excessive calcium ions 
(Ca
2+
) in cells through tears in the sarcolemma. Indeed, altered Ca
2+
 homeostasis has 
been implicated as a contributor to DMD pathophysiology with evidence of Ca
2+ 
accumulation and hyper-contracted fibres in muscle biopsies of patients (Deconinck 
& Dan 2007; Zeiger et al. 2010). Increased intracellular Ca
2+ 
(Mallouk et al. 2000) 
seen in DMD can be detrimental to the fibre as prolonged increases in Ca
2+ 
concentrations in skeletal muscle fibres leads to activation of cytosolic proteases, 
which exacerbate the damage and can lead to fibre necrosis (Spencer et al. 1995).  
Moreover, twice the normal Ca
2+
 levels have been observed in mdx myofibres 
(Vandebrouck et al. 2002). The mdx mouse model has shown that normal 
physiological control of Ca
2+
 homeostasis is lost, has leaky Ca
2+
 channels (Fong et 
al. 1990; Turner et al. 1993) and abnormal mitochondrial Ca
2+
 handling (Ruegg et al. 
2002).  
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In contrast, the extra-ocular muscles are spared in DMD and this may be due to 
superior control of Ca
2+ 
homeostasis in these muscles (as well as a reduced load-
bearing function) (Zeiger et al. 2010). In control animals, extra-ocular eye muscles 
have increased numbers of mitochondria (Felder et al. 2005) with associated 
enhanced abilities for  Ca
2+  
uptake (Zeiger et al. 2010). 
1.3.3 Inflammation Hypothesis 
Of particular interest in this project is the hypothesis based on immune activation 
and inflammation which has been proposed as the reason for the particularly severe 
pathology caused by loss of dystrophin in DMD. Chronic inflammation characterises 
DMD, with elevations in levels of cytokine and chemokine activation, leukocyte 
adhesion and complement system activation (Porter et al. 2002). Changes in the 
profiles of pro-inflammatory cytokines such as Tumour Necrosis Factor (TNF) 
(Abdel-Salam et al. 2009), Interleukin 1 (IL-1) and Interleukin 6 (IL-6) (Porter et al. 
2002) are detected early in the disease and the inflammatory response worsens with 
disease progression. 
NFĸB activation through the phosphorylation of Inhibitor of Kappa B (Iĸ-B) 
kinases can be due to pro-inflammatory cytokines including IL-6 and TNF (Karin & 
Delhase 2000) and NFĸB activated in patients with DMD (Kumar & Boriek 2003) 
even before pathophysiological changes are apparent and it is seen to be active in 
mdx mouse muscle too (Messina et al. 2011). In its active state, it can promote 
transcription of genes encoding various detrimental components of the inflammatory 
response; including chemokines, cytokines and adhesion molecule cells (Acharyya et 
al. 2007; Baldwin, Jr. 2001). The molecular mechanism underpinning the 
inflammatory pathogenesis in DMD is not fully understood, but NFĸB activation has 
been implicated (Messina et al. 2011). However, there is discord in the literature 
with regard to the activation as NFĸB activation as it diminishes with age, whereas 
the cytokine profile up-regulates (Messina et al. 2011). 
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Figure 1.3: Hypotheses of pathology in DMD 
Sarcolemmal integrity loss, calcium deregulation and an activated inflammatory 
process exasperate the pathology caused by dystrophin deficiency, leading to 
muscle fibre regeneration primarily and eventual fibrosis and necrosis and loss 
of functional muscle fibres. 
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1.4 Pathophysiological Changes Induced by Loss of Dystrophin 
Despite the striated muscle weakness and necrosis being the primary 
pathophysiological changes in patients with DMD, it is a multi-system disorder 
affecting both smooth muscle and nervous system tissue in patients.  
To understand the pathology of DMD and investigate potential therapeutic 
strategies, a preclinical model is required. The dystrophin-deficient mdx mouse was 
first identified in 1984 by Bulfield et al (Bulfield 1984) and is genetically 
comparable to the human form of DMD, that is, it lacks full length dystrophin. It 
does however diverge in severity in symptoms to the human condition. The 
phenotypical changes in skeletal, cardiac and smooth muscle in the rodent model 
differ to some extent as compared to the human disease. However, the mdx mouse 
has been the first step towards developing the therapies which are currently utilized 
in patients with DMD.   
1.4.1 Striated Skeletal Muscle 
The most obvious and pronounced effects of dystrophin deficiency in patients are 
apparent in skeletal muscle. Dystrophin comprises 0.002% of total skeletal muscle 
protein (Hoffman et al. 1987). In the human disease, weight bearing muscles are 
affected first, with weakness in the proximal lower and then upper limbs, which is 
followed by weakness of distal lower and then upper limbs (Barohn et al. 1998). 
DMD is characterised by pseudo-hypertrophy of the calf muscles (Schreiber et al. 
1987), which is caused by muscle destruction, necrosis of fibres and some 
subsequent fibre regeneration by satellite cells, resulting in  larger but significantly 
weaker muscle tissue. Eventually the necrosis overrides the muscles’ ability to 
regenerate and terminal loss of function occurs (Cros et al. 1989).  
Due to the degeneration and regeneration of myofibres and the associated 
activation of satellite cells, cell nuclei, which are normally peripherally located in the 
cells move to the middle of the fibres, and as such acts as a useful marker of muscle 
cell regeneration in histological analysis of DMD muscle (Mosqueira et al. 2013). 
Skeletal muscle centralised nuclei have been used as an indicator for dystrophic 
features in a variety of mdx muscles (Bulfield 1984) such as the soleus (Nakae et al. 
2008), tibialis anterior, extensor digitorum longus (Baltgalvis et al. 2009) and the 
gluteus (Payne et al. 2006). Mdx skeletal muscle similarly progresses through 
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continuous degeneration and regeneration of fibre repair, starting at 2 weeks, 
peaking at 12 months and continuing for the life of the mouse but the severity of 
fibrosis and loss of function is less than that noted in human patients (Dangain & 
Vrbova 1984; Coulton et al. 1988). A chronic inflammatory response, as evidenced 
by infiltration of inflammatory cells such as macrophages, is also characteristic of 
DMD and mdx mouse peripheral skeletal muscles (Grounds et al. 2008).  
Revertant Fibres 
Although DMD is characterised by lack of dystrophin, residual dystrophin can be 
detected in up to 50% of DMD patients who express revertant fibres containing 
dystrophin (Thanh et al. 1995; Yokota et al. 2006). These revertant dystrophin 
expressing fibres exist due to the splicing machinery bypassing the mutation which 
causes the disease and restores a physical dystrophin protein, although these 
revertant fibres only comprise 1-7% of all fibres (Hoffman et al. 1990; Nicholson et 
al. 1993), having little benefit on muscle function. However, revertant fibres are also 
expressed in mdx mice  (Hoffman et al. 1990). 
Interestingly, revertant fibres do not produce an immune response which has led to 
the hypothesis that dystrophin replacement would be a possible therapeutic 
intervention in the disease (Fall et al. 2006). In humans, there has been conflicting 
conclusions regarding a correlation between the amount of revertant fibres and 
phenotypic severity of DMD (Nicholson et al. 1993), with a study concluding that  
numbers of revertant dystrophin positive fibres do not correlate to phenotypic 
severity and furthermore that these levels of dystrophin-positive revertant fibres do 
not change in individuals as the disease progresses (Arechavala-Gomeza et al. 2010). 
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1.4.2 Diaphragm 
The diaphragm as a striated respiratory muscle, in constant use and is therefore 
affected dramatically by dystrophin deficiency. Patients with DMD exhibit 
diaphragm weakness in their early teens (De Bruin et al. 1997), where diaphragm 
muscle is thickened (De Bruin et al. 1997) due to accumulation of adipose and 
connective tissue. There is a  reduction in force production due to these changes, 
however few studies in human patients have been undertaken to test this (Beck et al. 
2006). This loss of force production leads to hypoventilation and hypercapnia in 
patients (Simonds et al. 1998). Indeed, respiratory failure is the most common cause 
of premature death in DMD, although artificial ventilation has led to improvements 
in life expectancy of patients with advanced respiratory weakness (Baydur et al. 
1990).  
In comparison, disease progression in the diaphragm of the mdx mouse most 
closely relates to the human condition with extensive fibrosis (Stedman et al. 1991) 
(Gosselin & Williams 2006), which is morphologically evident from 12 weeks of 
age and continues until death, although it is not as severe as the human condition 
(Huang et al. 2009). Force production is reduced in the diaphragm from an early age 
in mdx mice (Bates et al. 2013; Gehrig et al. 2008) with loss of mechanical work 
capabilities (Stevens & Faulkner 2000). 
The diaphragm most closely relates to the human disease and is utilised in 
studies, such as our study (Study 2) to firstly, characterise dystrophin deficiency 
pathology and secondly, to pre-clinically investigate potential therapies.  
1.4.3 Cardiac Muscle 
In cardiac muscle fibres, dystrophin is present on the sarcolemma, but is also found 
in the T-tubules (Torelli et al. 1999), which function in the transmission of excitation 
coupling, but not force generation (Kaprielian et al. 2000). Loss of dystrophin 
protein affects cardiac muscle by inducing arrhythmias and conduction irregularities. 
This is in part due to cardiac fibrosis, which is irregular in area but correlates to 
electrocardiogram (ECG) irregularities and ventricular dysfunction (Romfh & 
McNally 2010). These irregularities progress in the course of the disease (Nigro et 
al. 1990), although most symptoms are subclinical or masked to some degree due to 
the physical inactivity of the patients (Nigro et al. 1990).  Nonetheless, cardiac 
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damage is evident in one third of patients by age fourteen and in 100% of patients 
over eighteen years of age (Nigro et al. 1990).  
Mdx mice, similar to the human disease, exhibit myocardial damage. At three 
months of age mdx mice have altered metabolic processing associated with increased 
oxygen consumption, decreased cardiac efficiency and increased cell membrane 
fragility (Khairallah et al. 2007). At six months heart-to-body weight ratios suggest 
the mdx heart is hypertrophied compared to wild type controls indicating cardiac 
dysfunction in aged mice. This is also reflected in changes in electrocardiography 
(ECG) readings (Bia et al. 1999; Stuckey et al. 2012). From nine months, fibrosis is 
evident histologically and by fifteen months myocardial interstitial fibrosis is 
detectable in the endocardium, myocardium and epicardium of the ventricular wall 
and septum (Marques et al. 2009). 
 
1.4.4 Smooth Muscle 
1.4.4.1 Vascular  
Dystrophin is also expressed normally in the tunica media
 
of blood vessels, but is 
absent in vessels from mdx mice causing a loss of neurovascular control (Ito et al. 
2006). Abnormalities can lead to functional ischemia which may cause or exasperate 
the damage to myofibres due to abnormal blood flow (Engel & Hawley 1977). 
Because nitric oxide (NO) signalling is mediated though the DAPC (Ennen et al. 
2013), and NO signalling plays a vital role in vascular health (see review (Jin & 
Loscalzo 2010)) loss of dystrophin in the vascular smooth muscle can cause shear 
stress and abnormal basal tone of the muscle (Ito et al. 2006).  
1.4.4.2 Gastrointestinal  
Although less abundant than either skeletal or cardiac muscle, dystrophin is found in 
smooth muscle cells of the gut. Differing from skeletal muscle it appears less 
frequently (Byers et al. 1991). Its role in gastrointestinal (GI) function can be gauged 
by symptoms such as GI hypo-motility of the system observed in patients resulting 
in acute gastric dilatation and pseudo-obstructions, which can be fatal (Dinan et al. 
2003). GI symptoms including vomiting, pseudo-obstructions, diverticulum in the 
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colon in addition to functional abnormalities such as delayed gastric emptying time 
in the oesophagus and stomach (Leon et al. 1986).  
Symptoms such as constipation, hard stools and reduced colonic transit time 
were hypothesised to be due to immobility and weakening of the skeletal muscle 
abdominal walls. However, in a cohort of patients with DMD, it was found that a 
proportion of the patients had a GI dysfunction regardless of whether they were 
wheelchair-bound or not and this was found to be distinct from the severity of the 
skeletal dysfunction in the disease (Borrelli et al. 2005).   
Studies indicate that weakening of skeletal muscle is a definitive marker of 
DMD pathogenesis whereas abnormal electrogastrography (EGG) features may 
elude a to an equally important role of smooth muscle involvement in the DMD 
pathogenesis (Borrelli et al. 2005). Smooth  muscle pathology is described in 
autopsied stomach tissue of a patient with DMD (Barohn et al. 1988). GI symptoms 
become evident in the late stages of the disease (~15 years) (Boland et al. 1996).  
Investigations into the GI manifestations which arise clinically in patients 
have been explored in mdx mice. Faecal output was markedly reduced in mdx mice, 
however wet and dry weights were not changed (Mulè et al. 2010). In ilium 
preparations, higher amplitudes, or contractions were also reported in mdx mice, at 
8-12 weeks of age (Baccari et al. 2007). Migrating motor complexes (MMC) 
characteristic of the fasting period originate proximally and propagate distally in 
both control and mdx mice at 4 months, however mdx mice had a higher frequency of 
spontaneous dysregulated MMCs (Tameyasu et al. 2004). Mice aged between 12-18 
months underwent functional tests, gastric emptying after 20 minutes did not 
significantly change compared to WT mice, and transit rate was determined to be 
reduced however, without any evidence of small intestine length differences 
(Tameyasu et al. 2004).   
15 
 
1.5 The mdx mouse model as a model of DMD  
Because the mdx mouse pathology is not as severe and does not progress 
comparatively to human DMD except for the diaphragm muscle, several 
optimisation tactics have been employed to make the mdx mouse a more 
physiologically analogous model of DMD. 
1.5.1 Emulating the human disease severity in mdx mice 
1.5.1.1 Exercise 
Exercising mdx mice potentiates dysfunction associated with loss of dystrophin by 
increasing stretch-induced micro lesions which exacerbate myofibre necrosis and 
cause muscle strength deterioration (Moens et al. 1993), running causes damage to 
triceps, gastrocnemius and quadriceps muscles with an associated increase in plasma 
CK levels (Pierno et al. 2007).  
1.5.1.2 Genetic Modification 
The mdx52 (exon 52 knockout) mouse (Arakia et al. 1997) expels all reverent 
dystrophin fibres, which are advantageous in dystrophin replacement studies 
especially when expression of induced dystrophin is to be quantified. Despite 
evidence of increased hypertrophy in the mdx52 limb muscles, the disease phenotype 
remained similar to the mdx mouse (Bulfield 1984; Grounds et al. 2008).  
1.5.1.3 Utrophin 
The protein, utrophin exhibits 80% homology and shares structural and functional 
similarities with dystrophin and can interact with the same proteins that dystrophin 
binds within the cytoskeleton protein complexes (Matsumura et al. 2011). Under 
normal circumstances when dystrophin is expressed, utrophin is down-regulated in 
adult muscle and restricted to the myotendinous and neuromuscular junctions (Blake 
et al. 1996). However, with the loss of dystrophin, as is the case in mdx mice, 
utrophin can replicate the stabilizing function of dystrophin (Keep 2000) thereby 
preserving muscle function (Rybakova et al. 2006; Tinsley et al. 1998). Utrophin  
does however, differ from dystrophin in its pattern of localisation being found at the 
myotendinous junction and neuromuscular junction in adult tissue, whereas 
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dystrophin predominates in the sarcolemma of muscle fibres (Lewis & Ohlendieck 
2010). Knockout mice lacking both dystrophin and utrophin were created by 
crossing mdx and utrophin-knockout mice. The protective role of utrophin in mdx 
mice (Deconinck et al. 1997) is evident in these mice as they are phenotypically the 
most comparable to the human DMD condition, exhibiting variability in myofibre 
size, hypertrophy by connective tissue replacement and the infiltration of 
macrophages. Life expectancy is also reduced to less than 20 weeks due to post 
weaning weight loss, joint contractures and kyphosis. 
Increased expression of utrophin restores plasma membrane integrity and rescues 
dystrophin-deficient muscle in mdx mice (Gilbert et al. 1999) but in DMD muscle, 
while utrophin is up-regulated and redistributed to the sarcolemma, levels are not 
sufficient to prevent disease progression (Love et al. 1989).  
Both revertant dystrophin expression and a high rate of cycling regeneration have 
meant that some characteristics of DMD such as the extent of skeletal muscle 
hypertrophy do not appear in the mdx mouse. Exacerbating the disease in mdx mice 
has produced useful information about the nature of dystrophin deficiency in patients 
with DMD and the mdx mouse remains an economical and useful model of the 
disease. 
1.6 Inflammatory Mediators in DMD 
1.6.1 Interleukin-6: A Myokine Released from Damaged 
Muscle 
IL-6 is considered both a pro- and anti-inflammatory cytokine. Moreover, it is a 
myokine and is released from muscle fibres when contracted (McKay et al. 2009; 
Jonsdottir et al. 2000). IL-6 increases after eccentric exercise which causes ultra-
structural damage and is unchanged following concentric exercise, motion which 
does not cause structural damage (Jonsdottir et al. 2000; Pedersen & Febbraio 2008) 
evidence it is indeed released from muscle undergoing fibre damage. IL-6 is seen to 
increase in the plasma of healthy people after muscle contraction (Pedersen & 
Febbraio 2008)  and  is elevated in the case of muscle damage (Croisier et al. 1999),  
making  it an interesting marker and effector to look at in the context of DMD.  
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In other diseases associated with immune activation such as irritable bowel 
syndrome (IBS) and rheumatoid arthritis elevated levels of cytokines, including IL-6 
are detected in blood plasma and in intestinal tissue (in IBS) (Desreumaux 2000) . 
 It is released during the acute reactive phase of inflammation from tissues, in 
response to activated cells of the immune system, including leukocytes (Chrousos 
1995). It is also elevated in inflammatory diseases, such as Crohn’s Disease, a 
smooth muscle inflammatory disease, which can be worsened by psychological- or 
immune- stress (Gustot et al. 2005).  
Indeed, patients with DMD, in which there is a chronic inflammatory response, have 
elevated plasma levels of pro-inflammatory cytokines including; IL-1, TNF and IL-6 
(Chahbouni et al. 2010). IL-6 is also increased in patients with major depression and 
anxiety, and can be causative or a consequence of hypothalamic-pituitary-
adrenocortical (HPA) axis activation (see Figure 1.4 for schematic interaction 
between stress and immune activation) (Frommberger et al. 1997; Bob et al. 2010; 
Voorhees et al. 2013). 
1.6.2 Mechanism of action of IL-6 
The family of cytokines to which IL-6 belongs to are grouped by their interaction 
with the non-specific signal propagating membrane bound Gp130 molecules (Erta et 
al. 2012), this Gp130 complex is ubiquitously expressed in tissues (Taga 1997). 
Firstly, IL-6 must bind to its specific receptor (Lust et al. 1992). This 80kDa receptor 
exists in two forms; a soluble and transmembrane form. The transmembrane form of 
the IL-6 receptor (IL-6R) is expressed in a variety of cell types but primarily 
expressed in leukocytes (Lust et al. 1992). The soluble receptor can be found in 
bodily fluids due to differential splicing of the membrane bound protein (Rose-John 
2012).  
Therefore, in the pro-inflammatory environment due an assault or injury, cells can 
shed this membrane bound receptor (Rose-John 2012) as is the case in the shedding 
of neutrophils (Deleo 2013), attracting IL-6 and propagating signalling through the 
Gp130 complex (the complex formed between IL-6 and its receptor consists of two 
IL-6 molecules, two IL-6 80kDa receptors and two Gp130 proteins, see Figure 
1.4).This results in transcription of signalling cascades in tissues or cells though the 
JAK/STAT pathway and is primarily proinflammatory (Rose-John 2012; Hirano et 
18 
 
al. 1989; Yamasaki et al. 1988). Signalling in this way would not happen in the 
presence of IL-6 in a normal (devoid of soluble IL-6R) physiological state. Thus, 
trans-signalling can be carefully controlled in a distinct biological environment.  
 
  
Figure 1.4: Interleukin-6 Receptor 
signalling 
 
A) Shedding of the membrane bound 
receptor occurs in a mechanical injury 
or pathological state from cells 
expressing the receptor 
 B) This causes an increase in soluble 
receptor available to form a complex 
with IL-6 and gp130 
 C) When a complex is formed, 
signalling occurs through the 
JAK/STAT3 signalling pathway  
D) Causing a pro inflammatory 
response.  
E) Figure Legend 
Adapted from (Erta et al. 2012) 
E) 
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1.7 The occurrences of co -morbidities in DMD 
1.7.1 Depression in DMD 
Depression is hypothesised to be largely under-diagnosed in DMD, as compared to 
other central neurobiological deficits, such as cognitive deficits and evidence of 
intellectual disability (Sang-Jun et al. 2013). Symptoms such as apathy, fatigue, 
sleep disturbances and other classical symptoms are thought to result from a decline 
in motor abilities and sickness behaviour, caused by the disease (Fitzpatrick et al. 
1986; Yiu & Kornberg 2008). However, DMD patients often show psychological 
symptoms like fatigue, apathy, high anxiety levels and depressive signs (Rubinsztein 
et al. 1998; Roccella et al. 2003; Angelini & Tasca 2012) Moreover, fatigue worsens 
muscle symptoms by increasing the apathy of the patients and reducing their 
mobility suggesting that the emotional status of the patient directly interacts with the 
course of the disease (Angelini & Tasca 2012). 
Depression is a multi-faceted disease and has several key hypotheses to describe its 
pathophysiology. Brain regions which are involved in various hypothesis of 
depression include the limbic HPA axis. The HPA axis includes projections from 
brain areas involved in emotion; amygdala, hippocampus, to the hypothalamus 
which excretes a plethora of chemical signals which interact with the pituitary gland 
or peripherally in the adrenal glands, modulating the stress response (Chesnokova & 
Melmed 2002). 
1.7.1.1 Amines regulating mood, the classical hypothesis of 
depression 
“The Monoamine Hypothesis of Depression” is one of the most established and 
studied theories of major depression (Hirschfeld 2000). This hypothesis states that 
there is an imbalance or deficiency of monoamine neurotransmitters, notably 
serotonin (5HT), noradrenaline (NA) and dopamine (DA) and this hypothesis is 
supported by the antidepressant effects of tricyclic antidepressants and monoamine 
oxidase inhibitors, which elevate the levels of these neurotransmitters and alleviate 
the symptoms of depression (Hirschfeld 2000).  
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1.7.1.2 Inflammation causing depression 
Studies which show that major depression and immune dysregulation coexist have 
caught our attention given the inflammatory profile of DMD patients. In a meta-
analysis study, Dowlati et al, found a significant increase in TNF and IL-6 in 
depressed patients when compared to controls. Both these are released during 
infection or tissue injury, and as previously stated, are elevated in muscular 
dystrophy patients (Dowlati et al. 2010), although it is not known whether they 
contribute to depressive symptoms in DMD (Chahbouni et al. 2010). Nonetheless, it 
is known that blood-borne cytokines can cross the blood brain barrier and have 
effects on behaviours such as “sickness behaviour” (Larson & Dunn 2001; Dunn et 
al. 2005). 
In 1991, the macrophage theory of depression was first hypothesised. It was 
proposed that IL-1β and other macrophage derived cytokines were responsible for 
depression, because of the potent effect they have on the HPA axis. Further evidence 
supporting this hypothesis was published in 1994, (Strik et al. 2001) when depressed 
patients exhibited a significantly higher production of Interleukin-18 and IL-6 in 
culture supernatant of mitogen stimulated peripheral blood mononuclear cells than 
normal controls.  
This  “macrophage hypothesis of depression” is relevant in inflammatory 
disease as noted in ulcerative colitis and Crohns disease where patients exhibit 
depression and anxiety (Robertson et al. 1989). Indeed, macrophage derived IL-6 is 
shown to be dysregulated in inflammatory diseases including Crohn’s disease and 
rheumatoid arthritis (Nishimoto & Kishimoto 2004). In support of this hypothesis, a 
study compared an inflammatory arthritis (rheumatoid) with a non-inflammatory 
arthritis (osteoarthritis) and found a significantly higher percentage of depressive and 
anxiolytic symptoms in the chronic inflammatory arthritis group, even though both 
disease are similar in terms of pain and disability (Francisco et al. 2010).  
Cytokines have been shown to modulate hippocampal neurogenesis as 
astroglia expression of IL-6 decreased overall neurogenesis by 63% in the 
hippocampal dentate gyrus in a transgenic murine model (Vallières et al. 2002). 
Studies on plasma of depressed patients showed a significantly higher concentration 
of IL-6 and TNF than control patients (O’Brien et al. 2007). Studies have indicated 
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that (along with other cytokines) IL-6 can activate the limbic - HPA axis, which is 
seen in a number of depressed patients, and several studies indicate that tricyclic 
antidepressants improve “sickness behaviour” in animal models of depression better 
than selective serotonin reuptake inhibitors (Dunn et al. 2005). This may be an 
important therapeutic route in treating both mood disorders and inflammation in 
DMD.  
Interaction of these hypotheses 
Neurogenesis is implicated as a contributing factor in the pathophysiology of 
depression, due in part to stress causing a reduction in dentate gyrus neuron birth rate 
(Jacobs et al. 2000), due to glucosteroids release by the stress responses. Also, 
monoamines, notably 5HT, can enhance neurogenesis in this brain area and therefore 
may be important in the treatment of depression.  This relatively new theory may 
serve to help elucidate the full mechanisms of antidepressant action and indeed the 
pathogenesis of depression in diseases which have monoamine dysregulation and 
increased cytokine expression from chronic inflammatory diseases. However, It is 
not known if neurogenesis is reduced due to these deficiencies in DMD but 
hippocampal reductions in neurogenesis has indeed been seen in mdx brain, and 
rescuing this deficiency can reduce pathology in the mice  (Deng et al. 2009).  
1.7.2 Anxiety in DMD 
It is noteworthy to mention that there is a high prevalence of comorbidity between 
depression and anxiety. Anxiety covers a broad range of disorders including panic 
disorder, social anxiety disorder, post-traumatic stress, obsessive compulsive 
disorder, and generalised anxiety disorder (Lydiard 1991) (for review see Lydiard 
1991). A study of DMD patients indeed conclude anxiety type disorders occur in 
DMD patients (Fitzpatrick et al. 1986). Pharmacological treatments for anxiety 
disorders such as selective serotonin reuptake inhibitors and tricyclic antidepressants 
are also used for the treatment of depression (Lydiard 1991), and a cohort of patients 
have used pharmacological interventions to alleviate anxiety in DMD (Bushby et al. 
2010) especially during late stages of the disease to help improve the quality of life 
of patients. 
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1.7.3 Stress in DMD 
In the CNS, psychological stress can activate the HPA axis. In DMD, stress-related 
psychological and physical stress is apparent (Sabharwal 2014). Indeed a recent 
review reveals that not only psychological stress but physical autonomic dysfunction 
due to depression of the sympathetic nervous system has been identified in DMD, 
further indicating that the physical disease can influence the mental state of the 
patient (Sabharwal 2014).  
This biological response is beneficial during an episode of physiological 
stress, with advantages including preservation of homeostasis and induction of 
glucose metabolism (Karalis et al. 1997). In the central nervous system, the stress 
response describes the activation of the HPA axis, this initially causes the secretion 
of Corticotrophin Releasing Factor (CRF) from the paraventricular nucleus of the 
hypothalamus, which drives the release of adrenocorticotropic hormone (ACTH) 
secretion from the pituitary gland (Vale et al. 1981), and the stimulation of 
glucosteroids from the adrenal glands, including cortisol (Ferenc 1986) (see Figure 
1.5).  
However, chronic stress shares symptoms with depression and anxiety, with 
chronic activation of the HPA pathway known to worsen the state of inflammatory 
disease (Gerber & Bale 2012). Indeed, interactions have been seen between 
depression, stress and pro-inflammatory cytokines (Connor & Leonard 1998). Long 
term stimulation of the HPA axis and secretion of the key stress hormone, CRF from 
the paraventricular nucleus of the hypothalamus is associated with mood disorders 
such as anxiety and a variety of other different behavioural changes (Bale & Vale 
2004). Furthermore, CRF stimulates the sympathetic nervous system in the 
peripheral system and the cardiovascular system (Dunn & Berridge 1990) and can 
stimulate colonic motility (Taché et al. 1993). Stress is a known contributor in the 
pathogenesis of inflammatory diseases (O’Malley, et al. 2010), and it may be a 
contributing factor to the disease progression in DMD. 
CRF initiates its effects though G-coupled protein receptors (GCPR), of 
which there are two subtypes, CRFR1 and CRFR2 (Bamberger & Bamberger 2000; 
Chen et al. 1993). CRF has a high affinity for both CRFR1 and CRFR2  (Coste et al. 
2001).  
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Proteins of the same family with high homology to CRF have also been 
discovered, named Urocortin 1, Urocortin 2 and Urocortin 3. Urocortin 1 has a high 
affinity for the CRFR1 subtype, whereas Urocortin 2 had a high affinity for the 
CRFR2 subtype (Reyes et al. 2001), more so than CRF, and Urocortin 3 is specific 
to CRFR2 also (Martinez et al. 2004).  
These receptor subtypes have opposing functions, for example CRFR1 
mediates visceral nociception whereas CRFR2 can reduce visceral nociception. 
CRFR1 has been implicated in pro-inflammatory processes, potentially though 
lymphocytes (Kravchenco & Furalev 1994), whereas in the periphery CRFR2 has 
anti-inflammatory functions (Hinkle et al. 2007), causing apoptosis of macrophages 
(Tsatsanis et al. 2005) and has been found to modulate IL-6 levels following 
inflammation (Venihaki et al. 2001). 
1.8.3.1 Urocortin 2 – beneficial in dystrophin deficiency 
Interestingly, Urocortin 2,  which is expressed in skeletal muscle (Kishimoto et al. 
1995), signals through the CRFR2 subtype has significant beneficial effects on 
muscle. Urocortin 2 has been shown to improve muscle physiology in a range of 
pathological conditions. These include preventing nerve damage, immobilisation 
atrophy. It can act through modulating muscle mass and it has been hypothesised this 
mechanism may be through the interaction of corticosteroids released from the 
adrenocortex (Hinkle et al. 2003) in response to CRFR1 agonism and the stress 
response (Hinkle et al. 2004) in a protective manner, reducing the catabolic action of 
corticosteroids. 
Moreover, this beneficial effect of Urocortin 2 has been investigated in mdx 
mice where it caused a reduction in CK levels and an increase in muscle mass (Hall 
et al. 2007). CRFR2 agonism in diaphragm has been beneficial in slowing the 
progression of the disease, increasing specific force production in the diaphragm and 
showing histopathological changes, such as fibrosis and inflammation. Molecular 
gene expression characteristic of DMD, including immune cell genes  were also 
altered in treated mdx mice  (Hinkle et al. 2007). 
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1.8.3.2 The CRF Stress Response and IL-6 
There is significant interaction in the body between the CRF system and cytokines. 
IL-6, which signals through Gp130 in response to psychological, physical and 
inflammatory stress on the body (Karalis et al. 1997) has a major role in the 
modulation and control of acute and chronic inflammation. Its interaction with the 
HPA axis can control the circulating levels of IL-6 in the body i.e. IL-6 stimulates 
the release of glucocorticoid levels which then inhibits IL-6 levels (Venihaki et al. 
2001).  
Of particular interest in this project, is the peripheral interaction between 
CRFR2 agonists and IL-6. Previous studies have demonstrated that Urocortin 2 can 
induce IL-6 gene transcription in rodent aortic smooth muscle cell lines, and this is 
modulated through the CRFR2 receptor (Kageyama et al. 2006). Moreover, urocortin 
2 modulates IL-6 levels in stromal cell lines in a time dependent manner (Zoumakis 
et al. 2000). CRFR2 agonists can cause anti-inflammatory effects in vitro by 
inducing macrophage apoptosis (Tsatsanis et al. 2005) but CRFR2 agonism also 
induces the release of IL-6 through NFĸB, ERK and p38 MAP kinase 
proinflammatory signalling pathways in cardiomyocytes; however its role is not 
fully elucidated (Huang et al. 2009).  
CRF antagonism increases IL-6 levels in plasma in psychological stress 
models (Ando et al. 1998) and in rodents, during an inflammatory insult, IL-6 is 
necessary for the CRF-stimulated stress response and whats more, it regulates its 
own mRNA levels (Vallières & Rivest 1999). What we lack understanding in is the 
interaction between IL-6 elevation and the CRFR2 activation in muscle, and even 
more so in DMD, especially when CRFR2 agonism has been shown to benefit mdx 
muscle function (Hall et al. 2007; Reutenauer-Patte et al. 2012).  
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Figure 1.5: A schematic representing the interaction of the inflammatory 
response, stress hormones and the HPA axis 
Stress - be it psychological or physical causes activation of the stress response. 
Proinflammatory cytokines can be produced in the peripheral system and have 
central nervous system effects, such as activating the HPA axis and instigating a 
stress response - which in itself can modulate the pro inflammatory cytokine 
profile in the periphery. Adapted from (Glaser & Kiecolt-glaser 2005) 
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1.8 Current therapeutic strategies for DMD  
1.8.1 Genetic therapy 
1.8.1.1 Experimental Exon Skipping Therapy 
Exon skipping is a promising genetic strategy which can restore semi-functional 
dystrophin by coding the protein after the nonsense mutation. The use of antisense 
oligonucleotides to induce skipping of the selected exons resulted in some 
restoration of a functional dystrophin protein (Goyenvalle et al. 2004) (see Figure 1.6 
for schematic view of process). However, the practical application of this technique 
has initially been problematic.  
Although this strategy did rescue dystrophin expression for 4 weeks in mdx 
mice in both tibialis anterior and extensor digitorum longus muscles, the effect was 
localised and temporary (Goyenvalle et al. 2004). Restoration of dystrophin 
expression in mdx mice resulted in an immune response to the new protein (Lu et al. 
2003). Moreover, low expression levels were a problem with weekly intra venous 
administration of 2'-O-methyl phosphorothioates inducing dystrophin expression 
only in small areas of the diaphragm, gastrocnemius and intercostal muscles but 
never exceeding more than 5% of normal levels (Lu et al. 2005). 
Nonetheless, optimisations of delivery techniques in the mdx mouse have 
been more promising toward an effective delivery to patients with DMD. Increased 
dystrophin expression was found following both local intramuscular and systemic 
administration using 2-O-methyl-modified bases, which are widely used to alter pre-
mRNA processing (Fletcher et al. 2006). These studies suggest that antisense 
oligoribonucleotides may result in a rescued dystrophin transcription and a 
functional gene being produced. However, dystrophin expression was only induced 
for short periods of time and at very low levels (Fletcher et al. 2006).  
An alternative strategy using recombinant adeno-associated virus vector also 
showed positive effects in mdx mice, restoring muscle function and normal life 
expectancy when given systemically for a year. After 18 weeks of treatment, 
dystrophin was detected in the diaphragms and reduced centralised nuclei were 
detected. A two-fold increase in force producing capacity was also found in treated 
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mice and improved resistance to contraction induced injury (Gregorevic et al. 2006; 
Nakamura & Takeda 2011). 
Another method to induce exon skipping is using unmodified phosphorodiamidate 
morpholino oligomers (PMO); these differ from antisense oligoribonucleotides in 
design and can be transfected into cultured cells with higher efficacy (Lu et al. 
2005). Furthermore, regular weekly intra venous  injections of PMOs targeting 
mouse dystrophin exon 23 induced up to 50% of normal levels of dystrophin in 
body-wide skeletal muscles in the mdx mice, decreased CK levels, improved muscle 
strength significantly and improved muscle pathology (Winter et al. 2009).  
Due to the large percentage of DMD patients (up to 13%) with a nonsense 
mutation in exon 51, this is the most researched method of rescuing dystrophin 
through exon skipping (Lu et al. 2011). In a proof of concept study, four patients 
showed functional expression of dystrophin when given an intramuscular injection 
of antisense oligonucleotide named PRO051, showing this compound of clinical 
relevance (van Deutekom et al. 2007). A study to assess the safety, side effects and 
clinical relevance of systemically administered PRO051, this time by weekly 
subcutaneous injection in 12 patients showed an increase of dystrophin expression 
and few adverse side effects. Furthermore, PRO051 resulted in dystrophin 
expression in 60-100% of muscle fibres in 10 out of the 12 patients. Furthermore, 
this trial also showed modest increase in distance walked after twelve weeks of 
treatment (Goemans et al. 2011) indicating the potential for functional improvement. 
1.8.1.2 Utrophin up regulation 
An alternative strategy rather than trying to replace missing dystrophin would be to 
overexpress the compensatory structural protein, utrophin. Indeed, this strategy has 
been explored both pharmacologically and by using gene therapy. One study 
compared the efficacy of dystrophin versus utrophin in immune-immature neonatal 
mdx mice and concluded that both dystrophin and utrophin were mostly equivalent 
in ameliorating the development of dystrophic characteristic such as muscle necrosis 
and weakness in these neonates (Ebihara et al. 2000). Thus, in immune-competent 
adult mdx mice, up-regulation of utrophin would be a logical approach to genetic 
therapy for DMD. Consistent with this theory, increased utrophin expression in mdx 
mice reduced the numbers of centrally nucleated myofibres and the degree of 
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necrosis (Gilbert et al. 1999). Expression of Ca
2+
 channels, which are associated with 
fibre necrosis, was also normalised but other pathological characteristics remained; 
namely no increase in muscle force production (Squire et al. 2002). Additionally, an 
artificial zinc finger transcription factor to upregulate utrophin at promoter region A 
resulted in lower levels of inflammatory cell infiltration and fewer centralised 
myonuclei (Di Certo et al. 2010). 
Using the compound heregulin which induces up regulation of utrophin, it 
was observed that mdx mice exhibited a reduction in fibre necrosis in extensor 
digitorum longus and tibialis anterior muscles and a significant reduction in 
centralised nuclei, giving some credence to this therapeutic tactic (Krag et al. 2004). 
However, a caveat to these studies are the absence of functional tests such as limb 
grip strength or mobility, specific forces from diaphragm or cardiac muscle to further 
validate utrophin as an adequate replacement for dystrophin. 
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Figure 1.6: Antisense nucleotides as a therapy for DMD 
A – Splicing pre mRNA removes introns. B – in DMD Exon 50 is skipped and a 
premature stop codon is produced. C – When an Antisense Oligonucleotide is 
introduced at exon 51 protein is produced, which can restore some function in 
DMD. 
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1.8.2 Pharmaceutical Interventions targeting inflammation 
in DMD 
1.8.2.1 Corticosteroids 
Steroidal therapies such as prednisolone, prednisone or deflazacort, a derivative of 
prednisolone,  are commonly prescribed for DMD patients and thus far are the only 
efficacious pharmacological intervention shown to slow the progression of the 
disease (Yiu & Kornberg 2008). The mechanisms of action of these drugs have been 
investigated and have demonstrated a metabolic effect of prednisone, slowing 
muscle necrosis in patients (Rifai et al. 1995). In mdx mice myogenic repair was 
enhanced and muscle differentiation was improved by deflazacort (Anderson et al. 
2000). Importantly, prednisone and prednisolone have anti-inflammatory effects in 
mdx mice inducing a reduction in expression of macrophages, CD4
+
 and CD8
+
 T 
lymphocytes (Wehling-Henricks et al. 2004) and eosinophils (Marques et al. 2009) 
in skeletal muscle.  
Functionally, prednisolone increases the specific force of skeletal muscle but 
not muscle function following eccentric contraction injury and had no influence on 
fibre regeneration. Nonetheless, the decline in forelimb grip strength was delayed by 
this treatment and the life expectancy of mdx mice was lengthened (Baltgalvis et al. 
2009), although the mdx mouse does not mimic the shortened life-span to the extent 
a human patient does, therefore it seems this effect is not a directly transferable 
observation. 
Deflazacort can attenuate skeletal muscle pathology, attenuating dystrophic 
phenotype and may act to reduce apoptosis (Lim et al. 2004). A recent study has 
shown that using steroid treatment in long term studies (> 100 days) causes an 
increase in cardiac fibrosis and subsequently is associated with a decrease in cardiac 
health, with similar results in skeletal muscle (Sali et al. 2012). This raises the 
question as to whether mdx mice are an appropriate positive control in long term 
pharmacological studies or if steroidal treatment benefits can “wear off”, or even 
provide detrimental side effects in the longer term. The therapeutic efficacy of 
steroid treatments in DMD is limited, intermittent and is associated with a high 
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occurrence of side effects such as obesity, cataracts and a short stature (Schara & 
Mortier 2001) meaning that better treatment strategies are continually being sought. 
1.8.2.2 Synergistic therapy-steroid co-treatment 
Combination treatment with steroid and various compounds has been an important 
research area of pharmacological interventions for DMD. It is hoped that the 
synergistic effects of combined therapies may reduce dosages of corticosteroids 
required and thereby reduce the occurrence of unwanted side-effects from this 
palliative care. 
Co-administration of arginine butyrate, a butric acid salt of the amino acid 
arginine, with prednisone resulted in a two-fold change in expression of an array of 
genes important in disease progression by controlling inflammation, fibrosis, muscle 
growth and regeneration through several signaling pathways. This was more 
effective than prednisone alone, providing protection against DMD pathology in mdx 
mice (Lim et al. 2004).  
When taurine, an amino acid which can modulate sarcolemmal excitability 
and calcium handling is co-administered with prednisone in mdx mice the 
improvement in forelimb strength in mdx mice was enhanced as compared to either 
treatment alone. The mechanical threshold of the extensor digitorum longus 
myofibres was also improved, although this strategy did not lower CK levels nor 
improve histologically scored skeletal muscle pathology (Cozzoli et al. 2011). 
An alternative strategy examined the importance of nutrition in treatment. A 
combination of four nutritive supplements in addition to steroid treatment 
(prednisone) produced the best overall results in a study investigating the 
effectiveness of creatine monohydrate, conjugated linoleic acid, alpha-linoic acid 
and beta-hydroxyl- methylbutryte in DMD pathology. Grip strength was found to be 
improved in mdx mice whereas muscle fatigue and numbers of centralised myonuclei 
were decreased (Payne et al. 2006). 
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1.8.2.3 Anti-inflammatory and anti-fibrotic reagents 
Several therapeutic strategies tackling the inflammatory aspects of dystrophin 
deficiency have been investigated; thus far the results have been mostly 
disappointing. The precise mechanisms of fibrosis in mdx mice are largely unknown 
but are thought to be due to pro-inflammatory cytokines, and indeed mdx mice have 
raised pro-inflammatory profiles including transforming growth factor β1(TGF β1) 
(Andreetta et al. 2003), IL-6 (Kostek et al. 2012), TNF (Radley et al. 2008) and IL-
1β (Huang et al. 2009). Immunostaining for NFĸB in these fibres was reduced in 
green tea supplemented mdx mice (Grange 2011) and  inhibition of NFĸB improves 
whole body tension development (Siegel et al. 2009). 
Moreover, pyrolidine dithiocarbamate, an inhibitor of NFĸB nuclear 
activation reduced the number of necrotic myofibres in an age-independent manner 
(Carlson et al. 2005). Curcumin, another NFĸB inhibitor improved membrane 
integrity and muscle strength, decreased CK activity and levels of the pro-
inflammatory cytokines, TNF and IL-1 and inducible nitric oxide synthase (iNOS) 
which causes NFĸB mediated inflammation (Pan et al. 2008). 
mdx mice treated with a trimethylated xanthine derivative, Pentoxifylline – 
which had previously reduced TGFβ1 and type 1 collagen in a rat model of biliary 
fibrosis, was not effective in mdx mice nor did it reduce collagen metabolism 
(Gosselin & Williams 2006). Halofuginone which blocks TGFβ, stimulated collagen 
synthesis in four week old mice (Turgeman et al. 2008) and another drug targeting 
TGFβ, Pirfenidone attenuates fibrosis in interstitial pulmonary fibrosis but did not 
display effectiveness in targeting DMD fibrosis (Van Erp et al. 2006).  
Blockade of TNF reduced inflammation over a longer treatment protocol, 
resulted in reduced necrosis, lower CK levels and increased duration of voluntary 
exercise (Radley et al. 2008). Blocking IL-6 was seen to increase inflammation in 
histological sections, contrary to the group’s hypothesis, immunohistochemistry 
found Intercellular Adhesion Molecule 1 (I-CAM1) staining increased also, as 
ICAM1 is expressed where leukocyte infiltration occurs,  but no changes in muscle 
function or other mRNA levels of TNF was found (Kostek et al. 2012).  
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1.9 Conclusions 
Duchenne Muscular Dystrophy is primarily a skeletal muscle wastage disease; 
however from reviewing the literature it is clear it is not only a multi-level but a 
multi system disease, affecting striated muscle, the CNS, vasculature and smooth 
muscle. 
Despite advances in genetic therapies, there is currently no cure for DMD.  
Therefore, developing treatments to slow the progression of the disease or palliative 
care to reduce the suffering of patients is an important area of research in DMD to 
improve quality of life of patients. However, these options so far are limited. But not 
only do these studies go about testing the efficacy of compounds, but they 
importantly provide insight into the specific mechanisms of pathology in DMD, 
furthering the understanding of this disease.   
The mdx mouse model has been utilized to test these interventions pre-
clinically and has proven most useful in gaining knowledge about dystrophin 
deficiency pathology and this is somewhat transferrable to the human disease, 
despite its less severe phenotype. 
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1.10 Thesis Layout and Rationale 
 
 Study One:  Investigating the potential benefits of amitriptyline in treating 
inflammation and mood in mdx mice 
 
 Study Two:  The role of IL-6 and Urocortin 2 in diaphragm dysfunction in 
mdx mice 
 
 Study Three: The role of IL-6 and CRF in gastrointestinal dysfunction in mdx 
mice 
 
 
In the first study (Chapter Three), I studied the efficacy of the tri-cyclic 
antidepressant amitriptyline in reducing inflammation and its effects on potential 
psychological deficits in mdx mice. As discussed in chapter three, amitriptyline’s 
mechanism of action is still to be fully elucidated but it can provide anti-
inflammatory beneficial therapy to a variety of tissues. We were interested in its 
effect on IL-6, a major component of the immune response to muscle damage, 
especially as DMD is an inflammatory disease.  
In studies two and three the physiological benefits of neutralizing IL-6 signaling and 
activating CRFR2 were investigated. In study 2 (Chapter Four) we focused on the 
diaphragm, due to DMD being primarily a skeletal muscle disease and the 
diaphragm most closely relating to the human condition. And, similarly in study 3 
(Chapter Five) the colon of mdx mice was studied due to the apparent dysfunction in 
the smooth muscle and a potential role for IL-6 and CRFR2 agonism in 
inflammatory bowel environments. Each results chapter therefore, has a specific 
hypothesis and aims included. 
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Chapter 2: Methods  
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2.1 Ethical Approval and Animal License 
All animal experiments were approved and performed according to Animal 
Experimentation Ethics Committee (AEEC) regulations by the ethical committee in 
University College Cork (UCC). An animal license was acquired from the 
Department of Health and Children (Personal license number: REF /B100/4229) for 
behavioural testing and intervention studies. 
2.2 Animals 
Dystrophin-deficient C57BL/10ScSn-Dmd
Mdx
/J (mdx, dystrophic) and 
C57BL/10ScSn wild type (WT) controls purchased from Jackson Laboratories (Bar 
Harbor, Maine, U.S.A, http://www.jax.org/) were used for the studies. Breeding 
colonies of both mdx and WT were established and maintained in the Biological 
Services Unit, University College Cork. For the amitriptyline intervention studies 
(Chapter 3) mice were housed in individually ventilated cages (IVCs). The animals 
were moved to filter topped cages (FTCs) shortly before initiation of treatment or 
13-15 days before starting behavioural experiments (untreated groups). For other 
studies (Described in Chapter 4 and 5) mice were housed in FTCs. Weaned mice 
were housed in groups no greater than 4 per cage, and kept under an artificial 
light/dark
 
cycle provided with light between 06:00 and 18:00 hours, with 
 
free access 
to drinking water and standard chow. Regular health screens (see FELASA criteria, 
http://www.felasa.eu/) confirmed that the animals in the IVCs and FTCs were not 
suffering from any infections. Male mice were used for all studies between 6-12 
weeks. 
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2.3 In vivo Studies 
2.3.1 Stress Induced Defecation 
The anxiolytic environment of a brightly-lit exposed cage was used to measure 
stress-induced defecation in control and mdx mice, which acted as a marker of GI 
transit times (Julio-Pieper et al. 2010). Mice were transferred from home cages to 
brightly-lit individual cages (15cm x 13cm x 28cm) lined with absorbent paper and 
the number of faecal boli excreted during a 90 minute period was recorded. Faecal 
pellets were removed at 15 minute intervals and stored to prevent water loss and 
copraphagia. Pellet number per mouse was recorded in 15 minute intervals for a total 
of 90 minutes. Pellets were then weighed to calculate the wet weight and desiccated 
in an oven at 60
 o
C for 16 hours to calculate the dry weight. The water content was 
subsequently calculated as a difference in weight after they were desiccated 
compared to start wet weight.  
 
Equation: 
 
2.3.2 Behavioural Tests 
All behavioural experiments were carried out between 8:00-13:00. Room 
temperature was maintained at 22±1°C. Mice were taken from the holding room to 
the testing room 30 minutes prior to the start of the experiment to allow the time for 
habituation.  
 2.3.2.1 Open Field 
The open-field arena used for assessing anxiety in rodents (Prut & Belzung 2003; 
Dunn et al. 2005) was a brightly illuminated white square chamber measuring 60cm 
x 60cm, with walls of 60cm in height (see Figure 2.1). Mice from different 
experimental groups were tested in a random order.  The open field arena was 
cleaned with water and wiped dry between trials to eradicate scent markings of the 
previous animal. The behaviour of the mice was recorded using a camera (JVC G2-
MG750) positioned 70cm directly above the open field box. The floor of the square 
100 × (wet weight − dry weight) ÷ wet weight 
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open field was marked by an internal square of 30 cm length, and four transversing 
lines from the walls to the internal square (see Figure 2.1).  
 
Each trial was ten minutes in duration. On initiation of the trial mice were placed in 
the centre of the open field arena and behaviours were observed and recorded for the 
duration of the trial. Behaviours were scored through post-test offline analysis using 
the video recordings by the same researcher. 
 Behaviours assessed included:  
 time spent in the central square versus peripheral square,  
 degree of ambulation (number of lines crossed by the mouse),  
 rearing (number of times the mouse stood completely erect on its hind legs) 
 grooming (number of times the mouse scratched its face and fur with its 
forepaws). 
These behaviours are recognised indicators of anxiety, as discussed in chapter 3, 
which can be modified by anxiolytic pharmacological reagents (Prut & Belzung 
2003; Choleris et al. 2001). 
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2.3.2.2 Novel Object Recognition (NOR) Test 
NOR tests are used to test recognition memory in rodents (Antunes & Biala 2012). 
NOR tests were also performed in the open field arena, 24 hours after the open field 
test (trial 1). The second trial (trial 2) in the NOR test, to assess whether the animal 
remembered something it had encountered in trial 1, took place 24 hours later. 
Exploration of an object was defined as follows: directing the nose to the object at a 
distance of no more than 2 cm, sniffing the object and/or touching the object with the 
nose, sitting on the object was also considered as exploratory behaviour. The time 
spent exploring each object was recorded and analysed using the video footage later.  
Initially, a cylindrical multicoloured solid object on the left (height 10cm, diameter 
6.5cm) and a yellow square Lego® brick (10.2cm, 6.2cm x 6.2cm, height x width x 
length ) on the right (Figure 2.2) were present in the arena. The objects could not be 
displaced by a mouse. Twenty four hours later one of the items (the cylinder) was 
exchanged for a spiny blue rubber ball on a solid base (height 11.9cm, diameter 
9.3cm plus blunt spines of 2.7cm). The behaviour of the mice towards this new 
object was recorded and analysed a later time point. In order to avoid the presence of 
olfactory trails the objects were always thoroughly cleaned after each mouse. 
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  TRIAL 1 - Cylinder and Lego Block      TRIAL 2 -Blue Ball replaces Cylinder 
 
 
 
 
 
 
  
Figure 2.1: A diagram detailing the dimensions of the open field arena 
Figure 2.2:  Novel Object Recognition Test still images from video recording 
of trial 
 The cylinder is replaced in trial 1 with a blue ball for trial two. The yellow Lego 
block does not change between trials. 
Height 60 cm 
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2.3.2.3 Tail Suspension Test  
This test permits assessment of depressive symptoms in rodents and has been used to 
test the effectiveness of anti-depressant reagents (Steru et al. 1985).  Mice were 
suspended by the tail, using adhesive Scotch tape to a flat surface. The behaviour of 
the mice was recorded using a camera which was positioned 70cm in front of the 
mouse. The duration of the test was 6 minutes long, the final 4 minutes of the test 
were analysed, giving a habituation time for mice in the test, as per previous 
protocols (Cryan et al. 2005). The total sum period of immobility (duration of 
immobility) and latency to first period of immobility are measured for each mouse. 
 
2.4 Collecting and Processing Tissue 
Mice were sacrificed by isoflurane anaesthesia (5% in oxygen) and cervical 
dislocation. Trunk blood was collected following decapitation in eppendorf tubes 
coated with ethylenediaminetetraacetic acid (EDTA) to prevent coagulation and 
subsequently centrifuged at 1600g for 10 minutes. The plasma supernatants were 
removed and snap frozen in liquid nitrogen and stored at -80°C for future Enzyme 
Linked Immunosorbant Assay (ELISA) analysis.  
Brain regions of mice were dissected out and the prefrontal cortex, amygdala, 
hypothalamus, hippocampus, striatum and midbrain were micro dissected and snap 
frozen in iso-pentane, a cryo-protectant and stored at -80°C. A midline incision 
through the abdomen was performed and the diaphragm and colon tissue was 
removed, snap frozen in liquid nitrogen and stored at -80°C or kept in oxygenated 
Krebs’ physiological saline solution ((Krebs) Table 2.12) for functional studies. The 
right forelimb and distal colon sections were removed and stored in 4% 
paraformaldehyde at 4
o
C
 
for histological examination of tissues.   
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2.4.1 Histology 
2.4.1.1 Skeletal Muscle 
Muscle samples were dehydrated (50% ethanol, 70% ethanol, 95% ethanol, 30 
minutes each) and then placed in 100% ethanol (60 minutes x3) and the tissue was 
then cleared in a 1:1 ratio of 100% ethanol to xylene (30 minutes) and xylene (30 
minutes and 120 minutes) (Leica TP1020, Histokinet). The tissue was embedded in 
paraffin (Sakura Tissue-Tek TEC, Histolab Histowax embedding medium) in a pre-
programmed Histokinet and cross sections (10μm) were sliced using a microtome 
(Leica RM2135) and allowed to dry (overnight, 37°C) on gelatin-coated glass slides.  
2.4.1.2 Colon 
After sacrifice, full colon length from anus to caecum were extracted and measured 
to the nearest millimetre. Next, excised pieces of colon approximately 1cm from the 
anus were taken, placed in 4% paraformaldehyde for 24 hours, then transferred to 
30% sucrose in order to cryo-protect the tissue and subsequently stored at  -80
o
C 
until they were cryo-sectioned (CM1850, Leica) at 10µm thickness in preparation or 
Haematoxylin & Eosin (H&E) staining. 
Haematoxylin & Eosin Staining 
Slides were equilibrated to room temperature and washed in phosphate buffered 
saline (PBS) (Table 2.1) for five minutes then stained in Harris Haematoxylin (Table 
2.1) for four minutes washed in running water for five minutes then stained in 1% 
eosin (aqueous) for one minute and washed in water until slide is clear. The slides 
were then dehydrated in a series of alcohols (70% ethanol, 95% ethanol, 100% 
ethanol and 100% ethanol), immersed in xylene and cover slipped using a mounting 
medium (PVA-DAPCO, Sigma Aldrich), air-dried and visualised on a bright-field 
Olympus Proxis AX70 upright microscope with an Olympus DP50 camera.  
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Phosphate Buffered Saline  
NaCl 8g 
KCl 0.2g 
Na2HPO4 1.44g 
KH2PO4 2.44g 
up to 500mls dH20  
 
Harris' Hematoxylin Recipe 
 
Aluminium Potassium Sulphate 50g 
Hematoxylin 1g 
Sodium Iodate 0.2g 
Glacial Acetic Acid 20ml 
up to 1 litre of dH20  
Table 2.1: PBS and Harris’ Haematoxylin Recipe 
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2.4.2 Imaging Techniques 
2.4.2.1 Skeletal Muscle 
Transverse sections were cut through the belly of the muscle and altogether, 28 
images per section of H&E stained muscle per mouse were taken. Sections starting at 
a random point in the muscle and at systemic intervals 1mm away in a cross from 
this centre point were imaged. Muscle pathology was scored using Image J software 
(Abràmoff et al. 2004) by analysing both frequency and  total area of inflammation 
as identified by myo-phagocytosis of mononuclear cells (Figure 2.3), the number of 
central nuclei (central nuclei defined as nuclei located within a fibre) were scored 
and total number of nuclei were counted (muscle pathology in Figure 3.5). 
  
Figure 2.3: Representative image of the technique used to score striated skeletal 
muscle for myo-phagocytosis 
 Muscle was scored for inflammation and pathological changes using Image J software. 
Inflammatory events (as above), muscle fibre area, muscle fibre number, nuclei and 
central nuclei were counted and measured using Image J. 
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2.4.2.2 Colon 
Colons were cut transversely in 10μm sections, 40μms apart with 5 sections per 
colon on gelatin coated slides. Following H&E staining images of the sections were 
taken using an Olympus Proxis AX70 upright bright-field microscope equipped with 
an Olympus DP50 camera using the x10 objective lens and sections were 
subsequently analysed for differences in mucosal and muscle thickness (the mean 
taken from three measurements, Figure 2.4).  
 
 
 
 
  
Figure 2.4:  Representative image of colon scored for muscle layer thickness 
 Muscle layer thickness using Image J software. Similarly mucosal thickness was measured 
and total diameter. Three measurements were taken for each image and averaged. 
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2.5 Biochemical Analysis 
2.5.1 Protein Quantification 
To determine protein expression  in Extensor Digitorum Longus (EDL) muscle, 
diaphragm and whole colon, these tissues were prepared for Western blotting by 
homogenisation in 200µl Lysis buffer (Table 2.2) with added protease inhibitor (2µl, 
Expedeon). Samples were homogenised mechanically (OMNI GLH, General 
Laboratory Homogenizer) for 10 seconds and centrifuged (Boeco Germany, U-
320R) at 19,000g for 20 minutes at 4
o
C
.
 Supernatant was collected and diluted 1:100 
in deionised water (dH20) and a Bradford assay was carried out. Bradford protein 
quantification is a colorimetric assay which measures the shift in absorbance of 
Commasie Brilliant Blue G-250 (Bradford 1976). The concentration of protein was 
extrapolated in each sample from a standard curve of protein (Bovine serum albumin 
(BSA) ranging from 1µg/ml to 100µg/ml, Table 2.3) diluted in deionised water. 
Absorbance was read at 595nm on a spectrophotometer (Molecular Devices, 
SpectraMax M3, USA) and the concentration of protein was determined by SoftMax 
Pro 6 software package. 
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BSA Standard Protocol  
From 1mg/ml stock dH20 Concentration 
1µl 999µl 1µg 
5µl 995µl 5µg 
10µl 990µl 10µg 
15µl 985µl 15µg 
20µl 980µl 20µg 
25µl 975µl 25µg 
50µl 950µl 50µg 
100µl 900µl 100µg 
 
  
Lysis Buffer Final Concentration 
HEPES 10mM 
KCl 10mM 
EGTA 0.1mM 
EDTA 0.1mM 
Triton X-100 (v/v) 0.06%  
Table 2.2:  Lysis Buffer Recipe 
 
Table 2.3: Bradford Assay Standard Curve dilutions of Bovine Serum Albumin 
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Transfer Buffer   
Tris Base 23mM 
Glycine 192mM 
SDS 0.01% 
In 20% Methanol  
Running Buffer  
Tris Base 23mM 
Glycine 192mM 
SDS 0.01% 
Table 2.4 and 2.5: Running and Transfer Buffer Recipe for Western Blot 
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2.5.2 Enzyme Linked Immunosorbent Assay (ELISA) 
2.5.2.1 Muscle Homogenate 
An ELISA was performed on homogenised right forelimb flexor muscle samples of 
known total protein concentration after completion of a Bradford protein assay. An 
ELISA was performed as follows (per manufacturer’s instructions, eBioscience). 
A standard curve was prepared using a serial dilution of standard IL-6 protein 
supplied with the kit (0 pg/ml, assay diluent as blank, to 500pg/ml), a 96 well plate 
was pre coated with primary antibody over night at 4°C. It was subsequently washed 
5 times with wash buffer (PBS-Tween (0.5%, v/v)) and the wells were blocked for 1 
hour with assay diluent. Samples were then added and incubated overnight at 4°C, 
followed by 5 washes with PBS-Tween and the detection antibody, which was added 
for 1 hour at room temperature. After 5 washes of PBS-Tween, Avidin-HRP was 
incubated for 30 minutes, followed by additional washes and the substrate solution, 
which was added for 5 minutes. The reaction was then stopped with 2M sulphuric 
acid (H2SO4).  
The ELISA plate was read at 595nm using a multi well spectrophotometer 
(Molecular Devices, SpectraMax M3, USA). The standard curve was obtained using 
GraphPad Prism software and each sample concentration was calculated from the 
standard curve.  
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Colour Change 
Avidin-HRP 
Biotinylated 2º 
Figure 2.5:  Schematic of an 
Enzyme Linked Immunosorbent 
Assay in a 96 well plate well  
Primary antibody coats the bottom 
of the well, sample is added 
including protein of interest which 
binds to its specific primary 
antibody, a biotinylated secondary 
antibody binds to the protein of 
interest, Avidin-HRP is added, 
causing a colour change, which is 
read on a spectrophotometer at 
595nm.  
Interleukin - 6 
Plate coated in 1º 
Figure 2.5: Key 
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2.5.3 Western Blot 
Supernatant samples of known protein concentration were prepared for Western blot 
analysis using sample buffer (Expedeon, Run Blue LDS, Sample buffer). Sodium 
dodecyl sulfate (SDS) page gels were prepared using a resolving gel (Table 2.7) and 
a stacking gel (Table 2.8) which were loaded in a western blot upright tank (Pierce, 
Thermo Scientific) containing running buffer (Table 2.4). Five samples from each 
group were run on a gel with a molecular weight marker ladder (RunBlue prestained 
marker, Expedeon) on each gel for 90 minutes at 100 volts. In the same tank, gels 
were transferred to polyvinylidene fluoride (PVDF) membranes (2μm, Pierce 
Thermo Scientific) in transfer buffer (Table 2.5) for ninety minutes at 100 volts, 4°C. 
Membranes were stored in PBS until probed with specific antibodies (Table 2.6). 
Membranes were incubated in 5% blocking milk made up in PBS-T (Triton-X 
(0.05%) for 1 hour at room temperature and incubated with specific antibodies (anti 
IL-6, anti IL-6 receptors or anti- Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), see Table 2.6) in 2% milk overnight at 4
o
C. Washes were performed for 
ten minutes three times with PBS and secondary antibodies conjugated to hydrogen 
peroxidase conjugated secondary antibody for 1 hour room temperature. The labelled 
membranes were subsequently exposed to Enhanced Chemiluminescence (ECL) 
reagent in a 1:1 ratio of solution A and solution B (as per manufacturer’s 
instructions, Aftersham ECL prime Western Blot Detection Reagent, GE Healthcare 
Life Sciences) incubated and the membrane exposed to X-ray film (CL-Xposure 
Film, Thermo Scientific), (Figure 2.5). 
 The ubiquitously expressed protein identified on the same membrane acts as a 
reference protein and loading control for each run. Protein band densitometry was 
quantified using Image J software analysis and expression of the protein of interest 
was express as a ratio of the GAPDH expression per lane, therefore histograms are 
expressed as mean relative expression of protein of interest (IL-6 or IL6R) as a ratio 
of total GAPDH in each sample. 
See appendix for optimisation images. 
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PVDF membrane containing gel 
electrophoresis separated 
immobilized proteins 
Target protein binds specific 
primary antibody 
Which then binds to a HRP 
conjugated antibody 
ECL binds to the HRP and 
causes an emission of light, 
which can be captured using x-
ray film 
Molecular 
Weight 
Marker 
Figure 2.5:  Schematic of a PVDF 
membrane containing immobilised 
proteins which have been separated by 
electrophoresis 
 
A molecular marker aids in the 
determination of the molecular weight of 
a protein.  
A primary antibody specifically binds to 
the protein of interest, the HRP-
conjugated secondary antibody binds to 
the primary antibody and when ECL is 
added the light emitted can be detected 
on x-ray film. 
Figure Legend 
53 
 
 
 
 
  
Blocking solution     
Non-fat skimmed milk (w/v)  5%   
Tween-20 (v/v)  1%   
made in PBS     
     
Primary Antibodies Host Dilution  Duration Temperature 
Anti-IL-6 Rabbit 1 in 500  16 hours 4°C 
Anti-IL-6 receptor Goat 1 in 1000  16 hours 4°C 
Anti- GAPDH Mouse 1 in 20,000  16 hours 4°C 
Secondary Antibody      
Anti Rabbit Goat 1 in 2000  1 hour Room Temperature 
Anti Goat Rabbit 1 in 5000  1 hour Room Temperature 
Anti Mouse Goat 1 in 100,000  1 hour Room Temperature 
Table 2.6:  Table of antibodies used in Western Blot Technique including 
host animal, dilution and incubation time and temperature and blocking 
solution. 
54 
 
 
 
  
Resolving Gel 12%  
Bis-Acrylamide 30% 3ml 
dH20 2.45ml 
SDS 75µl 
Tris HCl (1M) 1.9ml 
TEMED 4µl 
APS 75µl 
Stacking Gel 5%  
Bis-Acrylamide 30% 500µl 
dH20 2.05ml 
SDS 30µl 
Tris HCl (2M) 375µl 
TEMED 4µl 
APS 100µl 
Table 2.7 and 2.8: Resolving and Stacking Gel Recipe 
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2.6 High Performance Liquid Chromatography (HPLC) 
Monoamine detection from brain areas 
HPLC is a technique which separates, identifies and quantifies a solute dissolved in a 
solvent. Standards of the proteins of interest peaks and retention time are used as a 
reference to quantify specific matching responses and are used to quantify the 
proteins. Snap frozen dissected brain regions (hypothalamus, prefrontal cortex, 
hippocampus, amygdala, midbrain, striatum) from WT and mdx mice, along with 
saline- and amitriptyline treated mdxmice were weighed and added to HPLC buffer 
(Table 2.9) in eppendorf tubes. These were kept on ice, and were sonicated 
(Sonoplus HD 2070, Bandelin) for two seconds. These sonicated samples were 
centrifuged (Mikro 22 R refrigerated centrifuge) at 19,000g for twenty minutes. 
300µl of supernatant were loaded into glass vials and placed in a pre-determined 
pattern with standards in the first positions, after half the samples and at the last 
position in the HPLC machine (SCL 10-Avp system controller, LC-10AS pump, 
SIL-10A auto injector, CTO-10A oven, LECD 6A electrochemical detector, 
Shimadzu).  
The chromatograms were processed using the Class 5-VP software using an equation 
to quantify the monoamines and metabolites with appropriate standards (Table 2.10). 
The peak heights of each monoamine in the samples were then entered into an excel 
spreadsheet where the sample concentrations in ng/g of tissue were calculated (Table 
2.11). 
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HPLC buffer  g/4l 
Citric Acid  84.056 
Sodium Dihydrogen Phosphate  55.196 
1-Octane sulfonic Acid  1.211 
EDTA disodium salt  0.1488 
with the addition of   
Methanol  400ml 
N Methyl 5 HT  2ng/20µl 
Table 2.9: HPLC Buffer Recipe 
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Amine mg/10ml 
NA (Noradrenaline, Norepeinephrine, Arterenol bitartrate Hydrate) 18.75 
L-Dopa (3,4 Diyhdroxy-L-tryptophan, L-3,4-Dihydroxyphenylalanine) 10 
DOPAC (3,4 Dihydroxyphenyl Acetic Acid) 10 
DA (Dopamine, Dopamine Hydrochloride, 3-Hydroxytyramine HCL) 12.38 
5HIAA ( 5-Hydroxy Indole-3-Acetic acid) 10 
HVA (Homovanillic acid, 4-Hydroxy-3 Methoxy Phenylacetic acid) 10 
5-HT (Serotonin, 5-Hydroxytryptamine creatinine Sulfate) 22 
Internal Standard, N-Methyl 5-HT ( N-Methy-5-Hydroxy-tryptamine Oxalate salt) 14.7 
Table 2.10: HPLC Internal Standards 
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(PHsample/PHIS, sample)xA stdm/Ai sm x AIS Sx1000x1000= A unk 
         PH standard/PH IS, standard                                         20        W 
 
 
PH sample   Peak Height of Amine in sample 
PH IS, sample   Peak Height of Internal standard in sample 
A stdm   Amount of amine in standard mix (ng/20ml) = 2 
AISm   Amount of Internal std in standard mix (ng/20ml) = 2 
AISS   Amount of Internal Std in sample (ng/20ml) = 2 
Aunk   Amount of Amine in sample (ng/g of tissue) 
PHstandard   Peak Height of Amine in standard mix 
PHIS,Standard  Peak Height of Internal standard in standard mix. 
W  Weight of tissue (mg) 
 
 
Table 2.11: Equation and Legend to determine Aunk, Amount of Amine in 
sample (ng/g of tissue) 
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2.7 Organ Baths 
2.7.1 Colon Organ Baths 
Excised colons, with faecal pellets carefully washed out, were transferred to ice cold 
Krebs’ saline. Organ baths consisted of a vertical 25 ml bath attached to a transducer 
which recorded isotonic contractions (PowerLab 2/25) and software (Chart 5 for 
Windows) at 37
 o
C. The transducer was calibrated using a one gram weight and 
tissue equilibrated for 20 minutes (as per Figure 2.6). One centimetre lengths were 
tied to both ends using cotton thread. Solutions were added to the bath containing the 
colon and between each addition the muscle and bath was washed with Krebs’ 
except after addition of Tetrodotoxin (TTX). Basal levels were measured as the 
millivolt (mV) recording just before the addition of any compound and amplitude 
change recorded as the change in this baseline to peak height in the twenty minute 
period. The frequency of contractions was also measured. 
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Krebs' Physiological Solution  
Monosodium Phosphate  1.2 mM 
Sodium Chloride  117mM 
Potassium Chloride  4.8 mM 
Magnesium Chloride  12mM 
Sodium Bicarbonate 25mM 
Calcium Chloride 2.5mM 
Glucose 11mM 
Table 2.12: Krebs’ Physiological Solution 
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Addition of 
compounds 
Force Transducer Recording tension 
changes in colon preparation 
Carbogen Bubbled Krebs Solution 
Colon Preparation 
attached to static hook at 
the bottom of the prep 
and a force transducer at 
the top 
Water Jacketed bath 
keeping Krebs at a 
constant 
physiological 
temperature 
Force Transducer 
Recording 
Contractions of 
colon preparation 
Computer 
generated traces in 
changes in tension 
in mV 
Figure 2.7:  Schematic of the colon organ bath set-up 
A water jacketed bath filled with Krebs solution is bubbled with Carbogen (95% 
O2/5% CO2). The colon preparation is tied to a static hook at the bottom and 
attached to a force transducer at the top with non-elastic thread. This force 
transducer generated a trace showing contractions in mV. 
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2.7.2 Diaphragm Organ Baths 
A 3mm strip of diaphragm was dissected with central tendon attached and extending 
to a rib. Cotton thread was tied to the central tendon and hung vertically in a tissue 
bath (as per Figure 2.9) with aerated Krebs solution at 37
 º
C, the rib was tied to a 
hook in order to record isotonic and isometric contractions in this muscle. The 
muscle strip was equilibrated for 20 minutes. 
A dual-mode force transducer (Aurora Scientific Inc.) was used to measure 
performance, which could hold the force or length, depending on requirements in 
each test. Electrical stimulation of the diaphragm strips was obtained through the use 
of two metal electrodes running vertically on either side of the diaphragm strip. 
Using ASI Dynamic Muscle Control (v5.300) software, the optimum length (LO, 
muscle length producing maximal isometric twitch force in response to supra-
maximal stimulation) was determined by incrementally adjusting the micropositioner 
between intermittent stimulations and tetanic stimulations (100Hz). Once 
determined, the muscle remained at this length for the full protocol. Next the muscle 
was allowed a ten minute equilibration period. A protocol as performed as timeline 
below (Figure 2.8). 
  
1o mins 
Tetanic 
Twitch 
Load “Step test” Equilibrate 
Repeated 
Stimulation 
Rest 
Dry diaphragm strip 
Weigh 
Figure 2.8: Protocol for diaphragm organ bath 
Following a 20 minute equilibration time at 37°C, a twitch was elicited at supra maximal 
stimulation and optimal length was determined. Next tetanic force was measured. The 
transducer was then used in an isotonic set up, to record muscle shortening at increments 
of total force for a “step” test. A repeated stimulation at 33% of total force was 
performed. The muscle strip was then left to dry and was weighed to determine the cross 
sectional area for analysis. 
63 
 
Holding the force transducer static, force was recorded in milli Newtons. A single 
isometric twitch force, contraction time, half-relaxation time and performance during 
repeated stimulation were then determined in response to electrical field stimulation.  
First, a single twitch was elicited (supra-maximal voltage, 1 ms duration).  
Twitch force, contraction time (time to peak force) and half-relaxation time (time for 
peak force to decay by 50%) and peak tetanic force were determined post-test using 
ASI 611A Dynamic Muscle Analysis (v5.100).  
Force was normalised to cross sectional area (CSA), density of muscle (1.06kg/L) is 
a constant.  
CSA= Muscle weight (grams)/Optimal length (cm)*density of muscle  
Shortening velocity was recorded from the first detectable length change in the strip 
for duration of 30ms.  
Work was calculated as the product of isotonic afterload and the amount of maximal 
shortening.  
Power was calculated as a product of isotonic afterload and shortening velocity.  
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Dual - Mode Force Transducer  
Electrodes to stimulate diaphragm  
Figure 2.9: Schematic of the diaphragm organ bath set-up 
Similar to the colon organ bath, water jacketed bath filled with Krebs solution is 
bubbled with Carbogen. The diaphragm preparation is tied to a static hook at the 
bottom and attached to a force transducer at the top with non-elastic thread. A 
computer generated trace is recorded in milli Newton and millimetre. Different 
from the colon set-up, two electrodes flank the preparation to stimulate the 
muscle. The force transducer can remain static to record isometric contraction or 
set at increments of stiffness to record contractions of the diaphragm strip. 
Bi-Phase Stimulator   
Dual-Mode 
Level System   
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2.8 Statistical Analysis of Data 
N numbers for each experimental group were decided using power calculations 
based on previous studies in our laboratory and studies in the literature. The 
minimum number of animals were used to garner data that would predict 
significance at the p<0.05 level. Unless stated otherwise, Graph Pad Prism was used 
to perform statistical analysis. Student’s t- test was performed between two groups, 
one way ANOVA or two-way ANOVA were performed between multiple groups 
and appropriate post-hoc tests were used to compare between groups. Statistical 
significance illustrated as *p<0.05, **p<0.01, ***p<0.001, ns not significant. 
2.9 Reagents 
Anti IL-6 receptor antibody (MR16-1) used in the intervention study (Study 2 & 3) 
was a kind gift from Chugai Pharmaceuticals Ltd., Tokyo, Japan. All other reagents 
were purchased commercially from Sigma Aldrich, Fischer Scientific or as stated in 
the text. 
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Chapter 3: Investigating the 
potential benefits of amitriptyline 
in treating inflammation and 
mood in mdx mice 
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3.1 Introduction 
3.1.1 Mood Disorders in Duchenne Muscular Dystrophy 
Although largely under-diagnosed, there is some evidence for mood disorders in 
DMD and in other muscular dystrophy. Patients have a low grade but persistent 
depression compared to age-matched healthy controls patients (Fitzpatrick et al. 
1986). However, understanding the aetiology or cause of these depressive symptoms 
in DMD has largely been overlooked as the more severe symptoms of DMD take 
priority such as progressive tissue inflammation and loss of function. Indeed, this is 
the most prevalent and chronic feature of the disease (Evans et al. 2009), but given 
the well-reported co-morbidity of depression in other inflammatory diseases, it is 
perhaps not that surprising that depression is also prevalent in DMD patients 
(Fitzpatrick et al. 1986; Bothwell et al. 2002; Abresch et al. 1998).  
Stress is known to directly contribute to inflammatory diseases, through increased 
secretion and activation of cytokines and by increasing numbers of leukocytes, 
natural killer cells and CD8+ T-lymphocytes and decreasing the numbers of B 
lymphocytes (Maes 2008; Connor & Leonard 1998) In contrast, the increased 
secretion of glucocorticoids characteristic of chronic stress (from the adrenal glands 
in response to cortisol is associated with decreased secretion of pro-inflammatory 
cytokines) and immunosuppression (Herbert and Cohen, 1993; Leonard, 2001; 
Raison and Miller, 2001). Recent interest in the connection between DMD 
pathophysiology and stress reveals a connection between sympathetic nervous 
system dysfunction and stress disorders in patients (Sabharwal 2014). Thus, like in 
other inflammatory diseases, regulating inflammation in DMD may have additional 
positive therapeutic effects on mood. Conversely, tackling depression and mood 
disorders in DMD  may have be beneficial in the regulation of inflammation (Du et 
al. 2013; Venihaki et al. 2001; Gerber & Bale 2012; Vallières & Rivest 1999). 
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3.1.2 Amitriptyline as a potential pluripotent anti-
depressant 
Amitriptyline is classified as a tricyclic antidepressant (TCA), with a wide range of 
pharmacological actions (Inglis et al. 1963), including anti-oxidant (Leduc et al. 
2002), anti-inflammatory (Achar et al. 2009) and anti-nociceptive effects (Abdel-
Salam et al. 2003), although full pharmacological profile and mode of action of 
amitriptyline is not completely understood. That said, the anti-depressant effects of 
amitriptyline are attributed to its affinity for receptor sites for noradrenaline and 
serotonin, inhibiting noradrenaline- and increasing serotonin (Giuseppe et al. 2007) 
reuptake at synapses. Along with other TCAs, amitriptyline is commonly used to 
treat chronic pain disorders including neuropathic and inflammatory pain (Abdel-
Salam et al. 2003). Studies have shown that amitriptyline attenuates pain in 
inflammatory and neuropathic pain in rats, especially when combined with opiates 
(Tai et al. 2006). Furthermore, in a model of tubule interstitial renal fibrosis and 
inflammation it decreases inflammation and slows the progression of fibrosis (Achar 
et al. 2009).  
Although TCAs have largely been replaced by newer antidepressants with fewer 
side-effects, the therapeutic characteristics of amitriptyline may have potential 
benefits in treating mood disorders and inflammation in DMD. Indeed, TCA’s seem 
to be more effective than the corticosteroid, prednisone in preventing muscle loss in 
a C. elegans model of dystrophin-dependent degeneration (Carre-Pierrat et al. 2011).  
Moreover, a recent investigation demonstrated that TCAs such as amitriptyline have 
beneficial effects on muscle function in mdx mice (Carre-Pierrat et al. 2011).  
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3.1.3 Hypothesis 
 
We hypothesise that depression in DMD is contributed to by inflammatory 
molecules which result in the dysregulation of the HPA axis. Thus, the TCA with 
anti-inflammatory actions amitriptyline is a promising candidate for treating 
symptoms in DMD. 
 
3.1.4 Specific Study Aims 
 
 To characterise the behavioural phenotype of the mdx mouse model of DMD and 
investigate the effects of amitriptyline on these behaviours. 
 
 Investigate changes in amine levels in the brain associated with mood disorders 
following amitriptyline treatment. 
 
 To examine the effects of amitriptyline treatment on skeletal muscle pathology 
and inflammation in the mdx mice. 
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3.2 Methods 
3.2.1 Animals and experimental design 
Male C57BL/10ScSn (wild-type (WT) control) and C57BL/10ScSn-mdx/J
 
(mdx, 
dystrophin deficient) mice (20g to 25g body weight) were
 
randomly assigned to the 
following groups: untreated WT versus untreated mdx and saline-treated mdx versus 
amitriptyline-treated mdx mice (Table 3.1).
 
Mice were administered one 
subcutaneous injection of amitriptyline (10 mg/kg body weight) or saline (0.9% 
NaCl) each day for 25 consecutive days.   
 
 
 
 
 
 
 
 
 
 
Groups 
 
Treatment  
 Untreated  Saline Amitriptyline 
C57/BL/10ScSn WT 10 7 7 
C57Bl/10ScSnDmdmdx/J(mdx) 10 7 7 
Table 3.1 Treatment groups and timeline 
 
The timeline illustrates the experimental protocol for comparing treatment with 
amitriptyline or saline in a number of behavioural tests including the open field 
arena, the novel object recognition test and the tail suspension test. 
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3.2.2 Techniques 
Open Field (chapter section 2.3.2.1) 
Novel Object Recognition Test (chapter section 2.3.2.2) 
Tail Suspension Test (chapter section 2.3.2.3) 
Collecting Tissue and Blood (chapter section 2.3.2.3) 
Mice were sacrificed 3 days after the last behavioural test by isofluorane anaesthesia 
and cervical dislocation. Brains were taken and prefrontal cortex, hypothalamus, 
striatum, hippocampus, amygdala were dissected out and stored at -80°C until HPLC 
was performed from WT and mdx mice treated with saline or amitriptyline. 
 Right Extensor Digitorum Longus (EDL) was dissected out and snap frozen for IL-6 
quantification. Left EDL was immersed in 4% PFA and processed for histology. 
Histology (chapter section 2.4.2.1) 
Paraffin embedded skeletal EDL muscles from untreated WT and mdx mice and 
amitriptyline and saline treated mdx mice were sectioned and stained with H & E as 
previously described in the methods section. Pathological markers such as 
percentage of centralised nuclei and infiltration of inflammatory cells within and 
between fibres were scored. 
Protein Quantification (chapter section 2.5.1) 
EDL muscle from WT and mdx mice was homogenised and protein was extracted for 
ELISA (as detailed in section 2.5.2.1) and HPLC (as detailed in section 2.6) analysis.  
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3.3 Results 
Part 1: Assessing mdx behaviours and skeletal 
inflammation 
 
3.3.1 Behavioral phenotype of mdx mice 
3.3.1.1 Anxiety behaviours 
Given rodent’s natural tendency to avoid bright open spaces combined with its 
instinct to explore new environments, the brightly-lit, exposed open field arena is a 
useful tool to measure anxiety-like behaviours between different strains or following 
therapeutic interventions in mice. Thus, comparably more time spent in the corners 
or edges of the arena are indicative of increased anxiety. Offline analysis of the 10 
minute trial found that mdx mice (81.5±10.06, n=10) spent less time in the centre 
than WT mice (100.6±6, n=7, p<0.05) in the first five minutes of the trial (Figure 
3.1iv). Similarly, mdx mice (70.2±5.6) spent less time in the centre compared to WT 
mice (74±6.1, p<0.05) in the second five minutes of the trial (Figure 3.1v) and 
indeed, overall, mdx mice spent  less time exploring the centre of the arena than WT 
control animals (p<0.05) (Figure 3.1vi). No differences were noted in the incidence 
of grooming, but differences were found in total time spent grooming (Figure 1i), 
which can also be indicators of anxiety (Maes et al. 2012).  
As loss of dystrophin is associated with loss of muscle function I examined 
ambulatory activity in the mdx mice to ensure that the apparent anxiety-like 
phenotype was not in fact due to impaired motor function. Thus, in the demarcated 
open field arena (Figure 2.1, methods chapter) the ambulatory activity of the mdx 
and WT mice was scored as the number of total crossings across each line. No 
differences in the number of crossings were apparent between the mdx (26.5±5, 
n=10) and WT (42.2±3.1, n=9, p>0.05) mice in the first five minutes (Figure 3.1i), 
the second 5 minutes between mdx (37.5±3.1, n=9) and WT (51.4±7.8, n=10, 
p>0.05) (Figure 3.1ii) or indeed, over the combined 10 minutes (Figure 3.1iii, 
p>0.05). A time trial of ambulation was also undertaken in one minute intervals and 
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no differences were found suggesting that the capacity to move and explore was not 
hindered in the mdx mouse at the time point examined. 
74 
 
  
Total Crossing 0 - 5 minutes
WT Mdx
0
50
100
150
200
S
ec
o
n
d
s
Total Crossing 5 - 10 minutes
WT Mdx
0
50
100
150
200
Total Crossing
WT Mdx
0
50
100
150
200
Time in Centre 5 - 10 minutes
WT Mdx
0
50
100
150
*
Total Time in  Centre
WT Mdx
0
50
100
150
**
Time in Centre 0 - 5 minutes
WT Mdx
0
50
100
150
*S
ec
o
n
d
s
Figure 3.1: Open Field Behavioural Analysis 
Student’s t tests results of locomotor activity assessed by time spent transversing lines in the 
arena in the first 5 minutes (i), second 5 minutes (ii) and total time (iii). Histograms (iv) 
illustrate the time spent exploring the centre of the arena in the first five minutes and in the 
second 5 minutes (v) and total time (vi). n=10, *p<0.05, **p<0.01 
i ii iii 
iv v vi 
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Figure 3.2: Open Field Behavioural Analysis 
 The histograms illustrate grooming behaviour in the first 5 minutes (i), second 5 
minutes (ii) and total time spent grooming (iii) during the open field trial. The incidences 
of grooming behaviour in the first (iv) and second 5 minutes (v) and total time (vi) of the 
trial are shown in the histograms. n=10, * p<0.05 
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3.3.1.2 Mdx mice and WT mice explore a novel object for 
comparable time in the NOR test 
The NOR test is used to assess learning and recognition memory in rodents (Antunes 
& Biala 2012). The time spent exploring the new object, which was only presented 
on day 2 in comparison to the  object consistently present on day 1 and 2 as a 
percentage of total exploration of both objects was comparable between  mdx mice  
and WT mice  (Figure 3.3,  n=10, p>0.05). 
3.3.1.3 Mdx mice exhibit depressive like-behaviour 
In the tail suspension test, which is an established test to indicate depression-like 
behaviour in rodents (Porsolt et al. 2001), the time spent immobile in the last 4 
minutes of a six minute test was analysed. Mdx mice spent more time immobile 
(154.3±12.2 seconds, n=8) during this inescapable stressor than their WT controls 
(106.9±11.2 seconds, n=7, p<0.05, Figure 3.4i). Moreover, the latency to 
immobility, or the time it took for the mice to display despair at the inescapable 
stress, was shorter in mdx mice (6.5±3 seconds, n=9) than WT controls (35.6± 5.5 
seconds, n=9, p<0.05, Figure 3.4ii). 
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Figure 3.4: Tail Suspension Behavioural Analysis 
 The time spent immobile (or despairing at the inescapable stressor) in the last 4 
minutes of a tail suspension trial is higher in mdx mice (i) whereas the latency to 
first period of immobility is shorter in mdx mice (ii). n=10, *p<0.05, 
***p<0.001 
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Figure 3.3: Novel Object Recognition Test Analysis 
 WT and mdx mice spent the same amount of time exploring a novel object 
compared to overall time exploring the two objects. n=10, p>0.05 
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3.3.2 Mdx striated skeletal muscle exhibit histological signs 
of regeneration and infiltration of mononuclear cells  
Inflammation was scored as the number of fibres with inflammatory events such as 
the infiltration of phagocytes into the muscle cells, termed myophagocytosis as a 
percentage of the total number of fibres per image. The area of inflammation as a 
percentage of the total area of fibres imaged was also analysed. The total area of 
inflammation in mdx mice (8.7±2.1, n=10 per group) was higher than in WT mice 
(1.1±0.1, n=10, p<0.001, Figure 3.5ii). Moreover mdx mice (12.9±1, n=10) had a 
higher number of inflammatory events than their WT controls (5.3±0.4, n=10, 
p<0.001) and the frequency of inflammatory incidents of immune cell infiltration in 
cross sections of EDL muscle histology (Figure 3.5iii). Centralised nuclei are a 
marker of regeneration. In EDL muscle in mdx mice (54.7±4.3, n=10) more 
centralised nuclei as a percentage of total nuclei per image were identified as 
compared to the WT muscle (20.7±3.2, n=10, p<0.001, Figure 3.5i). 
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Representative images of WT skeletal muscle (A and D) and muscle pathology 
found in dystrophin deficient mice (B, C, E & F) cut at 10µm and stained with 
haematoxylin and Eosin (H&E). Scale bar 100μm. 
A - C: Sections through H&E stained skeletal muscle.  
In A, muscle not showing pathology - a high number of peripheral nuclei is seen. 
In dystrophic muscle: B, chains of central nuclei can be seen in both fibres, 
along with normal peripheral nuclei, and in C a fibre undergoing 
myophagocytosis. Shown with arrows. 
D - F: Transverse sections through H&E stained skeletal muscle.  
In D, muscle not showing pathology – with peripheral nuclei and uniform fibre 
diameters. In dystrophic muscle, E a high number of central nuclei and varying 
fibre sizes are seen, in F fibres are being infiltrated, and there is some fibrosis. 
Shown with arrows. 
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Figure 3.5: Pathohistological Analysis of skeletal muscle inflammatory 
markers 
 Skeletal tissue from mdx mice have higher percentage of central nuclei than WT 
(a) a larger area of inflammation (b) and a higher incidence of inflammation (c) 
as compared to WT controls. n=10, *** p<0.001 
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3.3.3 IL-6 ELISA for Homogenized Muscle 
IL-6 is a known pro-inflammatory cytokine released from muscle fibres. Using 
ELISA analysis of homogenised right forelimb flexor muscle, IL-6 trended towards 
being increased in mdx (34.89±8.125) over WT mice (15.21±1.86, Figure 3.6, 
p>0.05), however, this was not statistically significant.  
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Figure 3.6: ELISA analysis of IL-6 in homogenised skeletal muscle of the 
forelimb 
Mdx mice have double IL-6 levels per milligram of protein than WT mice; 
however this is not statistically significant in a student’s t test. 
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3.4 Part 2 
Intervention Study - The effects of amitriptyline on mdx 
behaviour and inflammation 
 
3.4.1: The effects of amitriptyline on mdx behaviour and 
inflammation 
By characterising the behavioral profiles of mdx mice, I discovered they exhibit 
depressive and anxiety like behaviours in addition to extensive inflammation in their 
skeletal muscle. To assess the therapeutic efficacy of amitriptyline on any or all of 
these symptoms I compared two groups of mdx mice, a control group treated with 
saline and a group treated with amitriptyline. 
 
3.4.1.1 Amitriptyline had anxiolytic effects in mdx mice 
Mdx mice treated with amitriptyline spent more time in the centre of the open field 
(114.8±2.5s, n=7, p<0.05) than saline-treated mdx mice (35.2±6.3s, n=5) in the first 
five minutes of the trial (Figure 3.7iv) and a comparable amount of time in the 
second five minutes of the trial (Figure 3.7v, p>0.05). Overall, for the total ten 
minutes, amitriptyline-treated mdx mice spent more time exploring the centre of the 
arena (49.1±4, n=5) as compared to WT controls (57.2±7, n=7, p<0.05, Figure 
3.6vi). Ambulatory activity of both mdx groups was again scored as number of total 
crossings across each line and no differences were noted between amitriptyline- 
(64±7.2s , n=6) and saline-treated (67±7.7s, n=7, p>0.05) Mdx mice  in the first five 
minutes (Figure 3.7i) or between amitriptyline-treated mdx mice  (49.1±4, n=6) and 
saline-treated mice (57.2±5.9, n=7, p>0.05) the second five minute trial (Figure 
3.7b), or indeed, over the total ten minute trial (Figure 3.7iii). 
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Figure 3.7: Open Field Behavioural Analysis of amitriptyline treated mdx mice 
compared to saline mdx controls 
 Students t tests results analysing locomotor activity assessed by time spent transvering 
lines in the arena in the first 5 minutes (i), second 5 minutes (ii) and total time (iii)  time 
spent in the centre of the arena in the first five minutes (iv) and in the second 5 minutes (v) 
and total time (6) n=7, *p<0.05, **p<0.01 
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3.4.1.2 Amitriptyline increases exploration of a novel object 
in mdx mice  
While control mdx mice did not show any difference in the time spent exploring a 
new object as compared to the WT mice, treatment with amitriptyline resulted in 
mdx mice spending a longer time exploring the novel object (74.67± 4.8 seconds, 
n=7) as compared to saline-treated mdx controls (50.05±3.5 seconds, n=7, p<0.01, 
(Figure 3.8). 
3.4.1.3 Amitriptyline alleviates depressive behaviour in 
behavioural tests 
Amitriptyline-treated mdx mice spent less time spent immobile (78.4±13.7 seconds 
n=7) in the TST as compared to their saline-treated counterparts (89.5±3.7 seconds, 
n=7, p<0.05, Figure 3.9i) indicating an anti-depressant effect of amitriptyline. 
Moreover, amitriptyline treatment increased the latency to immobility in mdx mice 
(89.5±3.7 seconds, n=7) compared to saline-treated mice (24±5.4 units, n=7, p<0.05, 
Figure 3.9ii). 
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Figure 3.9: Tail Suspension behavioural Analysis of amitriptyline treated 
mdx mice compared to saline controls 
 
 Student’s t tests results analysing time immobile in the last 4 minutes of a tail 
suspension trial (i)  and latency to first period of immobility (ii) indicating 
amitriptyline alleviates depressive symptoms in mdx mice. n=7, *p<0.05, 
***p<0.001 
Figure 3.8: Novel Object Recognition Behavioural Analysis of amitriptyline 
treated mdx mice compared to saline mdx controls 
Results analysing time spent exploring novel object over total exploration shows 
amitriptyline increases novel object exploration. n=7, **p<0.01  
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3.4.2 Amitriptyline alters amine levels in several brain 
regions of mdx mice 
As monoamines have been attributed an important role in mood disorders such as 
anxiety and depression, the effects of amitriptyline on monoamine expression in 
several brain regions associated with mood disorders were determined using HPLC 
analysis. As detailed in Table 3.2, in the WT mice amitriptyline increased 
noradrenaline levels (p<0.01) in the hippocampus and in the midbrain (p<0.05), 
where alterations in neurotransmitters have been associated with depressive-like 
behaviour. DOPAC/DA turnover was also increased (p<0.05) in the midbrain. 
Amitriptyline did not change monoamine levels in any other brain regions examined 
in the WT mouse. 
In mdx mice, serotonin levels were increased in the amygdala, a region important in 
processing emotionally-evoked memories following amitriptyline treatment in 
comparison to saline-treated mdx mice (p<0.05). Amitriptyline also induced an 
increase in amygdalar HVA/DA turnover (p<0.05). In the hippocampus, 
amitriptyline increased 5HT (p<0.05), 5-HIAA (p<0.05) and DOPAC levels 
(p<0.05). Amitriptyline evoked a decrease in HVA (p<0.05). In the midbrain, DA 
(p<0.05) and DOPAC (p<0.05) were increased following administration of 
amitriptyline. Furthermore, amitriptyline stimulated an increase in 5-HIAA (p<0.05) 
and 5-HIAA/5HT turnover (p<0.05) in this region. Monoamine levels were not 
altered by treatment with amitriptyline in either the prefrontal cortex or the striatum 
(Summarised in tables in Figure 3.2 & 3.3, n=3-5 for each brain region).  
 
  
a b 
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  Table 3.2: HPLC monoamine analysis of areas important in depression and anxiety 
in WT – amygdala, hippocampus, hypothalamus, striatum, prefrontal cortex and 
midbrain in   amitriptyline treated WT versus saline treated WT mice. Data presented as 
mean ± SEM and n numbers. * p<0.05, **p<0.01 ( / = monoamine below detectable 
level) 
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Table 3.3: HPLC monoamine analysis of areas important in depression and 
anxiety in mdx– amygdala, hippocampus, hypothalamus, striatum, prefrontal cortex 
and midbrain in   amitriptyline treated mdx versus saline treated mdx mice. Data 
presented as mean ± SEM and n numbers. * p<0.05, **p<0.01 ( / = monoamine 
below detectable level) 
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3.4.3 Amitriptyline reduces histopathological changes in 
mdx mice  
Amitriptyline-treated mdx mice had a significant decrease in the number of 
centralised nuclei in cross-sections of EDL muscle (43.3±1.7%, n=7), compared to 
WT mice (51.4±1.8%, n=7, p<0.01, Figure 3.10i). Amitriptyline-treated mdx mice 
also displayed a decrease in the total area of inflamed muscle (2.3±1.1µm
2
, n=7) as 
compared to saline-treated mice (8±2.3µm
2
, n=7, p<0.05, Figure 3.10ii). The number 
of discrete individual areas of inflammation were also decreased in amitriptyline 
treated mdx mice (3.7±0.2 µm
 2
, n=7) as compared to saline treatment (6.1±0.2 µm
 2
, 
n=7, p<0.001, Figure 3.10iii). 
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Figure 3.10: Pathohistological Analysis Tail Suspension behavioural Analysis  of 
amitriptyline treated mdx mice compared to saline mdx controls 
mdx mice treated with amitriptyline have less central nuclei than saline treated mdx 
mice (i) a reduced area of inflammation (ii) and a less incidence of inflammation (iii) 
n=7, * p<0.05, ** p<0.01 *** p<0.001 
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3.4.4 Amitriptyline lowers IL-6 levels in plasma of treated 
mdx mice  
Amitriptyline treatment of plasma from mdx mice indicated that amitriptyline 
reduces circulating IL-6 levels in mdx mice (Figure 3.11, n=7, p<0.05). 
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Figure 3.1: ELISA analysis of IL-6 in plasma Analysis of amitriptyline 
treated mdx mice compared to saline mdx controls  
 
Student’s t test reveal mdx mice treated with amitriptyline have significantly less 
IL-6 than saline treated mdx mice.  n=7, * p<0.05 
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3.5 Discussion 
3.5.1 The behavioural profile of mdx mice 
Consistent with the human condition where the prevalence of anxiety disorders and 
depression is increased (Rubinsztein et al. 1998; Roccella et al. 2003)  our 
behavioural studies on dystrophin deficient mdx mice identified altered behavioural 
profiles. 
5.5.1.1 Anxiety in mdx mice 
The open field behavioural test is comprehensively described in the literature (Walsh 
& Cummins 1976; Prut & Belzung 2003), and in our test this brightly-lit exposed 
arena revealed that as compared to untreated WT mice, untreated mdx mice show 
signs of anxiety indicated by the avoidance of the brightly lit middle area, despite 
their innate exploratory drive. The anxiety-like behaviours in the open field are 
supported by a study carried out in other behavioural tests in mdx mice; the light-
dark box which similarly identified anxious traits in dystrophin deficient mice 
(Vaillend & Ungerer 1999). However, other behavioural assessments such as the 
elevated plus maze, did not detect any signs of anxiety in these animals (Sekiguchi et 
al. 2009) at this age.   
One concern with this type of behavioural test is whether deficiencies in motor 
function would reduce exploration of the open field. Indeed, when studying 
behaviours which are dependent on locomotion in this model, it is imperative that 
the age of the mice is considered. For this reason 8-10 week old mdx mice  were 
studied as they have high skeletal muscle regenerative capacity at this age, reducing 
the risk of motor deficits as a source of false results (Porter et al. 2002). As 
previously established mdx mice do not show motor deficiencies until 6 months of 
age (Pastoret & Sebille 1995) and have previously been used in behavioural testing. 
This is consistent with rotarod experiments at this age (Spurney et al. 2009) (~12 
weeks old) where no deficits were seen.  
Indeed, when overall movement during the course of the trial were compared 
between mdx and WT mice, no differences were detected which reassured us that the 
reduction in exploration and implied increase in anxiety, was not simply due 
impaired ambulation. Nonetheless,  one study states that during the dark phase mdx 
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mice exhibit less spontaneous locomotor activity than WT controls at this age 
(Nakae et al. 2012) although this spontaneous dark activity is dissimilar to our trial.  
5.5.1.2 Alleviating anxiety in mdx mice  
Amitriptyline treatment increased exploration of the middle of the arena when 
compared to saline controls, indicating an anti-anxiety effect of amitriptyline, similar 
to previous studies which described such an effect (Liu et al. 2007) in mice, to my 
knowledge this is the first report of alleviation of anxiety in mdx mice in the open 
field with treatment of amitriptyline. Dissimilar to our findings, amitriptyline did not 
have an anxiolytic affect in mice in the plus maze, but similar to our study it did not 
alter the ambulatory behaviour in mice. In our study mdx mice exhibited similar 
locomotor activity in the trial when compared to the saline mdx group.  
5.5.1.3 Depressive symptoms in the mdx mouse 
Clinical depression is common in DMD patients (Bushby et al. 2010) although this 
has often been attributed as a consequence of the severity and seriousness of the 
disease, and  a psychological cause rather than a pathophysiological one (Roccella et 
al. 2003). However, the TST revealed that mdx mice also exhibit depressive-like 
behaviours, showing increased despair in the face of an inescapable stress when 
compared to WT mice, thus indicating that the pathology associated with dystrophin 
deficiency may underlie the increased susceptibility of DMD sufferers to depression. 
Moreover, the reduced time for mdx mice to show this despair in their inescapable 
stress of the TST and their increased immobility indicates that these mice are pre-
disposed to depression-like behaviour.  
Again, caution is needed when using dystrophic animals in behavioural tests, indeed 
I did not find locomotor deficits, but the TST was chosen over the forced swim test 
because, although both tests are established behavioural tests of depressive like 
behaviour (Castagné et al. 2010), the TST requires less physical effort from muscle 
groups which would be affected first in the animals. 
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5.5.1.4 Amitriptyline as an anti-depressant in mdx mice 
Amitriptyline is an antidepressant known to alleviate depressive symptoms in people 
suffering from major depression, this was established more than 50 years ago (Inglis 
et al. 1963), and amitriptyline, however replaced with more specific drugs is still 
prescribed in cases of depression today (Leucht et al. 2012). Amitriptyline is 
efficacious in reversing despair depressive behaviours in TST in mice (Caldarone et 
al. 2003; Steru et al. 1985). Moreover when I tested the efficacy of amitriptyline, this 
depressive index was reversed in mdx mice compared to saline controls, further 
indicating the potential beneficial effects of this anti-depressant for improving the 
quality of life of DMD patients.  
A classic hypothesis of the pathogenesis of depression implicates the dysregulation 
of monoamines in subcortical brain regions underpins the development of major 
depression (Hirschfeld 2000) and as a consequence of this fact, treating depressed 
patients with compounds which regulate the levels of monoamines in the brain have 
been efficacious in treating depression  (Anderson 2000). There is clear cognitive 
defects in a cohort of DMD patients(Anderson et al. 2002) and defects in the central 
nervous system due to dystrophin deficiency may lead to changes in brain areas 
important in the pathogenesis of depression (Lidov et al. 1993).  
3.5.2 Altered expression of monoamines in mdx brain 
I found through monoamine analysis in the brain reveals mdx mice respond 
differently to amitriptyline treatment than WT mice, increased levels of monoamines 
involved in the aetiology of depression in mdx mice may indicate that amitriptyline 
works through the modulation of monoamines in DMD, as it does in other causes of 
depression.  
As previously discussed, given the behavioural results identified depressive and 
anxiety-like behaviours in the mdx mice  and consistent with its reported actions 
(Steru et al. 1985) and chronic administration of amitriptyline normalized these 
phenotypes. Amitriptyline acts as a serotonin noradrenaline reuptake inhibitor 
(SNRI) but with higher efficacy for the 5HT receptor (Giuseppe et al. 2007), and 
depression is now more often treated with selective-serotonin reuptake inhibitors 
(SSRIs), however this is due to fewer side-effects rather than improved efficacy 
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(Barbui & Hotopf 2001) and as mentioned amitriptyline is still occasionally 
prescribed for treatment-resistant depression (Broquet 1999; Leucht et al. 2012). 
To investigate the underlying chemical changes in brain regions associated with 
these mood changes, levels of brain monoamines were analysed in WT and mdx 
mice treated with saline or amitriptyline. In WT mice, amitriptyline treatment 
resulted in increased levels of NA in the hippocampus. DOPAC/DA turnover in the 
midbrain and 5HIAA/5HT turnover in both the striatum and the hypothalamus were 
increased following amitriptyline treatment. However, amitriptyline caused 
decreases in midbrain levels of 5HIAA and NA in the WT mouse.  In the mdx mouse 
a greater number of changes in monoamine expression were observed and the pattern 
of change was different to the WT mouse.  
As 5HT is the major neurotransmitter involved in depression, evidence of both 
receptor dysfunction, monoamine turnover rate changes 5HT/HIAA and levels are 
implicated in the disease (Cowen 2008) and consistent with the crucial role of 5HT 
in mood disorders (Naughton et al. 2000), the actions of amitriptyline resulted in 
increased concentrations of 5HT in two regions of the limbic system, the amygdala 
and the hippocampus and elevations of 5HIAA in the hippocampus of mdx but not 
WT mice. Neural circuitry in both these regions have been linked with anxiety 
(Rosen & Schulkin 1998) and depressive-like behaviour (Luethi et al. 2008). 
5HT/5HIAA turnover and 5HIAA concentrations were also elevated in the midbrain, 
a region which relays serotonergic signals to the hippocampus and is associated with 
depressive-like behaviour.  
Amitriptyline is thought to have some effect on NA uptake (Giuseppe et al. 2007) 
and NA levels were increased in the hippocampus of both strains. Moreover, 
glucosteroids receptors are modulated in the hippocampus by both monoamine levels 
and by amitriptyline in cultured hippocampal primary cells (Lai et al. 2003), and as 
discussed the HPA axis which is activated in depression and stress may therefore 
reap benefits from amitriptyline normalised the monoamine expression and thus the 
glucosteroids effects in the hippocampus. Interestingly, NA levels were decreased in 
the midbrain of WT mice following treatment. 
96 
 
Concentrations of DA and DOPAC were unchanged in WT brains but amitriptyline-
treated mdx mice displayed increased expression of DA and DOPAC in the 
midbrain, increased concentrations of DOPAC in the hippocampus and increased 
HVA/DA turnover in the amygdala. Interestingly, the hypothalamus of the mdx mice 
was the only region with decreased levels of DA and the DA metabolite, HVA. 
When comparing the WT and mdx mice, the greatest divergence appears to be in 
changes in the dopamine system following amitriptyline. 5HT and DA have 
extensive interaction (Damsa et al. 2004) and amitriptyline has been shown to 
increase DA receptor expression in the striatum of rats (Huzarska et al. 2006), 
however the precise mechanism of amitriptyline-induced changes in the DA system 
in dystrophin-deficient mdx mice requires further investigation.   
As absence of dystrophin has also been linked to increased prevalence of cognitive 
defects in DMD patients (Anderson et al. 2002) such as lowered IQ and memory 
deficits (Roccella et al. 2003). However, our studies examining object recognition 
memory in the novel object recognition test, revealed no memory defects in the mdx 
mouse. However, it has been previously reported that mdx mice exhibit impairments 
in long term memory consolidation (Anderson et al. 2002) and passive avoidance 
learning and retention (Muntoni et al. 1991). In relation to changes in monoamine 
levels, 5HT-dependent mechanisms are thought to contribute to hippocampal and 
amygdalar learning (Meneses et al. 1997), and therefore amitriptyline-induced 
enhancement of object discrimination memory in mdx mice may have occurred 
through modulation of 5HT in these areas. This is further supported by data that 
show a beneficial effect of central 5-HT2A receptor antagonism on cognition 
(Altman & Normile 1988). 
To summarise, it is apparent that amitriptyline is an accepted and effective 
antidepressant whose full mechanisms of actions are not fully elucidated (Leucht et 
al. 2012), it is known however to work through the modulation and normalisation of 
monoamine levels in the brain (Cowen 2008; Lai et al. 2003) and indeed it has 
changed monoamine levels in the areas studied, brain areas which are implicated in 
depression. Moreover, amitriptyline may also be modulating cytokine levels, as it 
can work as an anti-inflammatory in animal models of disease (Hajhashemi et al. 
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2010; Leduc et al. 2002), and as discussed raised cytokine profiles in disease can be 
a cause of depression in a subset of patients. 
3.5.3 Histopathological changes in mdx skeletal muscle 
While treatment of mood disorders in DMD is clearly important for patient 
wellbeing, the overwhelming and most debilitating symptoms of this disorder are the 
inflammation and subsequent loss of function in skeletal muscle leading to severe 
disability and ultimately a premature death. Thus, assessment of the effects of 
amitriptyline on inflammation in skeletal limb muscle was carried out.  
An increase of myophagocytosis, the infiltration of phagocytic white blood cells into 
the muscle (both number of discrete areas and total area of inflammation) was seen 
in mdx mice EDL muscles when compared to WT mice, which is consistent with 
previous reports (Gordon et al. 2012).  Moreover, mdx mice have a higher percentage 
of central nuclei in myofibres. This signifies regeneration of skeletal muscle, which 
is an early indicator of dystrophic muscle, whereas, normal skeletal muscle has 
around 3% central nuclei (Seidman 1983) some cases of mdx mice  in this study had 
up to 50% central nuclei. Consistent with other studies (Payne et al. 2006), in control 
mdx mice I observed inflammation indicative of regenerating myofibres in the 
extensor digitorum longus muscle tissue. The inflammation was in the form of 
immune cell infiltration.  
Our study has found that amitriptyline treatment results in a reduction of centralised 
nuclei and reduced levels of inflammation in the mdx muscle, with reduction of the 
total area of inflammation and the number of inflammatory events following 
treatment. The underlying mechanisms contributing to the anti-inflammatory effects 
of amitriptyline have not yet been fully reported but can reduce inflammation in 
(Hajhashemi et al. 2010) and reduce an immune response, implicating amitriptyline 
in depression as having the ability to normalise cytokine expression such as IL-6 
(Kubera et al. 2000).  
Accumulating evidence from studies in rodents indicates that TCAs, including the 
drug amitriptyline, have anti-inflammatory effects on various organ systems(Abdel-
Salam et al. 2003) which is in part due to the modulation of chemokines such as 
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TGFβ1, IL-6 or TNF (Tai et al. 2006; Xia et al. 1996). TCAs are also known to 
reduce macrophage infiltration, however full explanation of the mechanism of action 
will require further research (Achar et al. 2009). However, structurally similar TCAs 
such as fluoxetine induce an anti-inflammatory response due to its ability to interact 
with opioid receptors (Hajhashemi et al. 2010), therefore further investigation will be 
required to elucidate this mechanisms involved.  
3.5.4 Interleukin-6 - a key modulator of inflammation in 
DMD? 
I have demonstrated that the pro-inflammatory cytokine, IL-6 is elevated in the 
muscle of mdx mice however, the variation did not allow the test to reach 
significance. I analysed plasma levels of IL-6 in treated mdx mice and compared this 
to saline treated mdx mice, IL-6 plasma levels were reduced following therapeutic 
intervention with amitriptyline.  
As muscle inflammation is reduced by amitriptyline the release of IL-6 from 
skeletal muscle into plasma would also likely to be reduced and in this way IL-6 may 
be an important marker of inflammatory levels in skeletal muscle.  
However, amitriptyline may also be having a direct effect on IL-6 levels by 
reducing release of the pro-inflammatory cytokine from the immune cells (Xia et al. 
1996) and thereby reducing the pro-inflammatory effects of this immune mediator. 
Moreover, the effect may be a centrally controlled phenomenon – in the HPA axis, 
namely the hippocampus, by modulation of monoamines or glucosteroid receptors 
(Kubera et al. 2000).  
Since IL-6 is regarded as a marker of depressive symptoms in chronic 
inflammatory disorders like rheumatoid arthritis (Yusof & Emery 2013) and indeed a 
biomarker of depression  manifesting in patients with lung cancer (Du et al. 2013) – 
diseases which has a high depression/inflammation co-morbidity,  I hypothesised 
this may be a causative mediator in patients, and indeed in mdx mice. I did find an 
increase in IL-6 in mdx mice, consistent with other studies (Huynh et al. 2013; 
Kostek et al. 2012). This result did not show statistical significance at (p>0.05) 
although its mean pg/mg of tissue is almost double the amount of interleukin-6, this 
lack of power may be due to the nature of the tissue and the protocol used. 
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Homogenized muscle is a heterogeneous tissue containing blood vessels, adipocytes, 
and other material which could possibly be a source of IL-6. 
Therefore, it was decided to analysis IL-6 in blood plasma of drug treated 
animals to investigate if levels of IL-6 circulating changed, amitriptyline can reduce 
IL-6 levels from monocytes  and can  modulate various cytokines which interact 
with IL-6 (Xia et al. 1996). Indeed, IL-6 levels are reduced in the circulation 
following amitriptyline treatment. Taken with the data provided on the behavioural 
and histological benefits in mdx mice with the treatment of amitriptyline, we infer 
that IL-6 reduction in the mdx circulation is a clear benefit to the progression of 
disease in dystrophin deficiency. 
3.6 Conclusions 
Given its anti-depressant as well as anxiolytic and anti-inflammatory effects in the 
dystrophin-deficient mdx mouse, amitriptyline offers a potential therapeutic strategy 
which may have great benefits to some DMD patients. However, as Amitriptyline 
can have detrimental side effects, such as cardiac arrhythmias, cautious prescribing 
of this drug which is already on the market and has been used for many years in 
people for a range of diseases is advisable. This potential new use for an old drug 
could improve the quality of life for DMD sufferers without the delay imposed by 
clinical trials. 
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Chapter 4: The role of IL-6 and 
Urocortin 2 in dysfunction of the 
diaphragm in the mdx mouse 
101 
 
4.1 Introduction 
4.1.1 Dytrophin deficiency in the diaphragm 
Diaphragm dysfunction is a severe and detrimental symptom of dystrophin 
deficiency in patients with DMD; as repeated contraction and load bearing on 
striated muscle determines the severity of the pathological signature of each muscle, 
it is not surprising that the diaphragm undergoes degeneration of function in this 
disease. Patients suffer diurnal hypercapnia due to a loss of respiratory skeletal 
muscle tone, a reduction in vital capacity and sleep apnoeas (Simonds et al. 1998).  
Patients benefit from artificial ventilation as the condition continues into their 
teenage years (Finsterer 2006) which undoubtedly aids survival for patients 
(Vittorino et al. 1994) in the second decade of life.  Cardiopulmonary failure 
dominates the pathology in the late stages of the disease and this pulmonary 
insufficiency  is the leading cause of premature death in up to 90% of patients 
(Mosqueira et al. 2013; Beck et al. 2006).  
It is difficult to fully elucidate diaphragm pathology in patients of the disease 
through pulmonary function testing, however there is evidence of  reduced force 
generation capabilities and the muscle undergoes rapid progressive weakening, 
muscle fibre loss and fibrosis (Beck et al. 2006) evident by a thickened appearance  
in patients as early as ten years of age (De Bruin et al. 1997).  
4.1.2 Diaphragm dysfunction in the mdx mouse 
Animal models of DMD are useful to explore the mechanisms of disease progression 
in dystrophin deficient diaphragms. Diaphragm dysfunction in mdx mice diverges 
from the human disease in all skeletal muscle due to the high regenerative capacity 
of mdx skeletal muscle (Anderson et al. 1988), except for the diaphragm. Dystrophin 
deficient diaphragm muscle undergoes inflammation, the primary pathology of the 
disease and becomes fibrotic with collagen replacing  functional fibres which have 
undergone regeneration until exhaustion (Turgeman et al. 2008), and loss of force 
production in the muscle (Bates et al. 2013).  Different from limb skeletal muscle, 
functional changes are evident from an early age.  This feature of the mdx model of 
DMD provides an important tool to test the efficacy of therapeutic strategies, more 
so because the phenotype is mild in the limb skeletal muscle. 
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Striated muscle contractile function has previously been studied in mdx mice, 
especially under isometric conditions (generating force without length change). 
Twitch peak force production (one contraction) is reduced. Moreover, tetanic 
maximal force (force produced from a summation of stimuli, resulting in a full 
tetanus contraction) was also reduced, indicating dysfunction in the diaphragm at a 
young age. Moreover, twitch time to peak (speed of coupling) or 50% peak force 
decay time (uncoupling) are found to be unchanged compared to WT; these results 
ascertained from single fibre functional measurements illustrate that at three months 
of age, cross bridge kinetics or cycling rate are unaffected in mdx mice (Gosselin & 
Williams 2006).  
Although little is known about the isotonic kinetics (eccentric and concentric 
dynamic movements, muscle capable of shortening against a load) in mdx mice, 
power production has been investigated in stretched diaphragm lengths i.e., at 
lengths greater than optimal length, where power is reported to be reduced (Stevens 
& Faulkner 2000).  Intervention studies utilise these differences between mdx mice 
and WT controls to test the efficacy of palliative treatments (Gosselin & Williams 
2006; Gregorevic et al. 2002; Nakae et al. 2012). 
 
4.1.3 Investigating Potential Therapies 
4.1.3.1 CRFR agonists  
CRFR2 agonists have previously proven beneficial in treating muscle dysfunction in 
mdx mice. Their effectiveness is attributed to an ability to increase muscle mass, 
modulate proteolysis and activate signalling pathways, specifically anabolic 
pathways (Hall et al. 2007).  CRFR2 is a modulator of muscle hypertrophy and 
atrophy (Hinkle et al. 2003), and can reduce nerve damage, corticosteroid induced 
atrophy and immobilisation (disuse) loss of muscle mass (Hinkle et al. 2003). It is 
reported in the latter study that intervention with non-selective CRF receptor 
agonists can cause muscle loss (Hinkle et al. 2004), therefore an endogenous CRFR2 
selective agonist, Urocortin 2 is an attractive candidate for a therapeutic target in 
mdx mice, as opposed to a CRFR1 agonist, which works conversely to the beneficial 
CRFR2 agonist, these studies have begun to elucidate the role of CRFR2 in skeletal 
muscle function in health and disease.  
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4.1.3.2 Interleukin-6 and skeletal muscle damage  
IL-6 levels are raised in patients with DMD (Messina et al. 2011) and also in mdx 
mice (Gordon et al. 2012; Hunt et al. 2011; Klingler et al. 2012). It is long known 
that IL-6 plays a significant role in muscle regeneration after exercise and damage 
(Pedersen & Febbraio 2008), with an up regulation of STAT 3 signalling in muscle 
stem cells following lengthening induced damage (McKay et al. 2009) and in 
inflammation in skeletal muscle (Kostek et al. 2012). Blocking IL-6 signalling 
however, leads to a pro-inflammatory state in mdx mice although there was an 11% 
increase in hind limb strength (Kostek et al. 2012). Although limb strength can 
potentially be improved, no functional tests on diaphragm performance in the 
presence of an IL-6 signalling blocker have been reported. Of note, diaphragm 
isometric function has been rescued in mdx mice treated with an NFĸB blocker 
(Peterson et al. 2011), which may implicate a role for IL-6 signalling (Libermann & 
Baltimore 1990)  because as discussed, IL-6 can activate this signalling pathway 
(Huang et al. 2009). Although generally associated with inflammation, IL-6 may also 
act as an anti-inflammatory cytokine, signalling through its classic signalling 
pathway (Rose-John 2012), but it also modifies fibrosis throughout body tissues 
(Meléndez et al. 2010); attenuates fibrosis in liver cells (Nasir et al. 2013) and can 
reduce collagen deposits in the skin of multiple sclerosis (MS) patients (Shima et al. 
2010). Moreover,  it was suggested as a therapy for attenuating collagen damage in 
rheumatoid arthritis (Alonzi et al. 1998) and indeed, forms the basis of 
‘Tocilizumab’ human anti interleukin-6 antibody treatment. 
4.1.3.3 Co-treatment 
Following the interaction reported between the CRF family of proteins and IL-6 in 
other tissues (Kageyama et al. 2006; Ando et al. 1998; O’ Malley et al. 2011; 
Tsatsanis et al. 2007; Huang et al. 2009; O’ Malley et al. 2013), in the context of 
inflammation in cardiac myocytes (Huang et al. 2009) and GI dysfunction in IBD 
(O’ Malley et al. 2013), I speculated that this interaction may also play a role in 
diaphragm skeletal muscle dysfunction in mdx. 
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4.1.4 Hypothesis 
 
We hypothesise that blocking IL-6 signalling and stimulating the CRFR2 receptor 
using exogenous Urocortin 2 will ameliorate diaphragm dysfunction in dystrophin 
deficient mdx mice. 
4.1.5 Specific Study Aims 
 
 To characterise mdx diaphragm compared to WT controls under isometric 
and isotonic conditions ex vivo. 
 
 To examine IL-6 and IL-6 receptor levels in mdx compared to WT mice. 
 
 To test the therapeutic efficacy of anti IL-6 receptor ± Urocortin 2 treatment 
in vivo on mdx diaphragm function. 
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4.2 Methods 
4.2.1 Animals and study protocol 
Male C57BL/10ScSn (wild-type control) and C57BL/10ScSn-Mdx/J
 
(mdx, 
dystrophic) mice (12 weeks old at time of functional test, 29g±2g body weight) were
 
assigned at random to untreated or treated groups detailed in table 4.1.
 
Treated mice 
were administered monoclonal anti IL-6 receptor antibodies (0.3mg/kg) or the 
CRFR2 agonist, Urocortin 2 (30µg/kg) or both by subcutaneous injection (6 
subcutaneous injections, saline vehicle) for 2 weeks. Controls were treated with 
saline (0.9% NaCl (w/v)). 
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Groups Untreated
Saline Anti IL-6R Urocortin 2 Anti-IL-6R + Urocortin 2
Mdx 8 8 8 6 8
WT 8
Intervention Treatment
Table 4.1:  Experimental groups & details of intervention protocol 
Intervention study treatments are colour coded. Saline treated mdx mice are 
represented in grey, Anti IL-6 receptor antibody (anti IL-6R) in red, Urocortin 2 in 
blue and a co-treatment of anti IL-6R and Urocortin 2 in purple throughout the 
thesis. 
Six injections of the selected treatment (as indicated by the first six arrows) were 
given from day 1 to day 11. Stress induced defecation was performed on day 
13and animals were sacrificed for tissue on day 14. 
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4.2.2 Techniques: 
Organ bath (Section 2.7.2) 
Diaphragm strip preparation  
Isometric Protocol  
Isotonic protocol  
 
Protocol described above, Figure 2.7. 
Molecular Techniques: Western blotting (section 2.5.3) 
Diaphragms were homogenised in lysis buffer (Table 2.2) and western blotting used 
to quantify expression of IL-6 and IL-6Rs in diaphragm muscle from mdx mice 
which had undergone each of the experimental interventions. 
 
10 mins 
Tetanic 
Twitch 
Load “Step test” Equilibrate 
Repeated 
Stimulation 
Rest 
Dry diaphragm strip 
Weigh 
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4.3 Results part one: Diaphragm function in WT and mdx 
mice 
4.3.1 Diaphragm function in WT and mdx mice 
4.3.1.1 Mdx diaphragms have reduced maximal twitch and 
tetanic forces  
The length at which peak specific force is acquired by each muscle strip did not 
differ between strains, and the cross sectional area (CSA, cm
2
) was also similar 
between strains (see Table 4.2). 
Mdx diaphragms have reduced specific twitch force (force normalised to cross 
sectional area (CSA)) compared to WT mice (Figure 4.1, p<0.05, student’s t test). 
However, time to peak (TTP) and the time for the peak force to decay by 50% (½ 
RT) were not statistically different between the strains (Figure 4.1, p>0.05). 
Mdx diaphragms had reduced specific peak forces compared to WT mice (Figure 4.2, 
p<0.05). 
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Figure 4.1: Twitch Kinetics of WT and mdx mice diaphragm 
i A representative original trace of twitch force comparing WT (black line) to 
mdx (grey line) diaphragm. The arrow represents a single supra maximal 
stimulation (1ms).  ii Specific twitch force; analysis of maximal twitch force 
recorded at optimal length comparing WT and mdx diaphragm. iii Twitch 
contraction time to peak in seconds;  iv Twitch contraction with 50% decay of 
force. n=7 for all groups, * p<0.05 
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Figure 4.2: Peak Specific Force of WT and mdx mice diaphragm 
 i A representative original trace of peak tetanic force comparing WT (black line) 
to mdx (grey line). The arrow represents supra maximal stimulation at 100Hz 
lasting 300ms.  ii Specific tetanic force of maximal tetanic force recorded at 
optimal length in WT and mdx diaphragm strips. n=7, *** p<0.05 
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  Units Group 
    WT Mdx 
        
Optimal Length mm 9 ± 0.07071 9.3  ± 1.3000 
CSA cm
2
 0.005185  ± 0.001189 0.0375  ± 0.01837 
        
Peak Twitch Force N/cm
2
 3.528  ± 0.7327 1.31  ± 1.4441 
Time To Peak s 0.02267  ± .003432 0.026  ± 0.00237 
½ Relaxation Time s 0.01833  ± 0.002116 0.0236  ± 0.005009 
        
Peak Tetanic Force N/cm
2
 16.74  ± 3.329 2.53  ± 0.4994 
Table 4.2: Diaphragm preparation properties and isometric kinetic values 
WT and mdx mice 
Neither optimal length (cm) nor cross sectional area (CSA, cm
2
) differed 
between WT and mdx mice. Isometric kinetic values calculated from raw force 
measurements and normalised to CSA were also comparable between strains. 
Expressed as mean ± S.E.M. 
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4.3.1.2 Mdx diaphragms produce significantly less work 
than WT mice 
Load- Shortening Relationship 
Mdx diaphragm strips shorten in response to electrical stimulus to a similar extent in 
WT and mdx diaphragm strips (Figure 5.3iv, n=7, p>0.05) when normalised to 
optimal length. Peak specific shortening did not differ between strains (n=7, p>0.05, 
Figure 4.3iii). 
Load - Work Relationship 
Work production (force x distance shortened) was significantly lower in mdx mice 
compared to WT controls (Figure 4.4, n=7). Both load (p<0.0004) and work 
(p<0.0001) differed significantly, and a significant interaction was observed 
(p<0.0065, Two-way ANOVA). 
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Figure 4.3: Load-Shortening Relationship in WT and mdx diaphragm  
i Representative original traces of muscle shortening in a WT and (ii) mdx diaphragm in 
response to stimulation at different loads. iii Peak specific shortening, measured as a ratio  of 
shortening/optimal length (L/Lo) in WT and mdx diaphragms. (p>0.05, n=7 for both groups) iv 
Load/shortening relationship, measured as a ratio of shortening/optimal length (L/Lo) as a 
function of load. Two way ANOVA (genotype x load), revealed a significant effect of load on 
muscle shortening (*p<0.05), but no difference between WT and mdx diaphragms; there was no 
interaction. 
i WT ii Mdx 
iii 
50ms 
2mm 
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Figure 4.4: Mechanical Work  Production in WT and mdx diaphragm  
Work-Load relationship, expressed as Joules per cm
2
 as a function of load. Two way 
ANOVA (genotype x load), revealed a significant difference in muscle work between WT 
and mdx diaphragms; there was a significant effect of load and a significant interaction. 
n=7 for both groups. 
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4.3.1.3 There is no difference between mdx and WT 
shortening velocity over a series of loads and peak 
shortening velocities are not changed 
Peak shortening velocity was compared and no significant difference was detected 
between diaphragm muscle from mdx and WT mice (Fig 4.5 i, p>0.05). 
Shortening velocity was equivalent in mdx and WT diaphragms (P>0.05), two-way 
ANOVA; Figure 4.5 ii). There was a significant effect of load on shortening velocity 
(p<0.0001); there was no significant interaction (p>0.05). 
 
4.3.1.4 Mdx diaphragms produce less power compared to 
WT controls 
Peak power was compared using a Student’s t test. Mdx diaphragms produce 
significantly less power than WT diaphragms (Figure 4.6 i, p<0.01). 
Two-way ANOVA (genotype x load) of the Load-Power relationship, measured as 
the (shortening velocity x specific force as a function of load), revealed that mdx 
diaphragms generated significantly lower power (Figure 4.6 ii, p<0.0001) compared 
to WT. There was a significant effect of load on muscle power (p<0.0001), and a 
significant interaction (p<0.0001). 
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Figure 4.5: Load-Shortening Velocity relationship in WT and mdx diaphragm  
i Peak velocity of shortening (Lo/s) is equivalent in WT and mdx diaphragm 
strips(P>0.05). ii -  Two way ANOVA (genotype x load) revealed no significant difference  
in shortening velocity between WT and mdx. There was a significant effect of load on 
velocity of muscle shortening but no interaction.  n=7 for both groups. 
i 
ii 
Load –Shortening Velocity Relationship 
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Figure 4.6: Load - Power relationship in WT and mdx diaphragm  
 i Power production (Watts per cm
2
).–is lower in mdx diaphragm compared to WT  (P<0.01). 
ii - Two way ANOVA (genotype x load) revealed a significant difference in power between 
mdx and WT diaphragms. There was a significant effect of load and a significant interaction; 
**p<0.01, n=7 for both groups. 
i 
ii 
Load – Power Relationship i 
ii 
118 
 
 
4.3.2 Repeated Stimulation 
4.3.2.1 Mdx diaphragms shorten more than WT 
diaphragms in isotonic muscle fatigue test 
Shortening – Time Relationship 
Two-way ANOVA (muscle shortening x time) revealed that mdx diaphragms shorten 
more than WT diaphragms (p<0.05) during repeated muscle stimulation. There was a 
significant effect of time (repeated stimulation) on muscle shortening (Figure 4.7, 
p<0.05). There was no significant interaction. 
 
4.3.2.2 Mdx diaphragms have lower shortening velocity 
during repeated muscle stimulation  
Two-way ANOVA analysis of velocity decay over time revealed that shortening 
velocity was significantly different in mdx diaphragms compared to WT. There was 
a significant effect of time (repeated muscle stimulation) on muscle shortening 
(Figure 4.8, n=7, p<0.05). There was no significant interaction. 
 
4.3.2.3 Mdx mice produce lower power in muscle fatigue 
test 
Power – Time Relationship 
Two-way ANOVA of power decay over time during repeated muscle stimulation 
revealed that power was different in mdx and WT diaphragms (p<0.0001). As 
expected, time (repeated stimulation) was a significant factor (p<0.0001). There was 
a significant interaction (Figure 4.9, n=7, p<0.001). 
  
119 
 
  
Figure 4.7: Shortening-Time relationship in WT and mdx diaphragms during repeated 
muscle stimulation 
The graph illustrates the shortening of muscle strips following repeated stimulation. Two way 
ANOVA comparing shortening from WT and mdx revealed a significant difference between WT 
and mdx (* p<0.05), No time difference or interaction was observed. n=7 in both groups. 
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Figure 4.8: Velocity-Time relationship comparing WT and mdx diaphragm during repeated 
muscle stimulation 
 The graph illustrates velocity during repeated stimulation. Two way ANOVA comparing 
shortening velocity in WT and mdx revealed differences in time and velocity between WT and mdx 
diaphragms (p<0.0001).  There was no significant interaction. n=7 in each group. 
121 
 
  
Figure 4.9:. Power-Time relationship comparing WT and mdx diaphragms during 
repeated muscle stimulation 
The graph illustrates power production during repeated stimulation. Two way ANOVA 
comparing power in WT and mdx diaphragms revealed differences in time and power 
Interaction between the factors (time x power) was also significant. n=7 in each group. 
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Part Two: Effect of monoclonal IL-6R antibodies and/or a 
CRFR 2 agonist (Urocortin 2) on mdx diaphragm muscle 
function 
 
4.4.1 Diaphragm Function with intervention studies 
compared to saline treated mdx mice 
 
4.4.1.1 Anti IL-6R and/or Urocortin 2 increase twitch 
specific force in mdx diaphragm muscle 
Mdx diaphragms have reduced twitch force compared to WT controls. Treatment 
with anti IL-6R did not modify this (p>0.05, n=8). However, Urocortin 2 did cause 
recovery of twitch specific force compared to saline treated mdx mice (Figure 4.10ii, 
p=0.056, n=6-8). The beneficial effects of Urocortin 2 were moderated by co-
treatment with anti-IL-6R (p=0.06, n=6-8, figure 4.10 (i). Half relaxation time (iii) 
and time to peak (iv) were not changed by treatment. 
4.4.1.2 Mdx mice treated with anti IL-6R in the presence of 
Urocortin 2 have higher maximal tetanic force 
Similarly, mdx diaphragms have reduced specific tetanic force when compared to 
WT controls but anti IL-6R treatment with Urocortin 2 recovered this function 
(Figure 4.11ii, n=6-8, p<0.05, one way ANOVA). No significant effect was noted 
for anti IL-6 receptor blockade or Urocortin 2 treatment alone (p>0.05, Figure 4.11ii, 
n=6-8). 
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50ms 
Figure 4.10: Twitch Kinetics in mdx diaphragm with and without drug interventions 
 i Representative original traces of twitch force comparing mdx mice treated with saline (grey line), anti 
IL-6 receptor antibody (anti IL-6R, blue line), Urocortin 2 (red line) and a co- treatment of anti-IL-6R 
and Urocortin 2 (purple line).  ii The histogram shows specific twitch force values in treated mdx mice.  
Only Urocortin 2 significantly recovered the maximal twitch force recorded at the optimal length (n=6). 
iii The twitch relaxation (50% decay of force in seconds)was unchanged by treatments. iv The twitch 
contraction (time to peak in seconds) was unchanged by any treatment. n=6-8.  
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Figure 4.11: Specific Peak Force in mdx diaphragms with or without drug 
interventions 
i Representative original traces of tetanic force comparing mdx mice treated 
with saline (grey line), anti IL-6 receptor antibody (anti IL-6R, blue line), 
Urocortin 2 (red line) and a co- treatment of anti-IL-6 and Urocortin 2 (purple 
line). ii The peak specific force revealed a significant effect of anti IL-6R + 
Urocortin 2 co-treatment. One way ANOVA analysis revealed a treatment 
difference * p<0.05, n= 6-8. 
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Units
Saline Anti-IL-6R Urocortin 2 Anti-IL-6R + Urocortin 2
Optimal Length mm 8.938 ±0.6972 7.833 ±0.7817 9.8±0.5831 8.833 ±0.4944
CSA cm
2 0.003966 ±0.0007183 0.006247 ±0.0008684 0.003600 ±0.0005559 0.004770 ±0.0008181
Peak Twitch Force N/cm
2
1.146 ±0.3899 1.556 ±0.3330 2.524 ±0.4632 3.379 ±0.9091
Time To Peak s 0.02842 ±0.005294 0.0236 ±0.001288 0.0194 ±0.001435 0.0222 ±0.002948
½ Relaxation Time s 0.02042 ±0.003747 0.0192±0.0022 0.01863 ±0.002375 0.0180 ±0.001688
Peak Tetanic Force N/cm
2 5.341 ±1.957 7.692 ±1.843 11.26 ±3.032 15.54 ±2.677
Intervention Treatment
  
Table 4.3: Diaphragm preparation properties and isometric kinetic values for saline 
and treated mdx mice 
Neither optimal length nor CSA differed between treatment groups or vehicle (saline) 
treated mdx mice. Isometric kinetic values calculated from raw force measurements 
normalised to CSA. Represented as mean ± S.E.M 
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4.4.1.3 Blocking IL-6 signalling increases specific 
shortening and increases the length of shortening over the 
load continuum in the presence or absence of Urocortin 2 
In mdx mice treated with anti IL-6R in the presence or absence of Urocortin 2, or 
treated with Urocortin 2 alone, the diaphragms shorten significantly more than 
diaphragms from saline treated mdx mice (Figure 4.12, n=6-8, p<0.0001, two way 
ANOVA). As expected, load is a significant factor (p<0.0001) and there was a 
significant interaction between anti IL-6R treatment (treatment x load) compared to 
saline treated animals (p<0.0001). 
 
4.4.1.4 Blocking IL-6 signalling increases work production 
over the load continuum in the presence or absence of 
Urocortin 2, as does Urocortin 2 treatment alone 
Load - Work Relationship 
Work production was increased in all groups compared to saline controls. (Figure 
4.13, p<0.001 n=6-8). Load was a significant factor for each treatment (p<0.0001) 
but there was no significant interaction (treatment x load) (p>0.05). 
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Figure 4.12: Load-Shortening Relationship in mdx diaphragms with and without 
interventions  
Comparing mdx mice administered saline (black), anti IL-6 receptor antibody (anti IL-6R, 
blue), Urocortin 2 (red) and a co- treatment of anti-IL-6R and Urocortin 2 (purple).  
 i The graph shows the load/shortening relationship, measured as a ratio of 
shortening/optimal length (L/Lo). Peak specific shortening (L/Lo) increased following anti IL-
6R and co treatment of anti IL-6R + Urocortin 2 ii Two way ANOVA revealed a significant 
difference between all three interventions when compared to saline; there was a significant 
interaction also in the anti-IL-6 R treatment group.*p<0.05, n=6-8. 
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Figure 4.13: Mechanical Work Production in mdx diaphragms with and without 
interventions 
 The work - shortening relationship (Joules per cm
2
) in diaphragm muscle from mdx mice 
administered saline (black), anti IL-6 receptor antibody (anti IL-6R, blue), Urocortin 2 (red) 
or a co- treatment of anti-IL-6R and Urocortin 2 (purple) is graphed above. Two way 
ANOVA revealed a significant difference between all three interventions when compared to 
saline; there was no significant interaction, n=6-8. 
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4.4.1.5 Blocking IL-6 signalling increases peak velocity 
production and IL-6R and Urocortin 2 co-treatment 
increases muscle shortening velocity 
There was no significant difference in the peak velocity of muscle shortening in 
diaphragms taken from mdx mice from any treatment group with the exception of 
anti-IL-6R which stimulated an increase in the velocity (p<0.05, n=6-8, Figure 
4.14i).  
Mdx mice treated with anti IL-6R had significantly higher diaphragm shortening 
velocity (Figure 4.14ii, n=6-8, p<0.0001, two-way ANOVA) as did treatment with 
Urocortin 2 alone (p<0.0227), compared to saline treated mdx mice. Load was a 
significant factor (p<0.0001).There was no significant interaction. 
 
4.4.1.6 Power production was increased by anti IL-6R and 
Urocortin 2  
Peak diaphragm power was not different between saline and treated mdx mice 
(p>0.05, Figure 4.15i, n=6-8).  
The Load-Power relationship was measured as the velocity x specific load. Two way 
ANOVA revealed that all treatments increased diaphragm power production; anti IL-
6R alone (Figure 4.15ii, n=7, p<0.001) and in the presence of Urocortin 2 (p<0.001), 
and Urocortin 2 treatment alone (p<0.01) compared to saline treated mdx mice. Load 
was a significant factor (p<0.0001) but there was no interaction between power and 
load (p>0.05). 
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Figure 4.14: Load/Velocity Relationship in mdx diaphragms with or without 
intervention 
 The velocity of shortening (ratio of shortening/optimal length (L/Lo) over 300 milliseconds 
(ms) expressed as (Lo/s)) of mdx mice administered saline (black), anti IL-6 receptor 
antibody (anti IL-6R, blue), Urocortin 2 (red) and a co-treatment of anti-IL-6R + Urocortin 
2 (purple) is graphed above. i The peak shortening velocity is increased with anti IL-6R 
treatment. ii. Anti IL-6R treatment increases shortening velocity, as does treatment with 
Urocortin 2, (two way ANOVA). Load is a significant factor, but no interaction is seen in 
any treatment. * p<0.05, n= 5-8. 
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Figure 4.15: Mechanical Power Production in mdx diaphragms with or without intervention 
 Power production (Watts per cm
2
) in mdx mice treated with saline (black line), anti IL-6 receptor 
antibody (anti IL-6R, blue line), Urocortin 2 (red line) and a co-treatment of both (purple line) is 
graphed above. i  Peak Power was not changed by any treatment (p>0.05, one way ANOVA, n=7). 
ii Treatment with anti IL-6R in the presence or absence of Urocortin 2 increased power production 
over the load continuum, as did treatment with Urocortin 2 alone (Two way ANOVA, p<0.001, 
n=6-8) and a load effect in all intervention treatments. No interaction was observed between 
treatments, n=6-8. 
i 
ii 
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4.4.2 Repeated Muscle Stimulation 
4.4.2.1 Anti IL-6R and Urocortin 2 treatment increase 
shortening in a repeated stimulation protocol  
Over a load continuum, shortening is significantly increased in mdx diaphragm 
muscle treated with anti IL-6R, urocortin 2 or both. In a repeated stimulation 
protocol, two-way ANOVA revealed that in all treated mdx mice the diaphragm 
shortens (L/Lo) significantly more than saline treated mice. L/Lo was reduced to a 
greater extent with repeated stimulation in treated muscle compared to saline-treated 
controls, time (repeated stimulation) was a significant factor (Figure 4.16, p<0.0001 
n=6-8).  
4.4.2.2 Blocking IL-6 signalling in mdx mice significantly 
causes a higher velocity during repeated muscle stimulation 
compared to saline and other treatments 
Two-way ANOVA of shortening velocity decay over time, revealed a significant 
effect of anti IL-6R treatment (p<0.0001). There was no significant difference in 
Urocortin 2 treated mice compared to control and shortening velocity was reduced in 
anti IL-6R treated mice in the presence of Urocortin 2 (p<0.0001, Figure 4.17, n=6-
8). Time (repeated stimulation) was a significant factor and there was a significant 
interaction (velocity x time) in anti IL-6R treated mdx mice. (Figure 4.17, p<0.0001, 
n=6-8). 
4.4.2.3 IL-6R and Urocortin 2, significantly conserves 
power production in mdx mice 
Two-way ANOVA of power decay over time revealed that diaphragm power was 
significantly higher in all treated diaphragms compared to saline treated control mdx 
mice. Time was a significant factor (Figure 4.18, n=6-8, p<0.0001) but there were no 
significant interactions (p>0.05). 
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Figure 4.16: Muscle Shortening-Time relationship in mdx diaphragms with or without 
intervention 
The graph illustrates muscle shortening (shortening/optimal length (L/Lo)) in dx mice treated 
with saline (black line), anti IL-6 receptor antibody (anti IL-6R, blue line), Urocortin 2 (red 
line) and a co-treatment of both (purple line). In a repeated stimulation protocol diaphragm 
strips are stimulated at 33% specific force. Time is a significant factor for all treatments over 
the repeated stimulation protocol. Treatment with anti-IL-6R in the absence or presence of 
Urocortin 2 increases shortening over the repeated stimulation (p<0.0001) more so than 
Urocortin treatment alone (p<0.0418).There is an interaction observed with anti-IL-6R  
treatment (p<0.0001) (Two way ANOVA, n=6-8). 
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Figure 4.17: Velocity-Time relationship in treated mdx diaphragms with or without 
intervention 
The graphs shows velocity (shortening/optimal length per second over 300 milliseconds 
Lo/L)) in mdx mice treated with saline (black line), anti IL-6 receptor antibody (anti IL-6R, 
blue line), Urocortin 2 (red line) and a co-treatment of both (purple line).  In a repeated 
stimulation fatigue protocol, diaphragm strips are stimulated at 33% specific force. Time is a 
significant factor for all treatments over the repeated stimulation protocol (p<0.0001). 
Treatment is a significant in anti IL-6R treated mice in the absence and presence of 
Urocortin 2 (p<0.0001), but not Urocortin 2 treatment alone (p<0.2337). There is no 
interaction observed. (Two way ANOVA, n=5-8). 
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Figure 4.18: Power-Time relationship comparisons in mdx diaphragms with or without 
intervention 
The graphs shows power (Watts per cm
2
. in mdx mice treated with saline (black line), anti IL-6 
receptor antibody (anti IL-6R, blue line), Urocortin 2 (red line) and a co-treatment of both 
(purple line). In a repeated stimulation fatigue protocol diaphragm strips are stimulated at 33% 
specific force. Time is a significant factor for all treatments over the repeated stimulation 
protocol (p<0.0001). Treatment is a significant in anti IL-6R treated mice in the absence and 
presence of Urocortin 2 (p<0.0001), and with Urocortin 2 treatment alone (p<0.0166). There is 
no interaction observed. (Two way ANOVA, n=5-8). 
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4.4.3 Blocking IL-6 signalling in mdx mice significantly 
lowers IL-6 protein in diaphragm muscle 
 
Mdx mice treated with anti IL-6R have significantly less IL-6 protein in diaphragm 
homogenates than saline treated mice (Fig 4.19i, p<0.01, n=5). However, IL-6 
receptor expression itself was unchanged. IL-6 protein was not reduced significantly 
in Urocortin 2 treated mice or in the co-treatment group (Urocortin 2 + anti IL-6R). 
IL-6 receptor expression was also unaffected in the latter two groups (p>0.05, n=5). 
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Figure 4.19: Western Blot Densitometry 
analysis of IL-6 and IL-6 receptor 
expression in mdx diaphragms 
i The graphs and representative blots 
illustrate the change in expression of IL-6 
protein (n=5, p<0.01) and ii IL-6R 
(p>0.05) following treatment with anti IL-
6 receptor antibodies (IL-6R). iii The 
graphs and representative blots illustrate 
the change in expression of IL-6 protein 
(p>0.05) and iv IL-6R (p>0.05) following 
treatment with Urocortin 2. v The graphs 
and representative blots illustrate the 
change in expression of IL-6 protein ( 
p<0.01) and vi IL-6R (p>0.05) following 
co-treatment ** p<0.01, n=5. 
i
  
ii 
iii iv 
v vi 
IL-6rα ~70kD 
Saline GAPDH 
GAPDH 42kD 
Saline Anti-IL-6r 
IL-6 28kD 
IL-6 28kD 
IL-6rα ~70kD 
IL-6 28kD 
IL-6rα ~70kD 
Anti-IL-6r/Urocortin 2 Saline 
Saline Urocortin 2 
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4.5 Discussion 
Key findings: 
 
Mdx versus WT mice 
 
 Mdx mouse diaphragm exhibits a reduction in twitch force generation compared 
to age matched WT mice. 
 
 Mdx mouse diaphragm exhibits a reduction in peak tetanic force compared to 
WT mice. 
 
 Mdx mouse diaphragm exhibits a reduction in mechanical work production 
compared to WT mice. 
 
 Mdx mouse diaphragm exhibits a reduction in power production compared to 
WT mice. 
 
 Mdx mouse diaphragm is less resistant to fatigue than WT mice. 
 
Intervention Studies 
 
 Urocortin 2 alone or with anti IL-6R produces a higher twitch force compared to 
saline treated mdx mice. 
 
 Co-treatment of anti IL-6R and Urocortin 2 produces a significantly higher peak 
force compared to saline treated mdx mice. 
 
 Anti IL-6R alone and in conjunction with Urocortin 2 induces an increase in 
shortening of diaphragm strips compared to saline treated mdx mice. Anti IL-6R 
also increases the velocity of shortening. 
 
 All intervention treatments increase mechanical work production, with co-
treatment producing the largest increase. 
 
 All intervention treatments increase diaphragm power production. 
 
 All intervention treatments have moderate effects on fatigue, especially earlier in 
the trial. 
 
 IL-6 protein levels are reduced significantly in mdx diaphragms when treated 
with anti IL-6R compared to saline treated mice. 
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Muscle force generation and isometric fatigability of skeletal muscle comparing WT 
and mdx muscle is somewhat explored in the vast mdx literature; however  isotonic 
protocols exploring mdx diaphragm shortening kinetics, work and power are rarely 
investigated, although isotonic properties are perhaps more physiologically relevant 
in DMD. Isotonic, or muscle contraction that induces a length change in muscle 
cause micro lesions in muscle fibres, which then initiate a cascade of events which 
are detrimental to fibre health and function (Vilquin et al. 1998; Yang et al. 1998).   
As the diaphragm is the most affected skeletal muscle in the mdx murine model of 
DMD, it is often utilised to explore dystrophin deficiency and test the efficacy of 
potential palliative treatments (Coirault et al. 2002; Tinsley et al. 1998; Mizunoya et 
al. 2011; Hara et al. 2011), as I  do in this study. 
The focus of this project was to test both isometric and isotonic muscle contractions 
in untreated mdx mice and explore these properties following pharmacological 
intervention in vivo with a specific rat anti mouse IL-6 receptor antibody (MR16-1), 
the CRFR2 agonist, Urocortin 2 or a combination of both agents together in mdx 
mice. 
Because the pathology associated with dystrophin deficiency causes an inflammatory 
environment (Deconinck & Dan 2007; Porter et al. 2002; Manzur et al. 2007), and a 
loss of regenerative capacity of muscle fibre causes increased connective tissue 
(Klingler et al. 2012; Wehling-Henricks et al. 2008; Abdel-Salam et al. 2009) and 
weaker branched muscle (Lovering et al. 2009); I hypothesised that blocking a key 
pro-inflammatory cytokine, IL-6 which is involved in skeletal muscle metabolism 
and inflammation would improve function of the muscle (Pedersen & Febbraio 
2008; Jonsdottir et al. 2000; Nishimoto & Kishimoto 2004; Desreumaux 2000; 
Daisuke et al. 2014).  
Recently, a group have demonstrated that this antibody does not only reduce 
inflammation through the modulation of gene transcription in immune response 
cells, such as infiltrating macrophages – which I reproduced in study one (chapter 3) 
in mdx muscle, but can also promote muscle regeneration in injured muscle (Fujita et 
al. 2014). Counter-intuitively, blocking IL-6 receptor signalling using the same 
monoclonal antibody resulted in an increase in inflammation in limb skeletal muscle, 
although, the study did identify increased function of this limb. Additionally, this 
study is a chronic 5 week administration study of the antibody, indicating that 
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perhaps a long term blocking of IL-6 is detrimental due to its pleotropic anti- or pro-
inflammatory effects depending on cell type and environment. Controlling IL-6 
levels acutely in dystrophic muscle may be a more effective treatment (Kostek et al. 
2012).  
Similarly, studies relevant to this project which focus on stimulating the 
CRFR2 receptor have shown beneficial effects in mdx muscle. CRFR2 agonists can 
act as stimulators of anabolic signalling pathways, which can promote hypertrophy 
and reduce muscle necrosis. Studies have used both a synthetic analogue PG-873637 
(Hinkle et al. 2007; Hall et al. 2007) and a non-selective CRFR agonist, sauvagine 
(Hall et al. 2007) to explore this hypothesis in mdx muscle as a potential therapeutic 
strategy. Remarkably, PG-873637 treatment is comparable to corticosteroid 
treatment  (Hinkle et al. 2003). As steroid treatment is a somewhat affective 
palliative care in cohorts of patients, suggesting CRFR2 agonism may be of 
therapeutic benefit for patients with DMD, especially as long term steroid use can 
have detrimental side effects, or can “wear off” (Manzur et al. 2007).  
What has not been extensively studied however is the connection between 
IL-6 and CRFR2 agonists in skeletal muscle function and pathology in mdx mice. 
There is a well-documented interaction between the stress hormone system (CRF 
and the Urocortin family) and IL-6 in the enteric nervous system (Taché et al. 1993), 
in immune cells and in both smooth (Kageyama et al. 2006) and striated muscle of 
the cardiac system (Huang et al. 2009) in rodents. Our findings suggest that this 
crosstalk between the stress and immune systems also occur in diaphragm muscle.  
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4.5.1 Isometric contractile properties of mdx muscle 
Consistent with the literature (Gregorevic et al. 2002; Hinkle et al. 2007), specific 
twitch force reveals that WT mice can produce significantly higher forces in 
diaphragm muscle strips than mdx mice at the age studied (12 weeks). Mdx mouse 
diaphragm does not exceed 25% twitch force compared to WT control diaphragm. 
Similarly, peak specific force is significantly lower in mdx compared to WT controls 
consistent with other studies (Gregorevic et al. 2002; Hinkle et al. 2007; Bates et al. 
2013; Faulkner et al. 2008). Force generation is relative to the number of functional 
cross bridge connections made during skeletal muscle contraction (Attal et al. 2000; 
Lecarpentier et al. 1998) and in mdx diaphragm at this age, this dysfunction is most 
likely due to loss of functional muscle fibres (Lovering et al. 2009; Williams et al. 
1993) and an increase in connective tissue (Turgeman et al. 2008; Gosselin & 
Williams 2006), caused by the loss of dystrophin mechanical support (Batchelor & 
Winder 2006; Petrof et al. 1993).  
Whilst exploring the force generation capacity of diaphragm muscle, muscle 
kinetics can be extrapolated. In practice, the most useful parameters examined in 
mdx mice are time to peak (TTP) and time for the force to decay by half (½ RT). 
Changes in these kinetic parameters between mouse strains may indicate a change in 
fibre type and/or a change in calcium handling in myocytes. At this age, mdx mice 
start to exhibit changes in fibre type compared to WT mice, however the changes 
may not affect isometric twitch force kinetics (Gregorevic et al. 2002) as these 
changes in type 11x and type 11a fibres are known to generate a similar force 
(Geiger et al. 2000). However, it is generally accepted that fibre change does not 
start until mice are 16 weeks of age in dystrophic muscle (Guido et al. 2010), 
however I did not find changes.  As mdx mice age it is apparent that the velocity of 
the acto-myosin interaction slows (Coirault et al. 2002) due not only to contractile 
apparatus changes but to altered sarcoplasmic reticulum (SR) calcium handling 
(Kargacin & Kargacin 1996). However, in our study I found the TTP of a twitch 
contraction was not different between the strains nor was the 1/2 RT of the 
relaxation, which suggests no alterations in the actomyosin apparatus at 12 weeks of 
age. 
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Perhaps a limitation to this study is the calculation of force from the raw 
isometric output, force is calculated by utilising the CSA, assuming muscle density 
to be constant. In mdx muscle at three months, muscle weight may include split or 
necrotic muscle fibres evident with the histopathological studies of the diaphragm at 
this age (Claflin & Brooks 2008; Arakia et al. 1997). Thus, the determination of 
specific force (force normalised to CSA) may have exaggerated the muscle deficit. 
However, it is important to note than when absolute force measurements were 
compared (force in mN), mdx diaphragm was weaker than WT control, moreover 
optimal length does not differ between WT and mdx diaphragm muscle strip 
preparations nor does CSA. 
 
4.5.2 Effect of intervention on mdx isometric contractile 
properties 
When specific twitch force was compared across treatments, anti IL-6R and 
Urocortin 2 or a combination of the two agents bore interesting results. Differences 
between treatments and a partial additive effect were noted in twitch force. Anti IL-
6R therapy rescued the loss of muscle force noted in mdx muscle tissue.  Urocortin 2 
and anti IL-6R in combination with Urocortin 2 showed a trend towards an increase 
in specific tetanic forces, although this did not reach statistical significance. This 
appears to be due to a higher variability in mdx tissue contraction.  
These results suggest that blocking IL-6 signalling systemically can make the 
diaphragm produce a higher force than saline treated mice, and therefore a more 
capable, functional muscle. This may be due to a reduction in the inflammatory 
environment at a crucial time (10–12 weeks of age in the mice) and indeed molecular 
analysis results show a lower level of IL-6 protein in the receptor antibody treated 
group. This is likely beneficial to muscle contraction and may be indicative of a 
physiologically healthier muscle. 
Activation of the CRFR2 as previously described can reduce atrophy in 
skeletal muscle. In one study, a reduction in atrophy is reported in both 
immobilization and in non-immobilization models of skeletal muscle atrophy in the 
EDL (Hinkle et al. 2003). It was also reported that activation of the CRFR2 can 
increase maximum tetanic force, which is similar to the tetanic force increase 
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observed in this project. Interestingly, in their study CSA was increased, illustrating 
that CRFR2 agonists can increase muscle mass (Hall et al. 2007). In the present 
study, CSA of muscle fibres was not directly examined; rather muscle bundles of 
equivalent size were mounted for functional analysis. It is suggested that the increase 
in muscle force may be due to CRFR2 agonists’ ability to lower the catabolic muscle 
response induced by the pro-anxiolytic CRFR1 receptor activity in the HPA axis 
(Hinkle et al. 2003). CK levels in serum were reduced in treated mdx mice, and using 
Urocortin 2 as a CRFR2 agonist also results in the reduction of CK levels 
(Reutenauer-Patte et al. 2012), indicating a less “leaky” or damaged muscle fibre 
profile within skeletal muscle.  
Co-treatment did not elicit a complete additive effect on force production; 
however  it is established in other tissues that an interaction exists between IL-6 and 
CRF, namely in the nervous system (Vallières & Rivest 1999),  in striated 
cardiomyocytes (Huang et al. 2009), aortic smooth muscle (Kageyama et al. 2006) 
and colonic enteric neurons (O’ Malley et al. 2013) and a potential interaction in 
respiratory skeletal muscle could prove beneficial for dystrophic diaphragm of DMD 
patients given that studies have found anti-inflammatory treatments and CRFR2 
agonism to be beneficial. 
It is worth noting however, that CRFR2 agonism may also play a role in 
promoting a pro-inflammatory environment through NFĸB dependent induction of 
pro inflammatory IL-8 (Moss et al. 2007).  In colonic smooth muscle it also has a 
role in apoptosis in macrophages (Tsatsanis et al. 2005) through CRFR2 agonism  
acting as a paracrine anti-inflammatory signal, suggesting a self-modulating anti-
inflammatory role between CRF and its ligands. 
Investigating IL-6 levels in Urocortin 2 treated mice compared to saline 
treated mice, did not show a significant reduction in IL-6 or its receptor, suggesting 
the mechanisms through which it exerts its beneficial effects is more complex than 
simply an anti-inflammatory modulation of the pathological environment. It is likely 
however, that a reduction in IL-6 signalling results in a reduction in inflammatory 
induced pathology (Fujita et al. 2014). Urocortin 2 is likely promoting hypertrophy 
and slowing apoptosis of macrophages as well as slowing muscle atrophy through 
activation of CRFR2. 
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 The interaction is likely to be complex and is beyond the scope of the current 
project – it is evident however that Urocortin 2 in this study did not alter IL-6 levels, 
or receptor expression in the diaphragm muscle of mdx muscle compared to saline 
treated animals. 
 
4.5.3 Isotonic contractile shortening of mdx muscle 
compared to WT controls 
Exploring shortening over a load continuum revealed that at 12 weeks of age, mdx 
diaphragm strips “shorten” to the same extent (relative to resting optimal length) as 
WT diaphragms. The slope of the load relationship is similar between strains.  
These data suggest that at this age there is no difference in the actin-myosin 
contractile properties of the mdx fibres or more specifically, cross bridges kinetics 
and calcium handling in the SR (Claflin & Brooks 2008; Attal et al. 2000) contrary 
to studies reporting that dystrophic fibres undergo hyper-contractility (Claflin & 
Brooks 2008). However, the apparent discord between these results may be due to 
the study of skeletal limb muscles compared to diaphragm muscle of this study.  
Possibly, a limitation in the study is that optimal length was recorded only to the 
nearest millimetre. This may increase the margin of error in the ratio of shortening to 
optimal length. 
 
4.5.4 Effect of interventions on mdx isotonic contractile 
shortening properties 
Perhaps an unexpected result is the difference between treatments in the data for 
muscle shortening. Even though the optimal length of treated diaphragm strips were 
similar, anti IL-6R treatment alters muscle shortening which suggests IL-6 has a role 
in calcium handling and indeed it has been noted that chronic levels of IL-6 can 
interact with SR normal function and decrease contractility in cardiac muscle. 
Additionally, IL-6 can stimulate rises in intracellular calcium in enteric neurons 
(O’Malley et al, 2011), skeletal muscle from mdx mice exhibit elevated levels of 
both IL-6 and intracellular calcium (Allen et al. 2010) but it is unknown if IL-6 
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stimulates mdx diaphragm myocytes (Yu et al. 2005). Treatment with Urocortin 2 
had no significant effect.  
 
4.5.5 Isotonic mechanical work production of mdx muscle 
compared to WT controls 
Characterising mechanical work production in mdx diaphragm using an isotonic 
protocol is not commonly performed. Examining the contractile properties, including 
myosin isoforms (Petrof et al. 1993) and isometric force production is more common 
but has its limitations. It is not abstract to conclude that the differences in work 
production are due to the cross bridge numbers and function as opposed to 
actomyosin dynamic changes, as our isotonic results showing a large reduction in 
force generation capabilities and the lack of difference in shortening profile in the 
mdx mouse compared to the WT in our study. Work production has been examined 
previously in mdx mice diaphragm; this work however, was oscillatory stretch work 
using an isometric protocol, and the authors also found in support of our study that 
mdx diaphragm is capable of generating less mechanical work than WT mice 
(Stevens & Faulkner 2000). 
 
Our study examined mechanical work produced over a continuum of loads, WT mice 
produced a bell shaped curve, with peak work at 30-40% of  load, consistent with the 
literature (Attal et al. 2000) relating to specific muscle thermodynamics and cross 
bridge kinetics (Rall 1985). Work production in mdx mice was significantly lowered, 
and although shortening is similar between strains, force production is significantly 
reduced which accounting for the decline in mechanical work production (work = 
force x shortening).  
 
4.5.6. Effect of intervention on work production 
Mechanical work production was significantly improved by addition of the 
intervention treatments. Anti-IL-6R treatment improves work production as does 
Urocortin 2 treatment. This recovery is a result of a combination of a higher distance 
of muscle shortening and higher forces in the treatment groups. Urocortin 2 appears 
to shift the bell curve to the left, making peak specific mechanical work most 
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efficient at a lower percentage load. This indicates a change in the dynamic 
capabilities of the muscle. Addition of anti IL-6 receptor antibody in the presence of 
Urocortin 2 improves work production to the greatest extent, showing an additive 
effect. Interestingly, it also shifts the bell curve to the left, with peak work being at a 
lower percentage load than the other treatments or compared to saline controls, 
indicating that co-treatment is the most effective treatment in improving the 
pathophysiology in muscle dynamic contractile properties in mdx muscle. 
 
4.5.7 Isotonic shortening velocity and power production in 
mdx mice compared to WT controls and the change in 
shortening velocity following treatments  
Velocity of shortening 
Assessment of shortening velocity, which is measured during the isotonic 
contraction protocol over incremental loads, reveals no difference between mdx and 
WT animals in this study. Shortening velocity, similar to isometric kinetics (TTP and 
1/2 RT) is not affected in mdx mice at l2 weeks, it has been previously seen that 
actin-myosin coupling is changed in in vitro motility assays (Coirault et al. 2002). 
This suggests, as has previously been noted, that in vivo muscle actin-myosin 
coupling and detachment kinetics are not significantly different, but force generation 
is substantially lowered.  
Addition of anti IL-6R and Urocortin 2 alone or in combination increases the 
shortening velocity. Anti IL-6R increases the shortening velocity significantly and 
more than either Urocortin 2 alone or anti IL-6R and Urocortin 2 combined. 
Urocortin 2 alone or in co-treatment with anti IL-6R appeared to reduce velocity 
compared to anti IL-6R treatment alone, potentially due to its effect of increasing 
shortening. 
Muscle Power Production 
Although an important physiological muscle parameter, power production to contract 
and produce mechanical work is little examined in mdx mice, it was previously 
thought that power production was not decreased steadily, but it has been found to be 
33% lowered in a study investigating limb muscle (Lynch et al. 2001), (force x 
147 
 
velocity), consistent with our study where diaphragm power production is 
substantially decreased in mdx mice compared to WT controls. Due to a significant 
lowering of force and a slight lowering of velocity in mdx animals, the resulting 
power is depressed and there is essentially no power-load relationship such as that 
observed in the WT animals.  
Peak power does not differ between the treatments when compared to saline 
treated mdx mice – with maximal power production at 30% load. However, analysis 
of the power-load relationship shows a significant increase in power in the anti-IL-
6R treatment group compared to control. It has been reported that compounds which 
modulate atrophy can increase power production in mdx mice (Lynch et al. 2001), 
which may explain the benefits Urocortin 2 is having in power production. Co 
treatment with anti IL-6R have similar treatment effects greater than anti IL-6R 
treatment alone on power production. 
 
4.5.8 Repeated stimulation in mdx muscle – Isotonic Fatigue 
Protocol 
The diaphragm muscle is constantly contracting and relaxing to enable breathing; as 
such its fibre composition reflects its need to resist fatigue. As discussed in the 
context of force generation, fibre types at this age in mdx muscle do not exhibit a 
change in resistance (Guido et al. 2010) to fatigue. Fatigue has been studied in 
isometric preparations in mdx mice (Gregorevic et al. 2002) and in other skeletal 
muscles, which investigates the loss of specific force in response to repeated 
stimulation (Olivier et al. 2006). Isotonic fatigue however explores the capacity of 
muscle to perform work and generate power in response to repeated stimulation.   
Muscle shortening over 300 ms is significantly higher in mdx mice, 
compared to WT mice. The isotonic protocol is performed at 33% load (maximum 
specific force), and this was standardised for both groups. However it should be 
noted, at this load mdx muscle shortens to a greater extent than WT mice, therefore 
the protocol may have favoured mdx preparations. Nonetheless, mdx mice are 
similarly resistant to fatigue in the repeated protocol compared to WT animals, the 
slope of the shortening is equivalent to the WT animals, even though there is no time 
or interaction effect on either genotype. 
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Urocortin 2 alone did not affect isotonic fatigue, but anti IL-6R treatment had 
interesting effects. Even though there is a steeper slope of reduction in contraction, 
shortening starts from higher peak shortening compared to the other treatments, 
perhaps indicating a less stable modulation of calcium handling and cycling 
(Hortemo et al. 2013) within a myofibre in the absence of IL-6 and moreover IL-6 
has interactions of myosin light chain 2, which is dephosphorylated in repeated 
contraction protocols (Hortemo et al. 2013).  
Of most interest, co-treatment caused the muscle to be more fatigue tolerant than anti 
IL-6R alone and the latter 200 seconds of the test shows a significantly higher 
conservation of degree of shortening or loss of sustained shortening length and at the 
end of the test has a significantly higher capacity to shorten than saline treated or 
either treatment alone. This leads us to conclude that perhaps co treatment is best at 
conserving physiological ability of mdx diaphragm muscle to resist fatigue.  
 
4.5.9 Effect of repeated stimulation on velocity and power 
production  
Velocity of shortening 
Shortening velocity was altered in mdx mice compared to WT mice in the repeated 
stimulation protocol; revealing that WT mice are more resistant to fatigue induced 
reduction in velocity of shortening than mdx mice, the decline in shortening velocity 
with repeated stimulation in this specific protocol is greater in mdx diaphragms and 
although in skeletal muscle dystrophin deficiency does not seem to have effects in 
excitation contraction coupling compared to normal mice (Hollingworth et al. 1990), 
velocity is susceptible to fatigability in diaphragm muscle of mdx mice.  
Treatment with anti IL-6R reveals a higher peak shortening velocity than the other 
treatments resulting in a steeper slope and therefore a rundown of force conservation 
in mdx muscle, similar to its shortening profile. Urocortin 2 treatment produces a 
profile very different from anti IL-6R treatment, it has sustained shortening but a 
reduction in velocity, revealing slower but a more resistant profile to fatigue, perhaps 
due to the mechanisms discussed as per the shortening – time relationship. Urocortin 
2 did not produce a conservation of velocity compared to the other treatments, and 
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its profile is similar to that of saline treated mdx mice, indicating no therapeutic 
effect of Urocortin 2 on velocity maintenance.  
Power-time relationship 
There is a dramatic difference between the strains in power. WT mice show a 
progressive rundown in power with repeated muscle stimulation; mdx mice in 
comparison have very low initial power and show a further reduction over time. 
Power rundown in the repeated muscle stimulation protocol once again benefits from 
the treatment of anti IL-6R and Urocortin 2 treatment. Whereas all treatments lead to 
improved power compared to saline mdx mice, it would appear that co- treatment 
with both anti IL-6R and Urocortin 2 results in higher initial power and better 
maintenance of power during the fatigue trial. 
4.6 Conclusions 
Mdx diaphragm muscle contractile properties are significantly different from WT 
mice at 12 weeks of age. From the literature we know this dysfunction worsens with 
age in mdx mice, comparable to the human DMD condition. Force production is the 
most obvious physiological dysfunction and this affects mechanical work and power 
production in mdx diaphragms, similarly patients exhibit a reduction in force 
production and a thickened hypertrophic muscle. 
Taking an anti-inflammatory approach to therapy for ameliorating the progression of 
the disease, I treated mdx mice with MR16-1, an antibody which binds to and 
neutralises IL-6Rs, thereby blocking IL-6 signalling and this had a beneficial effect, 
increasing diaphragm force production. Moreover, treating mdx mice with a CRFR2 
agonist, Urocortin 2 also rescued force production in mdx mice. 
Interestingly, there is some interaction of these compounds in the mdx muscle, as a 
partial additive effect was observed in several key parameters of the study.  Because 
the two treatments appear to improve muscle physiology in different ways, for 
instance, anti IL-6R increases shortening and restores work, velocity and power 
whereas Urocortin 2 increases force, work and power, co-treatment of mdx with both 
agents produced the most beneficial effect in diaphragm contractile properties. This 
study has identified two key targets for potential new therapeutic strategies in the 
treatment of DMD.  
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Chapter 5: The role of IL-6 and 
CRF in gastrointestinal 
dysfunction in the mdx mouse 
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5.1 Introduction 
5.1.1 GI function is altered in patients with DMD 
GI function is compromised in patients with DMD, many patients exhibit 
gastrointestinal hypomotility (Barohn et al. 1988), pseudo obstruction (Leon et al. 
1986) and constipation which has been attributed to lack of mobility of the patient 
and weakened abdominal walls (O Borrelli et al. 2005), which aids the intestines in 
the movement of its contents. However, an additional consideration is the absence of 
dystrophin in smooth muscle in DMD patients (Hoffman et al. 1987; Byers et al. 
1991).  Indeed histological examination of post mortem smooth muscle from DMD 
patients reveals fibrosis and pathological features such as oedema and muscle wall 
fragility (Dinan et al. 2003) indicating pathological changes also occur in this tissue 
in the absence of dystrophin. Consistent with the human clinical presentation, adult 
(12-18 months) dystrophin-deficient mdx mice have altered GI smooth muscle 
dysfunction,  with evidence of slowed transit times in the colon, reduced faecal 
output but normal gastric emptying in vivo (Mulè et al. 2010).  Changes in electrical 
impulses controlling spontaneous contractions in the colon were also revealed in a 
study of younger (16 weeks) mdx mice (Tameyasu et al. 2004). However, of the 
mechanistic changes in GI smooth muscle underlying dysfunction is not well 
understood. 
 
5.1.2 Interleukin-6 and GI function 
IL-6 is a pro-inflammatory cytokine, which is released from a variety of tissues 
including skeletal muscle (Plomgaard et al. 2005). It is released in response to 
changes in metabolism of exercised muscle and also due to local inflammation 
(Pedersen & Febbraio 2008). However, it is also secreted by immune cells, neurons 
(März et al. 1998) and epithelial cells (Ding et al. 2000). As circulating IL-6 levels 
are elevated in DMD (Rufo et al. 2011; Messina et al. 2011) and membrane-bound 
IL-6 receptors are expressed on smooth muscle cells (O’ Malley, Dinan, et al. 
2011a), enteric neurons (O’ Malley, Liston, et al. 2013) and the mucosal cells in the 
GI tract (Atreya & Neurath 2005) in addition to the added sensitivity endowed by the 
soluble version of this receptor, this cytokine may contribute to GI dysfunction in 
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DMD. Indeed, IL-6 has been shown to play a role in other inflammatory GI disorders 
such as IBS (Barbara et al. 2006), colitis (Gustot et al. 2005), Crohns disease and in 
colon cancer (Atreya & Neurath 2005). 
 In the case of IBS, elevated IL-6 levels have been proposed as a biomarker 
of the disease (Clarke et al. 2009) but it has also been shown to have functional 
effects on GI secretion and contractility. The role of IL-6 in GI dysfunction in DMD 
is unknown. However, blocking IL-6 signalling with an IL-6 receptor antibody, 
MR16-1 surprisingly resulted in raised levels of inflammatory markers but was 
found to be beneficial in increasing forelimb strength in mdx mice. This was contrary 
to the hypothesis proposed in the study that blocking IL-6 signalling would reduce 
muscle damage, as opposed to a broad dampening of the immune response (Kostek 
et al. 2012), which has been reported to be detrimental to muscle repair (Summan et 
al. 2006; Chazaud et al. 2003). As discussed in chapter 4, recently, the elucidation of 
the mechanism by which MR16-1, and therefore IL-6 signalling blocking works has 
revealed that in skeletal muscle it reduces STAT3 phosphorylation and accelerated 
muscle regeneration (Fujita et al. 2014). However, no studies have examined the 
effect of blocking IL-6 signalling in bowel function in mdx mice. 
 
5.1.3 The role of the stress hormone - CRF in GI 
dysfunction in the mdx mouse 
Stress is a detrimental factor in many diseases, as is the case with both psychological 
(Bonaz & Bernstein 2013) and immune stressors in IBS. Moreover, there is high 
comorbidity between this functional bowel syndrome and mood disorders such as 
anxiety and  depression (Walker et al. 2011; Fitzgerald et al. 2008). In chapter 3, I 
discussed the prevalence of mood disorders in DMD and have provided evidence of 
depression- and anxiety-like behaviours in the dystrophin-deficient mdx mouse. 
Mood disorders can be exacerbated by stress, which is initiated by secretion of 
corticotrophin-releasing factor (CRF) from the paraventricular nucleus of the 
hypothalamus which subsequently stimulates the HPA axis (Bale & Vale 2004). 
CRF binds to two receptors, CRFR1 and CRFR2.  CRF receptors are also 
expressed in the GI tract where CRFR1 appears to have a stimulatory effect on 
colonic motility and contributes to visceral hypersensitivity in rodents inducing 
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functional GI changes including an increase in gastric motility, transit time and 
defecation (Martínez et al. 2002) and visceral hypersensitivity (Nijsen et al. 2005; 
Mart et al. 2004) whereas activation of CRFR2 inhibits motility in the gut, delaying 
gastric emptying  and can reduce sensitivity to induced visceral pain in rodents 
(Nijsen et al. 2005; Martínez et al. 2002) and also has anti-inflammatory effects 
(Tsatsanis et al. 2005).  
The related protein Urocortin 2 has a higher affinity for CRFR2 which are 
commonly expressed in the peripheral system; in macrophages (Tsatsanis et al. 
2005) and in the GI tract (O’Malley, Dinan, et al. 2010). Two studies examined the 
effects of CRFR2 antagonism in skeletal muscle in mdx mice where it was found 
have anti-inflammatory effects, improved diaphragm function and reduced mRNA 
levels of pro-inflammatory genes concluding that the effects of the CRFR2 
antagonism in the diaphragm is due to a pluripotent effect on the muscle 
(Reutenauer-Patte et al. 2012), and increase in muscle weight and decrease in non-
specific marker of disease serum CK levels (Hall et al. 2007). To date, CRFR2 
agonists have not been tested on smooth muscle function in mdx mice 
 
5.1.4 Interaction between IL-6 and the CRF family of 
proteins 
Crosstalk between IL-6 and CRF may be important in the exacerbation of GI 
symptoms in DMD as has been proposed in other GI disorders such as IBS (O’ 
Malley et al. 2013). IL-6 can activate the HPA axis, using a CRF dependent 
(Vallières & Rivest 1999) or independent pathway (Bethin et al. 2000). Moreover, 
IL-6 can stimulate the CRF pathway, namely ACTH which through the release of 
corticosteroids from the adrenal gland, in turn suppresses IL-6 (Venihaki et al. 2001) 
plasma levels, which implicates the CRF stress response in modulating the immune 
response. Besides in the central nervous system, crosstalk is apparent between IL-6 
and the CRF related proteins in various tissues,  as discussed  Urocortin 2 can induce 
IL-6 gene transcription in rodent aortic smooth (Kageyama et al. 2006) and 
modulates IL-6 levels in stromal cells (Zoumakis et al. 2000). Moreover, CRF 
antagonism increases IL-6 levels in plasma in psychological stress models (Ando et 
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al. 1998) and IL-6 is necessary for the CRF-stimulated stress response and can 
regulate its own mRNA levels (Vallières & Rivest 1999).  
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5.1.5 Hypothesis 
IL-6 and CRF-mediated signalling mechanisms have been linked to GI dysfunction 
in other disorders such as IBS. Therefore, we hypothesised that modulating IL-6 and 
CRF signalling would improve GI function in mdx mice. 
 
5.1.6 Specific Chapter Aims 
 To investigate whether loss of dystrophin causes morphological or functional 
changes in the GI tract of mdx mice 
 To assess the effectiveness of blocking IL-6Rs and/or activating CRFR2 in 
alleviating GI dysfunction in the mdx mouse 
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5.2 Methods  
5.2.1 Animals and Experimental Design 
Baseline values were compared between two groups of untreated 10 week old WT 
and mdx mice (n=12 mice per group). In the intervention study, mdx mice were
 
randomly assigned to one of four experimental groups (see Table 5.1, n=5-8 mice 
per group).
 
Mdx mice were subcutaneously injected with saline (0.9% NaCl), rat anti 
mouse IL-6 receptor monoclonal antibody (0.2mg/kg body weight, MR16-1 
provided from Chugai Pharmaceutical Co., Ltd, Tokyo, Japan), the CRFR2 agonist, 
Urocortin 2 (30µg/kg body weight) or both. The study of 6 injections lasted 2 weeks 
and as detailed protocol is displayed in Figure 5.1.; mice were randomly assigned to 
a group and received the dose in no more than 100µl of vehicle (saline), then 
underwent a stress induced defecation study on day 13 and were sacrificed for 
functional studies on day 14. 
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Table 5.1:  Experimental groups and N numbers & a timeline of injection and in vivo 
experimentation 
Intervention Study treatment are colour coded. Saline treated mdx mice are represented in 
grey, Anti IL-6 receptor antibody in red, Urocortin 2 in blue and a co-treatment of Anti 
IL-6 receptor antibody and Urocortin 2 in purple throughout the thesis. Six injections of 
randomly assigned treatment were given from Day 1 to Day 11, Stress Induced Defecation 
was performed on Day 13 and animals were sacrificed for organ baths on Day 14 
Groups Untreated
Saline Anti IL-6R Urocortin 2 Anti-IL-6R + Urocortin 2
Mdx 8 8 8 6 8
WT 8
Intervention Treatment
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5.2.2 Techniques  
Stress Induced Defecation (as described in chapter 2.3.1) 
 
Collecting Tissue and Blood (as described in chapter 2.4) 
Colons were excised, measured for length and stored in carbogen-bubbled ice-cold 
Krebs saline buffer for organ bath functional testing.  
Distal colon was frozen to -80
o
C for protein analysis. 
One centimetre of colon from WT and mdx mice were transferred to 4 % PFA 
fixative for histological processing.  
 
Organ Baths (as described in chapter 2.7.1) 
 
Protein Quantification (chapter 2.5.1) 
Distal colon were homogenised in 200µl lysis buffer and stored at -80oC for Western 
Blot analysis 
 
Western Blot (chapter 2.5.3) 
Protein quantification of IL-6 and IL-6Rs were determined using Western blot 
techniques in whole distal colon tissues from mdx mice which had undergone each of 
the experimental interventions 
 
Histology (chapter 2.4.1) 
Sections of distal colon were fixed, frozen, cryostat sectioned in the transverse plane 
and mounted on glass slides in preparation for H& E staining and subsequent 
analysis of smooth muscle histology measuring colonic layer thickness.
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5.3 Results 
Part One: Characterisation of distal colon physiology in 
mdx and WT mice 
 
5.3.1 Mdx faecal wet weight or water content does not differ 
from WT controls 
To investigate potential pathophysiology in mdx colons resulting from loss of 
dystrophin, mice at 12 weeks of age were compared to age matched WT mice. In 
vivo stress-induced defecation was assessed and faecal boli weight and water content 
examined, rate of defecation was recorded over a ninety minute period. The wet 
weight of expelled pellets was similar between mdx and WT mice (Figure 5.1ii, 
n=12, p>0.05). Moreover, the water content did not differ between mdx and WT 
mice either (Figure 5.1i, p>0.05) indicating that the consistency of the faecal matter 
wasn’t different in mdx mice.  
Nonetheless, in the first 15 minutes of the trial mdx mice (n=12) excreted fewer boli 
than WT mice (Figure 5.2i, n=2, p<0.05) and in the second 15 minute increment mdx 
mice excreted fewer boli than WT mice (Figure 5.2i, n=12, p<0.05). The 15 minutes 
from 45 to 90 minutes had similar excretory patterns (Figure 5.2i, p>0.05). When 
examined cumulatively, over 90 minutes, mdx mice excreted fewer boli than WT 
mice (Figure 5.2ii, n=12, p<0.05) suggesting that faecal transit, which is regulated by 
smooth muscle contractile activity, is slower in mdx mice.  
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Figure 5.1: Analysis of faecal weight and water content between WT and mdx mice  
 i Water content, as a percentage of total faecal pellet weight, does not differ between the 
strains nor does the ii wet weight of faecal boli excreted. n=12, p>0.05  
i ii 
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Figure 5.2: Analysis of faecal boli excreted between mdx and WT mice  
The number of faecal boli excreted by mdx mice in the first and second 15 minute intervals 
was lower than the WT control. No difference in excretory rate was noted in other time 
intervals (i). The cumulative number of faecal boli excreted was consistently higher in the 
WT mice over the 90 minute trial (ii).  n=12, * p<0.05, ** p<0.01 
i 
ii 
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5.3.2 Alterations in mdx colonic morphology 
5.3.2.1 Colon length is shorter in mdx mice compared to 
WT mice 
I looked at the colon as it is involved in motility in the distal GI tract (Sarna 2010) 
and symptoms such as motility and stool differences are apparent in DMD patients 
(Bushby et al. 2010) and patients with inflammatory bowel diseases (Ohama et al. 
2007; Atreya & Neurath 2005). I found that total colon length was shorter in mdx 
mice compared to WT mice (Figure 5.3iii, n=12, p<0.05) and this was due to a 
shortening of the distal colon in mdx mice (Figure 5.3ii, p<0.05) as no change was 
observed in proximal colon length (Figure 5.3i, p>0.05).  
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Figure 5.3: Colon Morphology in mdx and WT mice  
(i) The length (in centimetres) of the distal colon is shorter in mdx mice than WT controls 
whereas the length of the (ii) proximal colon (as indicated in the image (iv) was 
comparable between strains. (iii) The total colonic length was shorter in the mdx mice. 
(iv) A representative image of an mdx mouse gastrointestinal tract from the caecum to the 
rectum indicating the regions of the proximal and distal colon assessed. n=7, ** p<0.01, 
***p<0.001 
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5.3.2.2 Mdx muscle wall thickness is thickened when 
compared to WT colon wall thickness 
The thickness of muscle and mucosal layers in H&E-stained cross sections of distal 
colon indicated that the distal colonic muscle layer in mdx mice was thickened 
compared to WT controls (Figure 5.4iii, n=4, p<0.001), which may be indicative of 
muscle contraction or hypertrophy caused by loss of dystrophin. No strain 
differences were found in the thickness of mucosal layers in this region (Figure 
5.4iv, p>0.05) and both strain had comparable colonic diameters (Figure 5.4ii, 
p>0.05). 
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Figure 5.4: Histological analysis of colon layer thickness  
i The representative image of H&E stained colon (magnification x10) with scale bar 
100µm.(ii) No difference in colonic diameter was apparent but (iii) the muscle layer was 
thicker in mdx mice. (iv Mucosal thickness was similar in WT and mdx mice. n=7, *** 
p<0.001 
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5.3.3 Functional differences in mdx colon contractility  
Given that mdx colons are shorter than their WT counterparts and stress-induced 
faecal transit times are slower, dystrophin appears to contribute to normal GI smooth 
muscle function. Further functional studies were carried out in organ baths to 
determine the contractile activity in the mdx mouse. The amplitude of the contraction 
evoked in whole colonic sections from untreated mdx mice and WT mice, (n=5 per 
group) were assessed by normalising contractions evoked by IL-6 or CRF (200nM, 
20 minute duration) to a maximal response evoked, Carbachol (CCh, 100nM), which 
is a acetylcholine agonist, and causes contractions in smooth muscle tissue. 
Amplitude of contraction that is the change in mV from baseline to peak of largest 
contraction 
There was no difference in response to CCh in WT or mdx mice. Mdx mice 
was greater in exogenous recombinant IL-6 addition evoked colonic contractions in 
both WT and mdx tissues, however the amplitude of contractions in mdx was greater 
(Figure 5.5i, n=5, p<0.05) was added to the distal colon preparation. 
Addition of CRF evoked large contractile responses in both WT and mdx 
colons but there were no significant difference between the strains (Figure 5.5iii and 
iv). When both IL-6 & CRF were added together and regardless of whether this 
addition was carried out at the start or the end of the experiment, reduced contractile 
activity was noted in both strains (Figure 5.5iii).   
In WT mice, the presence of IL-6 appeared to suppress the contractile 
activity evoked by CRF (Figure 5.6i, p<0.0009,) whereas in mdx mice, the tissue 
appears equally sensitive to IL-6 and CRF with a reduced response when both are 
present does not (Figure 5.6ii, p>0.05). Two way ANOVA (Not shown) (strain x 
reagent) reveals no strain difference, but the effect of IL-6 and CRF were different 
(p<0.0031) and there was an interaction between the two factors (p<0.0409).  
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Figure 5.5: Amplitude change induced by addition of IL-6 or CRF to in vitro colon preparations in 
untreated mdx and WT mice in an organ bath 
 WT and mdx colon preparations produced amplitude change in mV with the addition of recombinant IL-
6, CRF or IL-6 in the presence of CRF. This reaction was normalised to the maximum amplitude change 
induced by Carbacol. ii, iv & vi A representative raw data trace comparing WT and mdx mice treated 
with IL-6 (ii), CRF (iv) or IL-6+CRF (vi) over a twenty minute period. Black traces represent WT mice 
colons, grey traces represent the mdx mice colons. IL-6 produced a significant increase in amplitude 
change (i) in mdx mice (ii) compared to WT mice. CRF had comparable reactions in WT and mdx mice 
(iii & iv,) and IL-6 in the presence of CRF had a similar and reduced reaction in WT versus mdx mice (v 
& vi). n=5, *p<0.05  
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Figure 5.6: Amplitude change induced by addition of IL-6 and CRF or both,  to 
in vitro colon preparations in untreated mdx and WT mice in an organ bath 
One way ANOVA shows a difference between compounds to the compounds added (i). 
mdx colon had similar reactions to each compound added (ii) A representative raw 
data trace comparing WT and mdx mice treated with IL-6 (iii), CRF (iv) or IL-
6+CRF (v) over a twenty minute period. Black traces represent WT mice colons. Grey 
traces represent the mdx mice colons.  
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To assess the component of the contraction which was neurally-mediated, the tissue 
was pre-incubated with the Na
+
 channel blocker, tetrodotoxin (TTX, 100nM, 
duration of incubation). In WT mice the presence of TTX did not alter the IL-6-
evoked contraction (Figure 5.7i, n=5, p>0.05) but reduced the amplitude of the IL-6 
& CRF-evoked contraction (Figure 5.5ii, n=5, p<0.05). Interestingly, in mdx mice, 
both IL-6- (Figure 5.7iii, p≤0.05) and IL-6 + CRF-evoked (Figure 5.7iv, n=5, 
p<0.05) contractions were sensitive to TTX indicating the importance of myenteric 
neuronal activity to these effects in this dystrophin-deficient strain. 
 
The frequency (number of contractions per minute over the 20 minute period) 
evoked by each factor was analysed. Addition of IL-6 caused comparable contraction 
frequency between WT and mdx mice (Figure 5.8i, n=3-6, p>0.05), as did CRF 
details (figure 5.8ii n=5, p>0.05) and IL-6 & CRF (Figure 5.8iii n=5, p>0.05). When 
a two way ANOVA was performed (strain x reagent), no strain difference, effect of 
reagent or interaction between the factors was observed figure (Figure 5.8iv, n=5, 
p>0.05). 
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Figure 5.7: Effect of amplitude change on reaction to TTX blocked colonic contractibility in 
excised colon preparations in an organ bath 
 There was no reduction in amplitude change in WT tissues in response to IL-6 (i) and a reduction 
in the amplitude of contraction in response to IL-6 and CRF (ii). in mdx tissues TTX causes 
inhibition of the responses to both IL-6 (iii) and IL-6 + CRF (iv). (n=3-6 colons per group) * 
p<0.05 
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Figure 5.8:  Frequency of Contractions evoked by IL-6 and CRF or both excised 
colon preparations in an organ bath 
The number of contractions did not differ between WT and mdx mice in addition of IL-
6 (i), CRF (ii) or IL-6 + CRF (iii) after comparing them using a student’s t test. When a 
two way ANOVA (iv) was performed, addition of neither compound, nor stain was 
significant, and no interaction was found. (n=3-6) p> 0.05  
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5.3.4 Summary of results Part 1 
Consistent with deficiencies in smooth muscle caused by loss of dystrophin, our 
studies found that mdx mice exhibited a number of changes in GI function as 
compared to WT controls. mdx mice excrete fewer boli compared to WT mice in the 
first 30 of a stress induced defecation protocol This indicates that mdx mice have 
functional changes in their lower GI tract resulting in slowed transit times and this 
significant effect is reflected in the cumulative result, where overall mdx mice 
excrete fewer faecal boli than similarly stressed WT mice. This is comparable to 
slowed GI transit in human DMD sufferers (Barohn et al. 1988). 
Consistent with this, gross morphological examination of the colon showed a 
shorter overall length and this stemmed from the distal colon. Histological 
examination of the colon showed a thickened wall, and this is conjunction with the 
shortening of the colon may indicate contraction of the gut in mdx mice. 
Alternatively, the thickened muscle layer may represent muscle cell hyperplasia. In 
contrast, there was no evidence of alterations in the thickness of the mucosal layer 
and analysis of the faecal water content suggests no abnormality in stool consistency 
which would indicate changes in absorpto-secretory function.  
Thus, loss of dystrophin appears to be specific to problems associated with 
smooth muscle function although unlike the characteristic inflammation in mdx 
skeletal muscle, histopathological analysis did not reveal obvious inflammatory 
infiltrate or fibrosis in colonic smooth muscle.  
To assess the functional consequences of these pathophysiological changes in 
mdx colonic smooth muscle, organ bath experiments assessed contractile activity in 
WT and mdx colons. When challenged with IL-6 than WT tissues and TTX blocks 
this effect demonstrating the neuronal component to this response. It appears that IL-
6 evokes contractions in WT colonic muscle through direct activation of smooth 
muscle, whereas loss of dystrophin and the associated smooth muscle dysfunction in 
mdx mice leads to contractile activity that is much more dependent on neural 
activity, probably mediated by the myenteric plexus. Thus, IL-6 likely binds to 
receptors on myenteric neurons subsequently activates contraction of GI smooth 
muscle cells in mdx colons. CRF stimulated large contractions in both WT and mdx 
strains and interestingly, this response was dampened when both IL-6 & CRF were 
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present, indicating potential crosstalk between these two factors which may be 
important in regulating GI activity. Moreover, this activity was sensitive to TTX 
indicating the importance of neural regulation of GI contractility and this may give a 
clue as to the neuronal site of interaction between IL-6 and CRF.  
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Part Two: Effect of blocking IL-6R signalling in the 
absence or presence of a CRFR2 agonist on mdx mouse 
colonic pathophysiology 
 
The second part of this study compares the pharmacological intervention of anti IL-6 
receptor antibody and Urocortin 2 or a combination of both on the histological and 
physiological readouts carried out on the control WT and mdx mice. 
5.4.1 Faecal output in mdx mice was not changed by 
intervention treatments 
The wet weight of expelled pellets was compared between four groups of mdx mice, 
those treated with a saline vehicle, a group which received anti IL-6R antibodies, a 
group treated with Urocortin 2 and a group which received both anti IL-6R and 
Urocortin 2. None of the treatments evoked any changes (Figure 5.9i, p>0.05,) in 
student’s t test compared to saline, or in a one way ANOVA comparing all 
treatments. Similarly no differences in water content were found between any 
treatment group and saline (Figure 5.9ii, p>0.05).  
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Figure 5.9: Faecal water content with or without intervention  
Wet weight (i) and water content (ii)does not differ between saline and each 
treatment group. n=5-8, p>0.05  
i ii 
 Faecal ater content ith or ithout intervention  
i   ater content (i ) does t iff  t  
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5.4.2 The effects of interventions on colonic motility in mdx 
mice 
 
To assess the efficacy of the interventions, each intervention was compared to saline-
treated mdx controls in the same stress induced defecation protocol as before. Pellets 
excreted by mdx mice were counted in 15 minute intervals and cumulatively over the 
90 minute open field trial and compared between saline and anti IL-6R (Figure 5.10i 
& ii, n=8), Urocortin 2 (Figure5.11i & ii), n=5-8), and anti IL-6R/Urocortin 2 
treatments (Figure 5.12i & ii, n=8).  
5.4.2.1 Saline vs. anti IL-6R Treatment 
Treatment with anti IL-6R increased faecal output in the first 15 minutes and the 
third fifteen minute intervals of the 90 minute trial (Figure 5.10i, p<0.05), and  
caused a significant increase every 15 minutes of the cumulative trial (Figure 5.10ii, 
p<0.05). 
5.4.2.2 Saline vs. Urocortin 2 Treatment 
Treatment with Urocortin 2 shows no significant difference between saline treated 
animals except in the 45-60 minute interval (Figure 5.11i, p<0.05), and no 
significant changes cumulatively (Figure 5.11ii, p>0.05). 
5.4.2.3 Saline vs. anti IL-6R/Urocortin 2 Treatment 
Treatment with anti IL-6R/Urocortin 2 increased faecal output in the third fifteen 
minute intervals of the 90 minute trial (Figure 5.12i, p<0.05), but not significantly in 
the cumulative trial (Figure 5.12ii, p>0.05). 
5.4.2.4 Comparing treatments 
No significant interaction is seen between treatments and time, but in the interval 2 
way ANOVA (Figure 5.13i, n=5-8) there is a time difference and in the cumulative 
two way ANOVA (Figure 5.13ii, n=5-8) both time and treatment differed 
significantly.  
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Figure 5.11: Analysis of faecal treatment times after treatment with Urocortin 
 Saline treated versus Urocortin 2 treated mice in 15 minute intervals (i) or 
cumulatively over 90 minutes trial (ii). n=6-8, ** p<0.005 
  
0: l i   f l boli excreted 
Saline treated versus anti-IL-6R trea ed mice (n=8) in 15 minute intervals (i) or 
8, * p<0.05, ** p<0.005 
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Figure 5.11: Analysis of faecal treatment times after treatment with 
Urocortin 2 
 Saline treated versus Urocortin 2 treated mice in 15 minute intervals (i) or 
cumulatively over 90 minutes trial (ii). n=6-8, ** p<0.005 
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Figure 5.12: Analysis of faecal transit times after treatment with anti IL-6R 
and Urocortin 2 
Saline treated versus anti IL-6R/Urocortin 2 treated mice in 15 minute intervals 
(i) or cumulatively over 90 minutes trial (ii). (n=8)* p<0.05 
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Figure 5.13: Faecal output comparing all treatments 
Comparing treatments in interval (i) and cumulative (ii) faecal output, no 
interaction is seen but a time effect is seen in 15 minute intervals (i) and both 
treatment and time are significantly different in the cumulative score of the 
protocol (ii). (n=5-8) p>0.05 
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5.4.3 Mdx colonic length following interventions 
 
5.4.3.1 Saline vs. anti IL-6R 
Total colonic length was decreased in mdx mice as compared to WT colons however, 
following treatment with anti IL-6R antibodies colons were longer than saline-
treated comparators (Figure 5.14i, n=8, p<0.05) and this was due to changes in the 
distal colon (Figure 5.14iii, n=8, p<0.05).  
5.4.3.2 Saline vs. Urocortin 2  
Treatment with Urocortin 2 (n=5-8) also resulted in slightly longer colons (Figure 
5.14iv, n=5-8, p=0.0647) which was significant in the proximal colon (Figure 5.14v, 
n=5-8, p<0.05) but not the distal colon (Figure 5.14vi, p>0.05).  
5.4.3.3 Saline vs. anti IL-6R/Urocortin 2  
Combined treatment with anti IL-6R/Urocortin 2 resulted in significantly longer total 
colon length in mdx mice (Figure 5.14vii, n=5-8, p<0.05) but no significant change 
in either the proximal or distal regions, indicating both proximal and distal length 
was moderately increased (Figure 5.14viii & ix, n=5). 
5.4.3.4 Treatment effect 
One way AVONA revealed that treatment had an overall effect in total colon length 
(Figure 5.15i, n=5-8, p<0.05), proximal colon lengths did not differ significantly 
(Figure 5.15ii) and there was a significant increase in distal colon length (Figure 
5.15iii, n=5-8, p<0.05).  
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Figure 5.14: Colon length measured with or without drug intervention 
 Treatment with anti-IL-6R increased total colon length (i) and distal colon 
length (iii), treatment with Urocortin 2 increases total colon length (iv) and 
proximal colon length (v).Treatment combining anti-IL-6R and Urocortin 2 
increased colon length (vii) but neither proximal or distal. (n=5-8) * p>0.05, 
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Figure 5.15: Colon length measured with or without interventions 
There is a significant difference in treatment in the total colon length 
amongst the groups (i) and distal colon length (iii), but no difference 
between proximal colon lengths (ii) In a one way ANOVA. n=5-8,*p<0.05 
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5.4.4 Interventions change the amplitude of contraction in 
mdx mice  
 
5.4.4.1 Mdx mice treated with anti IL-6R 
In mdx mice administered anti IL-6R antibodies the amplitude of the IL-6-evoked 
contraction was reduced when compared to saline treated mdx mice (Figure 5.16i 
and trace i, n=8, p<0.05). Not surprisingly, blocking IL-6 signalling did not change 
CRF-evoked contractions (Figure 5.16ii and trace ii, n=8, p>0.05) nor did it have 
any effect on contractions evoked by IL-6 & CRF (Fig 5.16iii and trace iii, n=8, 
p>0.05). One way ANOVA analysis of anti IL-6R (Figure 5.17i) showed no 
difference, 
 
5.4.4.2 Mdx mice treated with Urocortin 2 
IL-6 evoked smaller contractions in mdx mice treated with the CRFR2 agonist, 
Urocortin 2 as compared to mdx mice who received saline (Figure 5.16 iv and trace 
iv, n=5, p<0.05 ). There was no difference in the amplitude of the contraction evoked 
by CRF between Urocortin 2 and saline-treated mdx groups, but a significant 
reduction in the amplitude of the IL-6 & CRF-evoked contraction was noted in 
Urocortin 2-treated mdx mice (Figure 5.16 vi and trace vi, n=5, p>0.05). One way 
ANOVA analysis of Urocortin 2 treated mice shows a difference in amplitude 
change to the addition of IL-6 and CRF (Figures 5.17ii, p=0.09).  
 
5.4.4.3 Mdx mice treated with anti IL-6R and Urocortin 2  
Mdx mice treated with combined Urocortin 2 and anti IL-6R had a significant 
reduction in the contractile response evoked by  IL-6 compared to saline-treated 
mice (Figure 5.16vi and trace vi, n=8, p<0.05), there was no difference in responses 
evoked by CRF between groups, but a significant reduction in the amplitude of the 
contraction evoked by IL-6 & CRF was noted in mdx mice treated with anti IL-6R 
and Urocortin 2 (Figure 5.16ix and trace ix, n=8, p<0.05). Treatment with anti IL-
185 
 
6R/Urocortin2 shows no differences between compounds when analysed using one-
way ANOVA (Figure 5.17iii, n=8, p>0.05).  
5.4.4.4 Comparing treatments 
Two way ANOVA analysis (not shown, n=5-8) reveals no treatment effects, but 
there was a difference between the interventions and a significant interaction effect.  
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Figure 5.16: Treated mdx mice compared to saline in the addition of compounds; IL-6, CRF or IL-6+CRF 
 Saline vs anti-IL-6-r shows a reduction in amplitude change to the addition of IL-6 (i), and no changes with the addition of 
CRF (ii) or IL-6 & CRF (iii). Saline vs Urocortin  2 shows a reduction in amplitude change to the addition of IL-6 (iv), and 
no changes with the addition of CRF (v) or IL-6 & CRF (vi). Saline vs anti-IL-6R Urocortin 2 shows a reduction in 
amplitude change to the addition of IL-6 (vii), and no changes with the addition of CRF (viii) or IL-6 & CRF (ix). Labelled 
traces labelled corresponding to histogram it represents, 20 minute raw data (mV) (n-5-8) * p<0.05, ** p<0.005 
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Figure 5.17: Contractile properties of mdx treated mice with the addition of IL-6, CRF 
or both in an organ bath 
 
 One way ANOVA analysis of treated mdx anti-IL-6R treated mice in the addition of 
compounds; IL-6, CRF or IL-6& CRF. Saline vs anti-IL-6-R (i) shows no significant 
differences between treatments. Urocortin  2 treated mice shows a difference in  amplitude 
change to the addition of IL-6  and CRF (ii) Treatment with anti-IL-6R/Urocortin  2 shows no 
differences between compounds (iii), (n=5-8) *  p<0.05 
Representative traces (twenty minute trace, mV) show the differences between anti IL-6 
treated mdx mice (red line), Urocortin 2 treated mice (blue line) and co- treatment of anti IL-6 
and Urocortin 2 (purple line). Addition of IL-6 to these treatments is shown in (iv), addition of 
CRF is shown in (v) and addition of IL-6 in the presence of CRF in (vi). 
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5.4.5 Intervention studies change the frequency of 
contractions in mdx mice when compared to saline mdx 
mice 
5.4.5.1 Addition of IL-6  
Comparing contraction rates between treatments reveals treatment differences in a 
one way ANOVA. Addition of IL-6 (Figure 5.18i, n=8) shows significant 
differences between treatments namely between anti IL-6R vs Urocortin 2 (p<0.05) 
treated animals, anti-IL6r vs anti IL-6R/Urocortin animals (p<0.001) and saline vs 
Urocortin 2 treated animals (p<0.001), saline vs anti IL-6R/Urocortin 2 (p<0.001). 
5.4.5.2 Addition of CRF 
Addition of CRF (Figure 5.18ii) shows a significant increase in contraction rate in 
saline vs anti-IL-6 treated mice (p<0.05), saline vs Urocortin 2 treated mice 
(p<0.05), saline vs anti IL-6R/Urocortin 2 treated mice (p<0.001), anti-IL-6 vs anti 
IL-6R/Urocortin 2 (p<0.01) and Urocortin 2 vs anti IL-6R/Urocortin treated mice 
(p<0.05).  
5.4.5.3 Addition of IL-6 + CRF 
In mice treated with Urocortin 2, addition of IL6 & CRF (Figure 5.18iii) increased 
the colonic contraction rate as compared to saline-treated control mice  vs. Urocortin 
2 treated mice (p<0.05), saline vs anti IL-6R/Urocortin 2 treated mice (p<0.001) and 
anti IL-6R vs anti IL-6R/Urocortin 2 treated mice (p<0.01).  
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Addition of IL-6 (i) shows significant 
differences in the frequency of 
contractions between treatments 
namely between anti-IL-6R vs 
Urocortin 2 treated animals, anti-IL6r 
vs anti-IL-6R/Urocortin animals and 
saline vs Urocortin 2 treated animals, 
saline vs anti-IL-6R/Urocortin 2.  
 
 
 
 
 
 
Addition of CRF (ii) shows a 
significant change in contraction 
frequency in saline vs anti-IL-6 treated 
mice, saline vs Urocortin 2 treated 
mice, anti-IL-6R, saline vs anti-IL-
6R/Urocortin 2 treated mice and 
Urocortin 2 vs anti-IL-6R/Urocortin 
treated mice.  
 
 
 
 
 
 
 
Addition of IL-6 & CRF showed a 
significant increase in the frequency of 
contractions comparing saline vs 
Urocortin 2 treated mice, saline vs 
anti-IL-6R/Urocortin 2 treated mice 
and anti-IL-6R vs anti-IL-6R/Urocortin 
2 treated mice (iii).  
Figure 5.18: Frequency of Contraction per minute of mdx mouse colon preparations in an 
organ bath  
Addition of compounds compared between treatments as contraction per minute with the addition of 
compounds.  (n=5-8) * p<0.05 **p<0.001 ***p<0.001 
i 
ii 
iii 
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5.4.6 Intervention studies change levels of IL-6 and IL-6 
receptor in the colon of treated mice compared to saline 
controls 
5.4.6.1 Mdx mice treated with anti IL-6 receptor antibody 
Using western blot techniques, I determined that anti IL-6R treatment significantly 
reduces IL-6 levels (Figure 5.19i, n=5, p<0.05) in the whole distal colon compared to 
saline treated animals when IL-6 is expressed as a ratio of the housekeeper protein, 
GAPDH expression. Expression of IL-6 receptors in the colon was also reduced, 
although it did not quite reach significance (Figure 5.19ii, n=5, p=0.07). 
5.4.6.2 Mdx mice treated with Urocortin 2 
Treatment with Urocortin 2 also significantly decreases IL-6 levels (Figure 5.19iii, 
n=5, p<0.05) but not IL-6R levels (Figure 5.19iv, p>0.05).  
5.4.6.3 Mdx mice treated with anti IL-6 receptor antibody 
and Urocortin 2 
Co-treatment of mice with anti-IL-6 receptor/Urocortin 2 significantly decreases IL-
6 receptor expression (Figure 5.19v, n=5, p<0.05) but not IL-6 levels (Figure 5.19vi, 
n=5, p>0.05).  
a 
b 
c 
b 
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Figure 5.19: Western Blot densitometry 
analysis. IL-6 and IL-6r were analysed as a 
ratio to GAPDH. In anti-IL-6 treated mice 
IL-6 expression was reduced in colons (i) 
similarly IL-6R was reduced but not to a 
significant level (p=0.781). In anti-IL-
6R/Urocortin 2 mice IL-6 levels were 
unchanged (iii) but IL-6R expression was 
reduced. In Urocortin 2 treated mice IL-6 
expression was reduced significantly (v) 
and IL-6r was reduced but not significantly. 
(n=5) *p<0.05  
[vii] represents western blots for IL-6 and 
IL-6R in the treatments. 
i ii 
iii iv 
v vi 
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5.5 Discussion 
Main findings of the study: 
Mdx and WT mice 
 Mdx mice display altered defecation patterns. 
 Mdx mice have shorter colons, more so in the distal colon. 
 Mdx Distal colonic muscle walls are thickened. 
 The amplitude of contractions evoked in the excised colons of mdx mice in 
response to exogenous IL-6 was larger than WT controls. 
 Exogenous contractions evoked by IL-6 were ameliorated by TTX addition in 
mdx mice but not WT mice, implicating the enteric neurons as a source of IL-6 
induced contractions. 
 
Intervention Studies  
 Defecation rate improved with anti-IL-6 receptor antibodies, Urocortin 2 
treatment also increased total faecal output but this was somewhat delayed. 
 Colon length is increased by anti IL-6R treatment, more so in distal colon, by 
Urocortin 2 treatment in the proximal colon and in total length. 
 Contractile activity evoked by IL-6 in distal colon preparations from mdx had 
less IL-6-evoked activity in mice treated with anti IL-6R, with Urocortin 2 and in 
mice treated with both anti IL-6R and Urocortin 2. 
 Frequency of contractions evoked by IL-6 compared to saline-treated mdx mice 
were similar in anti-IL6r treated animals higher in Urocortin 2-treated mice and  
higher between co treatment or either treatment alone. 
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 CRF-evoked contractile activity was not changed in colons taken from mice 
treated with anti IL-6R, Urocortin 2 or both; however the frequency of 
contractions was increased in mice treated Urocortin 2 almost doubled in mice 
treated with both factors.   
 Colonic expression of the IL-6 receptor was reduced in anti IL-6R treated 
animals, it was also reduced in Urocortin 2 treated animals and co treated 
animals.  
 Levels of IL-6 were reduced in anti IL-6R and Urocortin 2 animals, but not 
significantly reduced in co treated animals.  
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The focus in this study was mdx dystrophin deficit colon and distal colon in 
particular, indicated as the portion of the GI tract most affected by a chronic 
inflammatory environments (Atreya & Neurath 2005; Bonaz & Bernstein 2013; 
Ohama et al. 2007), and more so because it is apparent there is an inflammatory 
response in DMD patients in the GI tract (Korman et al. 1991; Dinan et al. 2003), 
mouse colon expresses dystrophin in a variety of cells, namely myenteric neurons 
(Vannucchi et al. 2001), interstitial cells of cajal and  muscularis externa (Vannucchi 
et al. 2002). Mdx mice do not express dystrophin in the colon (Vannucchi et al. 
2001)  in the non-disease states and I aimed to investigate whether dystrophin 
deficiency in colon contributes to GI dysfunction and the role IL-6 and Urocortin 2 
play in this physiology. 
Cytokines such as IL-6 are overexpressed in DMD and mdx mice (Kumar & 
Boriek 2003; Fujita et al. 2014; Pan et al. 2008; Miles et al. 2011) and may 
contribute to colonic changes. IL-6 can activate the enteric neurons (O’ Malley et al. 
2013) and has a role in facilitating contractions in rat model of depression (Zhang et 
al. 2013) and along with IL-1 are seen to be neuromodulators in the gut, causing 
excitation by also suppressing cholinergic inhibition presynaptically (Kelles et al. 
2000) in enteric neurons therefore it is apparent IL-6 plays a key role in the 
physiology of the gut.  
It is not known however, how IL-6 induced changes are implicated in 
dystrophin deficient gut or whether patients could benefit from an anti- IL6 treatment 
in GI symptoms of the disease.  As patients share symptoms with other gut diseases 
it is intuitive to hypothesis these may share mechanisms which produce undesirable 
symptoms in the gut. Neutralisation of IL-6 in IBD has been seen to be efficacious in 
ameliorating inflammation (Wang et al. 2013), inflammation causes changes in 
motility due to changes in cytokine profile, changes in excitatory neurotransmitter 
receptor expression, disturbances in normal physiological action of calcium channels 
to name a few (Ohama et al. 2007). Moreover, as increased cytokines including IL-6 
(and TNF) are implicated in disease that exhibit slowed colonic motility, it is likely 
reducing IL-6 reduces this deficit  (Ang et al. 2012).  
CRFR2 receptors can  inhibit gastric emptying (Martinez et al. 2004; 
Martínez et al. 2002) but in distal colon does not seem to have an effect on 
contraction (Martínez et al. 2002) but in stress models can interact with localised 
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with CRFR1 receptors and an suppress stress induced contractions (Gourcerol et al. 
2011). An interaction between IL-6 and CRF, whereby immune activation and stress 
are proposed to exacerbate symptoms in IBS animal models (O’ Malley et al. 2013) 
and may similarly affect one another in the smooth muscle dysfunction and 
pathogenesis of the gut in DMD. 
Urocortin 2 exerts anti-inflammatory events through a number of cascades 
and this may be due to distribution of receptor types in different tissues. In the colon, 
Urocortin 2 binds with high affinity to the CRFR2 receptor, which has been shown 
to have anti-inflammatory effect by regulating the pro-inflammatory profile of the 
gut (Chang et al. 2007).  CRF and the Urocortins can supress secretion of several 
components of the inflammatory response including TNF-α from mice primary 
macrophages (Tsatsanis et al. 2007) and moreover activation of the CRFR2 subtype 
can induce macrophage apoptosis thereby modulating inflammation (Tsatsanis et al. 
2005). PG 873637, a CRFR2 agonist has been  found to be beneficial in mdx mice, 
albeit in skeletal muscle where its effects have been through increasing muscle 
hypertrophy (measured by weight of the muscle of both skeletal and cardiac muscle) 
(Hinkle et al. 2007) and a functionally healthier diaphragm muscle.  In the functional 
study of the diaphragm the CRFR2 agonist improved force generation, this 
improvement is associated  with a range of gene changes implicating anti-
inflammatory and anti-fibrotic effects in the muscle (Hinkle et al. 2007) . 
 
5.5.1 Faecal output changes in mdx mice  
The faecal transit times in WT and mdx mice were compared. Indicative of colonic 
health, I monitored the faecal output from mice when placed in a brightly lit stressful 
environment. Stress induced defecation is a well-established rodent behavioural test 
(O’Malley et al. 2010; O’ Malley et al. 2011b). In our protocol, I recorded output in 
15 minute intervals to examine time increments and to create a time line of faecal 
pellet output, but also to enable accurate calculation of water content through a 
desiccation protocol (Julio-Pieper et al. 2010). I also used a cumulative timeline of 
these 15 minute intervals to give insight on the number of boli excreted through the 
trial. As I discovered in Study 1 that mdx exhibit depressive and anxiety like 
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behaviours I would hypothesise a higher rate of defecation, induced from stress 
sensitivity in the colon.  
However I deduced from the reduced number of boli in the early interval 
faecal output times, in mdx mice compared to WT mice, as the literature reveals no 
evidence of increased sensitivity to stress in the WT mice I used, I concluded that 
colonic transport is slowed. This has been reported previously in small intestine 
transit time of mdx mice, although stomach gastric emptying times was not been 
affected (Mulè et al. 2010) – indicating the lower GI dysfunction is responsible for 
the altered output.  
 
In patients with DMD, orocaecal transit time has been previously studied in the 
1990’s, and no differences were reported from controls or compared to other 
neuromuscular diseases. However there are some limitations in this study; with 
previous histopathological evidence of GI smooth muscle fibrosis  and inflammation 
in post mortem tissue (Barohn et al. 1988) and symptoms (Gottrand 1991) indicating 
functional changes,  no differences were found in orocaecal transit time. However, 
these results should be treated with caution, as ingestion of liquid which passed 
through the pylorus was measured rather than a bolus of chyme (Korman et al. 
1991). Optimisation of the technique was used in a study and they reported a 
reduction in gastric emptying time in patients with DMD, through a radio-linked 
oatmeal meal (Barohn et al. 1988), reducing the slip-through effect of liquid which 
may have masked the slowed transit in earlier experiments.  
 
5.5.2 Faecal output changes in mdx mice and a role for IL-6 
signalling and Urocortin 2 in transit time 
In our studies, when mdx mice are treated with an anti-IL-6 receptor antibody for 2 
weeks, colonic transit time is faster than saline treated animal, an effect than may be 
beneficial for DMD patients, by normalising transit time. This normalisation is 
indicative of a beneficial effect of blocking IL-6 signalling in the colon, This action 
may be explained by blocking the pro-inflammatory effect of blocking IL-6 
signalling, a recent study utilising the MR16-1 antibody I used in my studies, have 
shown that blocking IL-6 signalling can reduce gene expression in macrophages in 
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damaged muscle tissue (Fujita et al. 2014). Moreover as increased cytokines 
including IL-6 (and TNF) are implicated in disease that exhibit slowed colonic 
motility, it is likely reducing IL-6 reduces this deficit (Ang et al. 2012), it may be 
due to the direct neutralisation of IL-6 receptors as IL-6 can elicit contractions 
through the neurons in the myenteric plexus (Zhang et al. 2013)  in disease states. 
Both IL-6 protein and IL-6 receptor expression was reduced in mice treated with 
MR16-1 treatment, blocking IL-6 signalling.  
CRF and the Urocortins can supress secretion of several components of the 
inflammatory response including TNF-α from mice primary macrophages (Tsatsanis 
et al. 2007) and moreover activation of the CRFR2 subtype can induce macrophage 
apoptosis thereby modulating inflammation (Tsatsanis et al. 2005). PG 873637, a 
CRFR2 agonist has been  found to be beneficial in mdx mice, albeit in skeletal 
muscle where its effects have been through increasing muscle hypertrophy 
(measured by weight of the muscle of both skeletal and cardiac muscle) (Hinkle et 
al. 2007) and a functionally healthier diaphragm muscle.  In the functional study of 
the diaphragm the CRFR2 agonist improved force generation, this improvement is 
associated  with a range of gene changes implicating anti-inflammatory and anti-
fibrotic effects in the muscle (Hinkle et al. 2007) .It is clear that Urocortin 2 exerts 
anti-inflammatory events through a number of cascades and this may be due to 
distribution of receptor types in different tissues. In the colon, Urocortin 2 binds 
more strongly to the CRFR2 receptor, which has been shown to have anti-
inflammatory effect by regulating the pro-inflammatory profile of the gut (Chang et 
al. 2007), and I found in animals treated with Urocortin 2, expression of IL-6 was 
reduced in colonic tissue.  An interaction between IL-6 and CRF, whereby immune 
activation and stress are proposed to exacerbate symptoms in  IBS animal models 
(O’ Malley et al. 2013) and may similarly affect one another in the smooth muscle 
dysfunction and pathogenesis of the gut in DMD, interestingly when Urocortin 2 was 
co-treated with anti-IL-6 receptor antibody it reduced IL-6 receptor levels, but not 
the protein, beyond  the scope of these functional tests however, it is indicative of a 
complex interaction of  IL-6 and Urocortin 2 in the gut. 
  
5.5.3 Faecal composition is not changed in mdx mice  
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The other main function of the colon is water and ion absorption and secretion; I 
found that the water content of mdx faecal boli was similar between WT and mdx 
mice. Water content, which is an indicator of the faecal form – ranging from watery 
unformed stools associated with diarrhoea to hard dry pellets observed in 
constipation, was not different between the WT mouse and the mdx strain as the 
pellet formation appeared normal and was no difference in wet of dry weight either.  
Although symptoms indicating a change in water and ion transport such as 
constipation and diarrhoea have been reported in DMD patients (Gottrand 1991), our 
studies do not find any evidence of altered stool formation in mdx mice in these 
measured parameters.  
Indeed, changes in gut barrier permeability which is important as a defence 
against inflammatory initiation from agents in the tract (Arrieta et al. 2006) has not 
been observed in smooth muscle of patients or mdx mice, and while aquaporin’s are 
expressed in the gut, in both neurons (Thi et al. 2008) and colonic epithelial cells 
(Tonghui & Verkman 1999) no evidence of dysregulated protein has been found in 
mdx mice. However, it has been implicated in skeletal muscle of patients (Frigeri et 
al. 2002) where its expression is reduced, this reduction is thought to be due to its 
association with the DAPC proteins (Frigeri et al. 2002).  
It is likely however that the divergence in mdx and human disease may 
contribute to the lack of pathology of this type. Symptoms such as constipation are 
attributed to immobility of patients or weakened abdominal wall skeletal muscle 
controlling motility of the GI tract (Gottrand 1991) as opposed to aberrant absorption 
or secretion. The consistency of the faecal pellets was not affected by any of the 
interventions.   
5.5.4 Morphological changes in mdx mice 
To investigate further I examined excised colon length in WT and mdx mice. Simply 
calculating colon length to the nearest millimetre yielded some interesting results. 
Mdx colon length is reduced compared to WT mice. Although, this seems counter 
intuitive when you take into consideration that transit time is also reduced, it may 
actually explain the dysregulated propulsion through the colon.  
I hypothesised this shortening may be due to changes in contraction 
mechanics or due to an inflammatory and fibrotic environment. Evidence exists that 
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shortened colon length is due to inflammation in animal models with inflammatory 
disease, such as colitis, and is used a disease marker (Kwon et al. 2008) and indeed 
in patients with DMD, GI fibrosis and inflammatory events have been seen post-
mortem (Barohn et al. 1988). 
However in other regions of the GI tract a reduction in thickness of smooth 
muscle walls are reported in patients (Dinan et al. 2003), however this apparently is 
organ specific as diaphragm thickening has also been reported (De Bruin et al. 1997) 
.  
Thickened muscular walls in distal sections of colon are consistent with increased 
contraction of the circular muscle layer which may contribute to the shortened colon. 
Indeed contracture (a contracted state which is a pathological sustained contraction) 
in skeletal muscle is common in patients with DMD (Allen & Whitehead 2011) and 
seen in mdx muscle (Claflin & Brooks 2008).  
I hypothesised this may be the case in smooth muscle. However, no inflammatory 
infiltrate which dominates in skeletal muscle pathology (Arakia et al. 1997) was 
apparent in the colonic cross-sections at this age, despite the raised cytokine profile 
at this age (Porter et al. 2002) and GI dysfunction our study has elucidated.   
5.5.4.1 Morphological changes in mdx mice by blocking IL-
6 signalling and CRFR2 agonism 
Thus, the capacity of anti IL-6 receptor antibody treatment to cause elongation of the 
mdx colons is unlikely to be caused by blocking the pro-inflammatory effect. 
However, it may be due to modulation of myenteric neurons which regulate smooth 
muscle function, specifically circular muscle contraction (Natale et al. 2003; O’ 
Malley et al. 2013) Alternatively, the thickening of the smooth muscle layer may 
indicate muscular hypertrophy as seen in cardiac tissue (Meléndez et al. 2010), thus 
IL-6 may be associated with this pathology. 
Treatment with Urocortin 2 also results in a lengthening effect in the colon, 
especially so in the proximal colon. This is different to anti IL-6R treatment, which 
is not entirely surprising, although CRFR2 promotes anti-inflammatory mechanisms; 
it does so differently to blocking IL-6 signalling. It has been seen to reduce to 
inflammation through the induction of apoptosis of pro-inflammatory macrophages 
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(Tsatsanis et al. 2005). However, in the absence of evident inflammation, Urocortin 
2 may be having a direct effect on muscle mass as has been seen in other muscle 
types (Hinkle et al. 2003; Hinkle et al. 2003; Hall et al. 2007) or indeed, stimulating 
changes through actions on the myenteric neurons (Maillot et al. 2002; Chang et al. 
2007; O’Malley et al. 2010).  
It is clear that CRFR2 agonism has beneficial effects in mdx mice skeletal muscle, 
increasing muscle mass (Hall et al. 2007) Co-treatment of anti-IL-6 and Urocortin 2 
does indeed increase colon length, but not specifically in the proximal or distal 
colon, the lengthening occurs in both portions presumably.  
5.5.5 Colonic contractile changes in mdx to exogenous 
stimuli 
5.5.5.1 Colonic reactivity to IL-6, CRF or a combination of 
both 
As mentioned mouse colon expresses dystrophin in a variety of cells, namely 
myenteric neurons (Vannucchi et al. 2001), interstitial cells of cajal and  muscularis 
externa (Vannucchi et al. 2002). mdx mice do not express dystrophin in the colon 
(Vannucchi et al. 2001).  
The loss of dystrophin affects the electrical activity in cells, resting 
membrane potentials in smooth muscle cells increased to -36mV in mdx cells 
compared to -50mV in normal conditions. This is somewhat attributed to the 
derangement in NOS which is associated with the DAPC (Serio et al. 2001), but the 
cause not fully elucidated. Furthermore, loss of normal GI pressure, propulsion and 
fluid ejection is indicative of a nervous system dysfunction due to dystrophin 
deficiency from the normally expressing neurons of the enteric nervous system 
(Mancinellia et al. 1995). 
To complement the transit time and propulsion in vivo study which indicated 
that there were changes to mdx smooth muscle function I excised distal colon 
sections and recorded electrical changes using an organ bath which measured 
contractile tension in the muscle. Moreover, I used exogenous IL-6 to ascertain if it 
had a role in the contraction of mdx smooth muscle, I also used CRF, and a 
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combination of both to investigate if there is crosstalk between the two in the control 
of contractions in mdx mice, as seen in other inflammatory disease models. 
  Our studies found that whole colon preparations of mdx mice react differently 
to WT controls when distal segments of colon are stimulated with IL-6 or CRF, or a 
combination of both. IL-6 causes an amplitude change in mdx mice far greater than 
that in WT mice, and the contraction had characteristics consistent with an increased 
and sustained tension.  This change in amplitude, bigger contractions than WT colon 
preparation includes circular and longitudinal muscle and the enteric nervous system 
however, so elucidating the particular cause of contraction is difficult to ascertain 
using only this technique. 
However, as previously mentioned mdx colons are particularly sensitive to stimuli as 
their cells are easier to depolarise due to the change in the resting potential (Serio et 
al. 2001). IL-6 is known to interact with myenteric neurons of the colon and can 
excite myenteric neurons in rodents (O’ Malley et al. 2011; O’ Malley et al. 2013). 
IL-6 can cause excitation of enteric neurons consequently causes contractions(O’ 
Malley et al. 2013), however myogenic contractions are reported in patients with 
IBDs caused by IL-6, and indeed IL-6 can be secreted by human smooth muscle 
cells in culture (Salinthone et al. 2004). Thus, IL-6 appears to have a role in normal 
colonic morphology and function and loss of dystrophin seems to interfere with this. 
5.5.5.2. Neuronally mediated contractions are evoked by IL-
6 in mdx mice 
Inhibition of voltage gated sodium channels with TTX indicated the importance of 
neural activity to IL-6 evoked contractions in mdx mice but not the WT controls 
(Bartoo et al. 2005; Holmberg et al. 2007). It has previously been reported in 
proximal colon segments pre-incubated with TTX produce a higher amplitude of 
spontaneous contractions which is comparable to WT proximal colons, however this 
is attributed to circular muscle layer and recorded as changes in intraluminal pressure 
(Mulé et al. 1999), and no spontaneous basal tone contractions were recorded after 
addition of TTX in our experiments this distal in the colon. Moreover it has been 
shown that IL-6R are located, not only in smooth muscle cells but also in the 
myenteric plexus of the colon in rodents and this is where the stimulatory effect is 
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propagated in animals which have raised systemic inflammatory cytokine profiles 
(Zhang et al. 2013).  
5.5.5.3 Treatment with anti IL-6 receptor and CRFR2 
agonism using Urocortin 2 effects on colonic reactivity to 
IL-6, CRF or a combination of both 
In mdx mice where IL-6 signalling is inhibited through the immuno-neutralisation of 
IL-6 receptors, predictably the amplitude of the colonic contraction evoked by IL-6 
was normalised and was thus similar to the response in WT mice. Interestingly 
however, when IL-6 and CRF were used to stimulate colons from these mice, there is 
an increase in the amplitude of the colonic contraction, although it doesn’t quite 
reach significance, which may indicate an additive effect of CRFR2 activation. 
Indeed, co-localisation of CRF receptors and IL-6 receptors is known to exist in 
neurons in the hypothalamus (González-Hernández et al. 2006) and in the propia 
lamina, in the mucosae and enteric neurons of rat colon sections (O’ Malley et al. 
2013; O’ Malley et al. 2011).  
Interaction between these receptors has not been researched in smooth 
muscle; however it is clear that the lack of dystrophin changes sensitivity of colonic 
smooth muscle to IL-6 and Urocortin 2, which has implications for diseases that are 
exacerbated by inflammation and stress as is the case in DMD. 
Similarly, and in support of the hypothesis that there is crosstalk in the colon 
between IL-6 and CRFR2, is the fact that IL-6-evoked colonic contractions were also 
reduced in colons taken from mdx mice treated with Urocortin 2.  
Moreover, the contraction evoked by IL-6 and CRF was also reduced in 
Urocortin 2 treated mice, but no change was observed when CRF was added by 
itself.  
However comparing the addition of IL-6 and CRF in Urocortin 2 treated 
mice shows a significantly higher contraction amplitude change to CRF compared to 
either IL-6 alone or a combination of IL-6 and CRF and binding to CRFR2 can 
decrease the compounding amplitude and increase of the amplitude of contractions 
to IL-6, but increases the frequency of smaller contractions.   
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The additive effect of a CRFR2 agonist and IL-6R neutralising antibodies 
was noted in a reduction in amplitude change to IL-6, and a reduction in amplitude to 
IL-6 and CRF, and when contractions were counted in the 20 minute period the 
compound was incubated with the colon I saw an increase in contraction frequency, 
which is additive for both IL-6 and CRF. 
The effects of Urocortin 2 may be due to its beneficial effect on muscle 
health. Evidence exists that colons in IBS patients (Dinan et al. 2003) exhibit 
inflammation,  and share symptoms of inflammatory colonic disease, however I did 
not see obvious infiltration in colons, it may be reducing the inflammatory 
environment (la Fleur et al. 2005; Tsatsanis et al. 2005; Moss et al. 2007). This 
positive effect on colon may reducing the contracture trace profile (the loss of full 
relation and a “stepping up” of contractions) of the smooth muscle contractions and 
therefore allowing more frequent but smaller, less sustained contractions .  
Similarly for CRF incubations, which almost doubles contractions for IL-6 
and CRF, incubated together, suggesting if there isn’t a straight forward interaction 
between the two. In several systems, eg gut-brain axis, a complex interaction has 
been hypothesised previously (O’ Malley et al. 2013) in IBD’s. The result suggests 
that this co-incubation, in the colon preparations have an additive effect in regard to 
contraction frequency and reduction in amplitude. Evidence from previous results, 
including the different changes in lengthening (anti IL-6 receptor antibody 
lengthening the distal colon, and Urocortin 2 lengthening the proximal colon, and a 
combination treatment lengthening not one segment in particular) indicates they may 
work through very diverging mechanisms. 
Not surprising perhaps is the significant decrease in IL-6 levels and IL-6 
receptor levels in the colons treated with anti-IL-6 receptor antibody at this 
dose/duration.  
This indeed validates the treatment, and reveals that blockage of the receptor 
by the antibody can reduce the IL-6 expression in colon, a reduction in IL-6 levels 
and in particular the reduction in active IL-6 receptor may underlie the changes in 
amplitude and frequency of contractions. This may be mediated through the 
myenteric neurons in inflammatory environments in rodent colons (Zhang et al. 
2013). Interestingly, mice treated with Urocortin 2 also had a reduction in IL-6 levels 
in colonic tissue, but not IL-6R expression. As discussed this may be due to the 
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overall anti-inflammatory effect of CRFR2 agonism, and the emerging apparent 
interaction between the family of CRF proteins and IL-6. It is interesting to see a 
significant reduction in IL-6 levels in the mice treated with Urocortin 2, IL-6 is 
released from neurons (März et al. 1998), smooth muscle (Kageyama et al. 2006) 
inflammatory cells and in contracting muscle (Erta et al. 2012), so it is difficult to 
fully explain the reduction in IL-6 level here. It may be indicative of a healthier state 
of the organ i.e. less inflammation, as the CRF system can regulate IL-6 during 
inflammation (Venihaki et al. 2001) or signalling interaction between the CRF 
system and IL-6, which is already begun to be elucidated in other tissues (Ando et al. 
1998; Tsatsanis et al. 2007). 
In contrast, combination treatment did not significantly reduce IL-6 levels but 
did decrease IL-6R expression. Evidence of a complex interaction is obvious, 
however when a co-treatment of anti IL-6 receptor antibody with Urocortin 2, as 
when administered separately they reduce IL-6 levels but together do not decrease 
amplitude levels.  
However, anti IL-6 receptor antibody did still block IL-6 receptor signalling 
in the presence of Urocortin 2, it is likely however, this is happening on a local tissue 
level (Kageyama et al. 2006) and that systemic IL-6 and Urocortin 2 are interacting 
in a manner which is both modulating IL-6 levels itself, and through the central HPA 
axis (Vallières & Rivest 1999), perhaps by modulating CRFR1 corticosteroid 
catabolic effects on either skeletal muscle (and thus this damaged muscle releasing 
circulating IL-6)(Hinkle et al. 2004), or a more direct, but as of yet unknown, effect 
on colonic smooth muscle cells.  
 
5.5.6 Conclusions 
This study investigated the GI consequence of dystrophin deficiency by comparing 
colonic function and morphology in mdx and WT mice. As symptoms in patients 
suffering from DMD include vomiting, constipation and DMD colons exhibit 
fibrosis and inflammation in their GI tract, it is speculated that dystrophin deficiency 
causes IBD type pathology in mice. In inflammatory diseases blocking IL-6 
signalling can reduce some GI pathological features, and is a readily available 
treatment, tolerated well in patients with Crohns disease (Ito 2005; Daisuke et al. 
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2014) in this study I have showed in vivo pathological differences in mdx mice 
compared to WT mice, such as slowed GI motility, thickened muscle walls, and 
shortened colon length. 
Blocking IL-6 signalling using the MIR16-1 monoclonal anti IL-6R Ab 
(Tamura 1993) increased transit time, but did not change the composition of the 
faecal pellets, it also reduced the IL-6 induced contractions, which are likely to be 
regulated by myenteric neurons, in which is in contrast to the WT mice which appear 
to be mediated through direct effects on the muscle cells.  
Urocortin 2 has less beneficial effects than anti IL-6R, in colonic motility but 
still elicited some effects. although CRFR2 agonists have been beneficial in mdx 
skeletal muscle (Hinkle et al. 2007) and I see here, that systemic injection of 
Urocortin 2, acts to benefit smooth muscle.  
Stimulating colonic preparations however did reveal an additive effect of the 
drugs on contraction frequency and a similar pattern of amplitude change to the 
recombinant exogenous IL-6 and CRF additions demonstrating a likely crosstalk 
between these two factors in this tissue.  
These studies provide evidence of the potential benefits of therapeutic interventions 
targeting IL-6 receptor signalling and/or the effects of the stress hormone, CRF. 
Largely, left untreated due to the debilitating effects of deterioration of other bodily 
systems, improving gut function in DMD offers an important potential improvement 
in the quality of life of patients. 
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Chapter 6: Summary and 
Conclusions 
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6.1 Summary of Results 
In chapter 3, I utilised the mdx mouse model of DMD, to investigate behavioural 
changes associated with dystrophin deficiency (Anderson et al. 2004) or possibly  
chronic inflammation and its crosstalk with the stress system (Varghese et al. 2006; 
Camacho 2013; Gerber & Bale 2012). Our studies identified behavioural profiles 
consistent with increased anxiety and depression. I subsequently assessed the effects 
of amitriptyline, a TCA, on the altered behaviours and on chronic skeletal muscle 
inflammation, which is characteristic of the mdx mouse.  
Predictably, amitriptyline had anti-depressant-like effects but it also 
improved the anxiety exhibited by the mdx mice in the open field test. Indeed, 
monoamine analysis in several brain regions revealed that mdx mice respond 
differently to amitriptyline treatment than WT mice, indicating that amitriptyline 
works through the modulation of central monoamines.  
However, the full mechanisms by which amitriptyline works in mdx 
pathology is not yet completely understood. In addition to the mood altering effects 
of amitriptyline, inflammatory cell infiltrate in skeletal muscle sections was 
decreased following treatment and number of myofibres with centralised nuclei, 
which are indicative of regenerating fibres was reduced. In dystrophic muscle, 
regeneration is a precursor to loss of function. Because of the central role of 
inflammation in DMD, I investigated changes in the pro-inflammatory cytokine, IL-
6 which is involved in inflammation, but also stress and depression. Amitriptyline 
reduced circulating IL-6 levels. 
 
In the subsequent studies the direct roles of IL-6 and the stress factor, CRF in DMD 
pathophysiology were investigated. I first examined diaphragm function which, in 
the mdx mouse model most closely recapitulates human DMD (De Bruin et al. 1997; 
Grounds et al. 2008). Monoclonal antibodies against the IL-6 receptor and the 
Urocortin 2, the CRF receptor 2 agonist, which has beneficial peripheral effects on 
mdx muscle (Hall et al. 2007; Hinkle et al. 2007) were investigated. I also included a 
group which was treated with both of these factors as crosstalk between IL-6 and 
CRF proteins (Ando et al. 1998; Kageyama et al. 2006; Kageyama & Suda 2003; M. 
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Huang et al. 2009) suggested that they may have beneficial effects if administered 
together.  
Our studies determined that isometric force generating conditions, mdx 
mouse diaphragm exhibits a reduction in twitch force generation and Urocortin 2 or 
co-treatment of anti IL-6R rescued this to some extent. Moreover, co-treatment 
produced a significantly higher peak force compared to saline treated mdx mice. 
Interestingly, anti IL-6R alone and with Urocortin 2 induced an increase in 
shortening of diaphragm strips. Anti IL-6R also increased velocity of shortening of 
mdx diaphragm, through as of yet an unknown mechanism.  
In an isotonic setup, where muscle shortening as a percentage of its maximal 
specific force load is recorded, mdx mouse diaphragm exhibits a reduction in 
mechanical work production. All intervention treatments increased mechanical work 
production, with co-treatment of anti IL-6R and urocortin 2 produced the largest 
increase. Mdx mouse diaphragm exhibits a reduction in power production compared 
to WT mice. All intervention treatments increase diaphragm power production, 
which is important because of the continuous contraction and relaxation of the 
diaphragm muscle. The fatigue ability of this muscle was also assessed and mdx 
mouse diaphragm was found to be less resistant to fatigue. However, this was 
improved moderately by all intervention treatments. 
 
In chapter 5, I utilised the same cohort of treated mdx mice to investigate the colonic 
deficits which have been reported in DMD patients (O Borrelli et al. 2005; Korman 
et al. 1991) and has also been observed in mdx mice (Tameyasu et al. 2004; 
Vannucchi et al. 2004; Mulé et al. 1999). Consistent with deficiencies in smooth 
muscle caused by loss of dystrophin, our studies found that mdx mice exhibited a 
number of changes in GI function as compared to WT controls. Mdx mice exhibited 
slowed transit times and excrete fewer faecal boli than similarly stressed WT mice. 
This is comparable to slowed GI transit in human DMD sufferers (Barohn et al. 
1988). Moreover, colon lengths were shorter and the muscle wall appeared thickened 
which may indicate aberrant smooth muscle contraction or muscle cell hypertrophy. 
Thus, loss of dystrophin appears to be specific to problems associated with smooth 
muscle function although unlike the characteristic inflammation in mdx skeletal 
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muscle, histopathological analysis did not reveal obvious inflammatory infiltrate or 
fibrosis in colonic smooth muscle.  
To assess the functional consequences of these pathophysiological changes 
colonic contractile activity in response to IL-6, CRF or both were assessed in WT 
and mdx tissues. Although control responses evoked by the cholinergic agonist 
Carbachol were comparable, mdx colons were more sensitive to the stimulatory 
effects of IL-6 which is neurally-mediated probably through activity of the myenteric 
plexus. This contrasts with the stimulatory effects IL-6 in WT colons which do not 
have a neural component, thus, loss of dystrophin and the associated smooth muscle 
dysfunction appears to lead to a compensatory mechanism which relies on neural 
activity. CRF stimulated large contractions in both WT and mdx strains and 
interestingly, this response was dampened when both IL-6 & CRF were applied 
together, indicating potential crosstalk between these two factors which may be 
important in regulating GI activity when the stress system and the inflammatory 
response are both chronically activated which is likely to be the case in DMD.  
To investigate the potential of therapeutically targeting IL-6Rs and/or CRFRs 
in mdx. GI function, colonic tissue from mice treated with IL-6R, Urocortin 2 or both 
was assessed. Indeed, the treatments did have functional effects with anti IL-6RR 
increasing transit time, colonic length and resulting in a reduction in the amplitude of 
IL-6-evoked contractions although the frequency of contractions was unaffected. The 
amplitude of CRF- and IL-6 & CRF- evoked contractions was unchanged by anti IL-
6R treatment but the frequency of the contractions was increased by both.  
Urocortin 2 treatment was also associated with increased faecal transit times, 
although this was noted later in the trial and to a lesser extent. No change in colonic 
length was evident but the amplitude of IL-6-evoked contractions was reduced in 
these mice even though the frequency of contractions was unaffected. The amplitude 
of CRF- and IL-6 & CRF-evoked contractions was not altered by Urocortin 2 
treatment but again, the frequency of the contractions was increased by both 
stimulants.  
mdx mice which received both anti IL-6R and Urocortin 2 did not show the 
same increase in faecal transit as those mice treated with IL-6R alone, indicating that 
Urocortin 2 may have a moderating influence on this readout. However, colonic 
length was increased in comparison to saline-treated mdx mice and the amplitude of 
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IL-6-evoked contractions was reduced. The amplitudes of CRF-evoked contractions 
were unchanged but contractile activity evoked by IL-6 & CRF was decreased. 
Moreover, the frequencies of contractions evoked by IL-6, CRF and IL-6 & CRF 
were all increased significantly.  
IL-6 is a marker of inflammation and also indicative of structural damage in 
contracting muscles (Jonsdottir et al. 2000; Pedersen & Febbraio 2008), however, I 
have also demonstrated that IL-6 has functional effects in terms of colonic 
contractility. CRF, the key stress hormone released by the hypothalamus, can also 
evoke colonic contractions and I have provided evidence that crosstalk between 
these factors, which may occur when both inflammatory and stress systems are 
chronically activated, can modulate both colonic tissue structure and function. In 
terms of normal GI function, targeting IL-6Rs and CRFR2 in mdx mice has proven 
to be beneficial. 
  
6.2 Limitations 
Perhaps the first limitation in this study was the mdx mouse model. Although a 
genetic mimic of DMD, the pathological signature of dystrophin deficiency deviates 
from the human disease, therefore in extrapolating the implications of the 
experimental data, leaves questions as to whether these are transferable to the human 
disease. 
In the first study, I was unable to quantify IL-6 levels to a satisfactory level in 
skeletal muscle which exhibited evidence of inflammation. In the studies that 
followed I aimed to rectify this by quantifying IL-6 levels in the muscle using 
Western blots. Nonetheless, I did determine that circulating IL-6 levels were reduced 
following treatment with amitriptyline.  
In study two, I detected novel protective effects of anti IL-6-R and/or Urocortin 2, 
however, further research will be required to elucidate the underlying mechanisms 
which regulate these effects. Moreover, it is noteworthy to mention that studies have 
found absolute measurements of power in mdx mice were normal compared to WT 
until it was normalised to fibre numbers in the preparation, indicating the weight of 
muscle can conceal true ability of the muscle to produce force. As our results were 
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calculated using CSA, this may mask more specific results. CSA assumes that the 
weight of the muscle preparation is composed of muscle fibres and in the calculation 
of CSA muscle density is considered a constant. This limitation could be overcome 
by using single fibre preparations; regrettably, this was unavailable for the current 
study in our laboratory.  
6.3 Future Studies 
It would be interesting to examine isotonic capabilities of IL-6 and Urocortin treated 
mice in single fibre preparations. Moreover, although not available for this study, 
histological analysis of the diaphragm muscle for signs of inflammation and changes 
in cell type during treatment would go to further elucidate the mechanisms by which 
anti IL-6Rs are having their effects. Understanding the complex interactions between 
IL-6R and CRFR signalling at a cellular level both in WT and mdx skeletal and 
smooth muscle and in associated neural cells will require alternative experimental 
techniques such as calcium imaging or electrophysiology  
6.4 Implications 
The results of our study on Amitriptyline, a drug already on the market for the 
treatment of depression, stress, pain and inflammatory diseases, suggests a potential 
new use for this old drug in. However, caution is to be used when prescribing tri 
cyclic antidepressants and it is important it is on a patient to patient basis as it has 
been implicated in cardiac toxicity and DMD patients have weakened heart muscle.  
In study 2 and 3, I demonstrated that blocking IL-6 signalling can benefit both 
diaphragm and GI function. Monoclonal antibodies against IL-6 receptors are 
already prescribed for use in rheumatoid arthritis, but we have identified a new 
disease in which this therapy may be effective, perhaps when co-administered with a 
CRFR2 agonist.  
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For our proteins of interest, therefore a starting point to prevent saturation of 
GAPDH (highly expressed, more so than IL-6 or IL-6R in tissues).  
 
GAPDH  
Protein expression per sample compared to GAPDH expression 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anti-GAPDH at 1:2000, secondary at 10:10,000 (A) produces a signal but high non-
specific binding, as does a primary concentration of 1:5000, secondary at 
1:20,000 (B), a reduction in current (optimised blots run for 90minutes at 
100volts) to prevent unevening running of bands was performed at this stage. 
 
  
Primary 1:2000 
Secondary 1:10,000 
Primary 1:5000 
Secondary 1:20,000 
A 
B 
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Primary omission 
 
 
 
Final concentration used for GAPDH western blots was 1:20,000 with secondary 
concentration 1:100,000, reducing background, which is still apparent in 
1:50,000 concentration in (C), in (D) a negative control (sample buffer without 
protein), and again in (E). (D) and (E) also reduce in antibody concentration.  
  
Primary 1:20,000 
Secondary 1:50,000 
C 
D 
E 
Primary 1:10,000 
Secondary 1:75,000 
Primary 1:20,000 
Secondary 1:100,000 
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IL-6R  
Previously optimised in laboratory with 40ug of protein at. 1:1000, secondary 
1:5000. 
 
 
 
F 
G 
Primary 1:2000 
Secondary 1:10,000 
Primary 1:1000 
Secondary 1:2,000 
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In (F), starting at a concentration of 1:2000 showed a faint signal and background, 
increasing concentration to 1:1000 and secondary of 1:2000 (G) produced high 
background as did 1:2000 and secondary of 1:4000, double banding (red arrows 
in (H)) represent dimerization of the IL-6 receptor at the predicted molecular 
weight, which is a result found in this specific protein (Schuster et al. 2003), 
yellow arrow represents a negative control lane (no protein in lane).  
H 
Primary 1:1000 
Secondary 1:4,000 
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Yellow arrow in (I) represents a negative control, at this stage, washes were 
increased from 5X3 minutes to 10X3 minutes to remove any residual non-
specific binding. (J) A primary omission was performed with secondary 
concentration of 1:5,000, no bands were visible. 
 
I 
J 
Primary 1:1000 
Secondary 1:4000 
Primary OMMITED 
Secondary 1:5,000 
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 IL-6 
Previously used at 1:500 in rat tissue, secondary at 1:2000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(K) and (L) show different antibody concentrations, arrows indicating IL-6 
molecular weights, however high background signal was apparent and washes 
were increased (as with IL-6R) from 5X3 minutes to 10x3 minutes. The 
negative control in (L) is not obvious due to pooling of secondary antibody non-
specific binding; this was overcome using a rotating incubation and an increase 
of volume of secondary antibody to reduce pooling in specific areas on the 
membrane. 
K 
L  
Primary 1:800 
Secondary 1:5000 
Primary 1:300 
Secondary 1:2,000 
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(M) and (N) are blots attempting to produce a signal with little background, negative 
controls (yellow arrow lanes) suggest low background, and bands at predicted 
molecular weights. 
  
M
  
N 
Primary 1:500 
Secondary 1:2,000 
Primary 1:500 
Secondary 1:2000 
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Loading control example 
 
 
  
 
(O) is an example of loading controls, GAPDH 1:20,000, secondary 1:100,000. (P) is 
an example of a membrane which went through a stripping process to re-probe, 
in order to compare IL-6/IL-6R concentration to GAPDH expression, after 
membrane was stripped, it was re-ECLed, it is apparent no antibody producing 
signal is bound to the membrane. 
O 
P 
Primary 1:20,000 
Secondary 
1:100,000 
ECL on stripped 
membrane 
